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ABSTRACT

I. Comparison of translesion bypass of guanine–N2 monoadducts of
mitomycin C and guanine-N7 monoadducts of 2,7-diaminomitosene by
T7 exo-, Klenow exo-, eta and Klenow exo+ DNA polymerases.

II. Structure-based design, synthesis, structure-conformation and
structure-activity

relationships

studies

of

D-Phe-Pro-D-Arg-P1’-

CONH2 tetrapeptides with inhibitory activity for thrombin.
By
Cristina C. Clement

Adviser Part I: Professor Maria Tomasz
Adviser Part II: Professor Manfred Philipp
The guanine (G)-N2 DNA monoadduct of mitomycin C (MC), a cytotoxic anticancer
drug, inhibits translesion bypass by DNA polymerases.

2,7-Diaminomitosene (2,7-

DAM) is the major metabolite of MC in tumor cells, generated by the reduction of MC.
2,7-DAM alkylates DNA in the cell in situ, forming an adduct at the N7 position of 2’-
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deoxyguanosine (2,7-DAM-dG) and is noncytotoxic. In part I of this study we tested a
potential correlation between the lack of cytotoxicity of 2,7-DAM and the relative ease of
bypass of this adduct as compared with the MC adduct. 24-mer and 27-mer templates,
adducted at a single guanine either with MC or 2,7-DAM were synthesized and submitted
to extension of primers by T7 exo-, Klenow exo-, Klenow exo+, and eta DNA
polymerases.

The G-N7-2,7-DAM adduct was bypassed by all four polymerases,

resulting in the production of a fully extended primer. In sharp contrast, the G-N2-MC
monoadduct was not bypassed beyond the adduct position under the same conditions by
any of the four polymerases. In parallel experiments in cell free systems, template
oligonucleotides containing a single 2,7-DAM-dG-N7 adduct directed selective
incorporation of cytosine in the 5'-32P-labeled primer strands opposite the adducted
guanine, catalyzed by Klenow (exo-) DNA polymerase. These results showed for the first
time that the dG-N7-2, 7-DAM lesion is non-mutagenic in cell-free systems.
In part II of this research structure-based design and molecular docking were
employed to design in silico libraries of peptides as potential reversible inhibitors of
thrombin. The candidate inhibitors were selected from two original classes of amino
acids sequences (1)-D-Phe-Pro-Arg (P1)-D-Pro(P1’)-P2’-P3’-CONH2 and (2)-D-PhePro-D-Arg(P1)-P1’-P2’-P3’-CONH2. For the first time in the field of peptides inhibitors
for thrombin we showed that the presence of D-Pro at P1’ Position and the use of D-Arg
instead of L-Arg at P1 Position is responsible for inhibiting hydrolysis of these of
peptides by thrombin, causing these sequences to be inhibitors. In vitro kinetics of
thrombin inhibition showed a specific structure-activity relationship at P1’ position in the
peptide sequence space (2)-D-Phe-Pro-D-Arg(P1)-P1’-CONH2. The lead peptides (D-
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Phe-Pro-D-Arg-D-Ala-CONH2, D-Phe-Pro-D-Arg-D-Thr-CONH2, D-Phe-Pro-D-Arg-DCys-CONH2, D-Phe-Pro-D-Arg-D-Ser-CONH2 had competitive or mixed inhibition with
respect to thrombin and are characterized by inhibitory constant in the 20-0.8 micromolar
range.
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PART I

Comparison of translesion bypass of guanine–N2 monoadducts of
mitomycin C and guanine-N7 monoadducts of 2,7-diaminomitosene by
T7 exo-, Klenow exo-, eta and Klenow exo+ DNA polymerases

By
Cristina C. Clement
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ABSTRACT
The guanine (G)-N2 DNA monoadduct of mitomycin C (MC), a cytotoxic anticancer
drug, inhibits translesion bypass by DNA polymerases as shown previously. The noncytotoxic MC metabolite 2,7-diaminomitosene (2,7-DAM) forms a G-N7 DNA
monoadduct in vitro and in vivo. We tested a potential correlation between the relative
ease of bypass of this adduct (as compared with the MC adduct) and the lack of
cytotoxicity of 2,7-DAM. 24-mer, 27-mer and 36-mer DNA templates, adducted at a
single guanine either with MC or 2,7-DAM were synthesized and submitted to extension
of primers by T7 exo-, Klenow fragment, eta (η) and Klenow (exo+ polymerases). In the
27-mer template/15-mer primer and 24 mer template/15 mer primer systems the G-N72,7-DAM adduct was bypassed by all four polymerases, resulting in the production of a
fully extended primer. However, the extension was at a slower rate as compared with the
control, non-alkylated template; build-up of abortive products before the lesion was
observed suggesting that the polymerases are loosing the processivity as they encounter
the bulky adducts. The fully extended primer and the abortive products each represented
15-20 % of expected 100 % extended primer, observed with control template. Each of
the four polymerase had different extension efficiency: klenow exo- had the highest
efficiency of bypassing the lesion followed by T7 exo- with the lowest efficiency being
observed for klenow exo+ and eta polymerases. In all cases substrate: enzyme ratios
(S:E) of 1: 1, 2:1 and 3:1 were allowing a higher efficiency for translesion synthesis of
both bulky adducts than S:E ratios of 5:1 or higher. In sharp contrast, the G-N2-MC
monoadduct was not bypassed beyond the adduct position under the same condition by
none of the four polymerases. These results suggest a positive correlation between
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cytotoxicity and inhibition of DNA synthesis in the case of the two mitomycin
monoadducts.

CHAPTER 1
Mitomycin C adducts with DNA: Structure-Activity Relationship
INTRODUCTION
Mitomycin C (MC-1, Scheme 1) is an antitumor antibiotic used clinically as a
chemotherapeutic agent against several types of cancer (1). 2,7-Diaminomitosene (2,7DAM; 2) is a major metabolite found in cells and tissues treated with MC (2, 3). The
antitumor activity of MC is believed to be based on its ability to alkylate DNA to form
several monofunctional adducts and cross-links in DNA (4). MC requires reductive
activation for the DNA alkylation process (5). However, the activated hydroquinone
species 3 is partitioned between the pathway of DNA alkylation and a predominant
metabolic pathway, which produces a new quinone, 2,7-DAM (Scheme 2a; 2, 3, 6).
Scheme 1. Structures of mitomycin C (MC) and its metabolite 2,7-diaminomitosene
(2,7-DAM).
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Scheme 2. (a) Reductive metabolism of MC;
(b) Reductive alkylation of DNA by 2,7-DAM.
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In MC-treated tumor cells, six major covalent DNA adducts are formed and the same six
adducts can be isolated in reconstituted cell-free systems using flavoreductases or
chemical reducing agents for activation of the drug. The structures of the DNA adducts
are shown in Figure 1. Four of the six adducts (4-7) are generated directly from the active
form of MC by alkylation of the 2-amino group of guanine in the minor groove of DNA
to give both monofunctional (6, 7) and bifunctional (4, 5) DNA adducts (7). Adducts 8
and 9 are products of 2,7-DAM. This was shown by direct treatment of the cells or DNA
in vitro with purified 2,7-DAM itself, which resulted in the selective formation of adducts
8 and 9, at high efficiency. 2,7-DAM lacks the aziridine ring and alkylates DNA
monofunctionally at the guanine-N7 and -N2 positions (Scheme 2b). The alkylation, like
with MC, requires reductive activation; the relative proportions of the two adducts vary,
depending on the conditions of their formation (7, 8).
Earlier studies of guanine-N2 adducts of mitomycin C site-specificially
incorporated in plasmids indicated that the major MC-guanine-N2 monoadduct is
cytotoxic in bacteria (10). MC itself is highly cytotoxic when administered to bacterial or
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mammalian cells, but the metabolite 2,7-DAM is non-cytotoxic (11). It is proposed that
the effect of structurally distinct 2,7-DAM adduct on DNA function may be different
from those of MC-DNA adducts. Treatment of mouse mammary tumor cells EMT6 with
MC resulted in the isolation of a predominant product, the specific guanine N7-adduct of
2,7-DAM in the major groove.
This result supports the idea that 2,7-DAM is the major bioreductive metabolite of
MC. In contrast with MC, 2,7-DAM-guanine-N7-DNA adduct has a dramatically lower
cytotoxicity under both aerobic and anaerobic conditions. The different effects of MCDNA and 2,7-DAM adducts supports the concept that specific structural features of the
DNA damage may play a critical role in the cytotoxic response to a DNA-targeted
chemotherapeutic agent (12).
Another major difference between the reactivity of 2,7-DAM and MC is the
sequence specificity requirements for guanine alkylation and also the nitrogen of the
purine ring which is chemically modified. It has been shown that both MC and DMC
(decarbamoyl mitomycin C) have Pur d(CpG)Pyr . Pur d(CpG)Pyr sequence requirement.
This is so because the guanine N2 atom of GpPyr is more reactive toward the drug than
that of GpPur, due to the favorable effect of the negative dipole of the O2 of the Pyr on
the reaction (13).
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Figure 2: The major adducts of MC and 2,7-DAM (9).
The mechanism of selective monoalkylation to N2-guanine was shown previously
to be attributed to specific H-bond between the drug and the 2-amino-group of guanine
(14). In addition, 5’C is required for H-bond of carbamate to the non-target G-2-NH2
group in the opposite strand which facilitates the covalent reaction at the target G-NH2
(15). In contrast, the alkylation of guanines in the major groove of DNA by 2,7-DAM
requires the sequence context of longer poly(dG)n . poly(dC)n tracts. The intrinsic SN2-
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type reactivity of 2,7-DAM renders it to alkylate selectively the much more nucleophilic
G-N7. Thus, increasing of (G)n tract length enhances the reactivity of G-N7, since the
there is an increase in the negative molecular electrostatic potential minima

at N7

guanines as compared with single guanine residues. The guanine-N7 atoms in (G)n tracts
are the most nucleophilic sites in B-DNA and are subjected to SN2-type of alkylation
(16).
One important biological function related to the cytotoxic effect exerted by MC
adducts is the replication of DNA. Monoadducts of mitomycin C can act as strong blocks
of the replication fork, thus inhibiting the polymerase reaction. Previously, an in vitro
polymerase reaction assay was designed containing site-specifically modified
oligodeoxynucleotides at guanine residues with MC as templates and three different
polymerases (T7 DNA (Sequenase), AMV reverse transcriptase and E. coli DNA
Polymerase I (Klenow fragment) exo- and exo+ forms) were used in the polymerase assay
(17). The alkylation of oligodeoxynucleotides was performed under conditions which
determined the formation of specific N2-guanine monoadducts. The polymerase reaction
was designed such that both the primer extension and single nucleotide incorporation
opposite the MC-dG were investigated in order to determine whether the DNA
polymerase can bypass the lesion and, in the case of a translesion bypass, whether the
nucleotide incorporation was correct (17).
In contrast with other site-specifically located adducts induced by carcinogens or
antitumor drugs which exhibit a translesion bypass, in the case of MC monoadduct DNA
synthesis was terminated nearly quantitatively at the nucleotide 3' to monoadducts sites,
instead of primer extension to full length of the template. There was no translesion
bypass when exo- Klenow fragment was used in presence of Mn2+ at high concentration
7
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of deoxynucleotide triphosphates, even though the incorporation of nucleotides opposite
the adduct took place (17).
The block of replication induced by the MC monoadducts is proposed to be due to
the increased stability of a distorted conformation of the template/primer since the
thermal melting of a typical template/primer complex showed higher Tm values for the
templates containing MC adduct (∆Tm 0.8-1.0) (17).

Additional molecular modeling

studies of the modified templates/primer supported the thermal melting results by
showing unique hydrogen-bonding between 10”-OC(O)NH2 group of the bound
mitosene and bases from the primer/template junction. In addition the 2-“ NH3+ group
has three H-Bonds to various electronegative atoms on the template strand (17). The
position of 3’-OH was shown not to be altered but the base-pair formation of a nucleotide
triphosphate to the MC modified guanine was proposed to be blocked by the large 10”carbamate group which is stabilized by its H-bonds in an obstructive conformation (17).
The replication studies performed in this paper suggested an unexpected role of the
mitomycin C monoadducts in the induced-cell cytotoxicity described by earlier studies of
Tomasz et al. (11, 12).
The structures of both monoalkylated and cross-linked MC-DNA complexes have
been elucidated by NMR spectroscopy, combined with computational molecular
modeling methods (18). The monofunctional adducts (figure 1) are located in the minor
groove, at the exocyclic amino group of guanine residues, with the selective d(C-G)·d(CG) sequence specificity. The NMR solution structure of the 2,7-DAM-DNA complex
was also determined and showed that the 2,7-DAM molecule is anchored in the major
groove of DNA. The presence of 2,7-DAM in the major groove does not alter the overall
B-DNA helical structure (19). Alignment in the major groove was proposed to be a novel
8
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feature of the complexation of 2,7-DAM with DNA; other known major groove
alkylators such as aflatoxin, possessing aromatic structural elements, form intercalated
complexes (20-30). In figure 2 the modeled structures of the two monoadducts of
mitomycin C and 2,7-DAM are presented together with the pdb ID code which was used
to obtain the atomic coordinates from PDB.
We hypothesized that different structures of the MC and 2,7-DAM monoadducts
with DNA may induce different distortions in the templates/primer and thus may affect
differently their recognition by the DNA polymerases.

These differences in the

interaction between the polymerases and the modified DNA templates may play an
important role in inducing different cytotoxic effects of MC and 2,7-DAM monoadducts.

guanine-N2-monoadduct of MC
(7)

guanine-N7-monoadduct of
2,7-DAM (8)

guanine-N2-monoadduct in
minor groove of DNA
199D.pdb

guanine-N7-monoadduct in
major groove of DNA
1JO1.pdb

Figure 3: NMR-solved structures of the monoadducts 7 and 8 (18, 19). The atomic
coordinates for each structure were downloaded from PDB data bank and modeled using
the software Rasmol.
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PART I: ORIGINAL CONTRIBUTION
The first part of the thesis focused on the relationship between the structure of N7-dGmonoadducts of 2,7-DAM and the N2-dG- monoadducts of MC and their activity related
to the inhibition DNA replication in isolated in vitro simple systems composed of
primer/template (substrates) and 3 major DNA polymerases, T7 exo-, Klenow exo- and
eta (η).
The research presented in Part I of the thesis had 3 major specific aims:
(I)

Synthesis of DNA templates with chemically modified guanines at 2N-and N7
position with MC and 2,7-DAM, respectively.

(II)

In vitro translesion synthesis (TLS) and single nucleotide incorporation
kinetics opposite the MC and 2,7-DAM monoadducts performed with
Klenowexo-, T7 exo-, eta and Klenow exo+ DNA polymerases.

(III)

Physical-chemical investigations (thermal melting) of d(G-T-G-G(4)-T-A-TA-C-C-A-C) (duplex III) self-complementary DNA duplex alkylated at one
single guanine (G4) with 2,7-DAM.

The original findings related to the in vitro TLS of these 2 major bulky adducts of MC
and its derivative 2,7-DAM contributed both to the knowledge of SAR in the field of MC
as an anticancer drug and to the more complex field of the enzymology of different DNA
polymerases and their efficiency of performing the DNA replication past structurallydifferent damaged DNA lesions. A relative new isolated adduct of N2-dG-2,7-DAM (23)
was also used to generate templates-substrates for different DNA polymerases and the
preliminary experiments related to the translesion synthesis of this adduct are presented
in Chapter 2. Of course, we are just at the beginning of understanding the molecular
10
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mechanisms underlying the recognition and the efficient processing of damaged DNA
(both at the replication and at the repair levels) and the MC-monoadducts can be used as
useful tools in probing more complex questions related to the structural basis of DNA
polymerases for recognition of chemically modified templates and their catalytic
efficiency of performing the DNA replication with or without error during TLS. Thus,
the relationship between the MC-monoadducts structure and their mutagenic potential
was further explored in this original thesis project and presented as a starting point for
further detailed investigations as described in Chapter 2.
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CHAPTER 2
Different translesion bypass of guanine–N2 monoadducts of mitomycin
C and guanine-N7 monoadducts of 2,7-diaminomitosene by eta, Klenow
exo-, Klenow exo+ and T7 exo- DNA polymerases

2.1. INTRODUCTION
In the field of eukaryotic translesion synthesis (TLS), DNA polymerases were the
enzymatic systems which were investigated at all molecular levels, from structural to
more biochemical and cell biological levels. The fidelity, mismatch extension ability,
and lesion bypass efficiencies of different polymerases were studied in the context of
their structures (1-55). One major conclusion is that, despite the overall similarity of the
basic structural features, there is a high degree of specificity of their lesion bypass among
the Y-family of DNA polymerases (which are involved primarily in the DNA lesion
bypass with high error rates in DNA synthesis) and the replicative DNA polymerases
(which synthesize DNA with high degree of accuracy) (11-25). Some DNA polymerases
(either from Y-family or from the replicative DNA polymerase family) are able to bypass
a particular DNA lesion whereas others are efficient at only the insertion step or the
extension step of lesion bypass. Both the structures of the enzymes and the structures of
the adducts (i.e. the type of DNA damage) are final determinants of the efficiency and
accuracy of lesion bypass (25-66).
In this original research project we took advantage of the structural difference
between the well characterized monoadducts of MC and 2,7-DAM (Figure 1, Chapter-1)
and synthesized templates containing site-specific alkylated guanines with bulky adducts
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of MC or 2,7-DAM and further performed in vitro translesion experiments and single
nucleotide insertion kinetics addressing the efficiency of these lesions bypass by four
DNA polymerases, Klenow exo-, T7-exo-, eta and Klenow exo+.
Bioorganic and molecular biology methods were used to synthesize 24-mer, 27mer and 36-mer DNA templates adducted at a single guanine either with MC or 2,7DAM.

The alkylated templates were further annealed with complementary primers

which were further used as substrates to conduct the in vitro translesion synthesis (TLS)
with T7 exo-, Klenow fragment exo-, eta (η) and Klenow (exo+) DNA polymerases.
In the 27-mer template/15-mer primer and 24 mer template/15 mer primer
systems the G-N7-2,7-DAM adduct was bypassed by all four polymerases, resulting in
the production of a fully extended primer. However, the extension was at a slower rate as
compared with the control, non-alkylated template. In sharp contrast, the G-N2-MC
monoadduct was not bypassed beyond the adduct position under the same condition by
any of the four polymerases. Single-nucleotide incorporation kinetics using Klenow exopolymerase showed that dCTP has the highest frequency of incorporation followed by a
very low frequency (<1%) of dGTP incorporation opposite the G-N7-2,7-DAM lesion,
while no detectable levels of dATP, dTTP incorporation opposite the same lesion were
observed. These results suggest a positive correlation between cytotoxicity and inhibition
of DNA synthesis in the case of the two mitomycin monoadducts and support the in vivo
findings that the G-N7-2,7-DAM lesion is not mutagenic (9).
In contrast with polymerase Klenow exo-, polymerase eta was more prone to
errors since dGTP was having the highest frequency of incorporation opposite the G-N72,7-DAM lesion, a result which is in agreement with other published data related to errorprone replication by polymerase eta (20-30). An interesting outcome was the formation
14
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of a double adduct -5’-(GG)-(2,7-DAM)2- which showed in a similar single nucleotide
kinetics assay a higher frequency for the incorporation of dTTP and dGTP opposite the
G-N7-2,7-DAM lesion, suggesting that the double adduct is mutagenic in contrast to the
single monoadduct. Preliminary results performed with 24 mer templates adducted at
one single guanine residue with 2,7-DAM but at the N2 position, showed a lower
efficiency of primer extension directed from templates adducted with G-N2-2,7-DAM
lesion by T7 exo- and Klenow exo- DNA polymerases as compared with the primer
extension directed from templates adducted with of G-N7-2,7-DAM lesion. We are still
investigating the kinetics of single nucleotide incorporation opposite other lesions of 2,7DAM, namely -5’-(GG)-(2,7-DAM)2- and G-N2-2,7-DAM together with the G-N2-MC
lesion, using polymerase eta.

2.2. MATERIALS AND METHODS
2.2.1. MATERIALS
MC was obtained from Dr. Dinesh M. Vyas, Bristol Myers Squibb Co. (Wallingford,
CT). 2,7-DAM was obtained by reduction of MC with H2/PtO2 as previously described
(3). [ -32P]ATP was from DuPont New England Nuclear (Boston, MA) or from PerkinElmer Life Sciences (3000 Ci/mmol, 10 mCi/mL). T4 DNA ligase (400 units/ L) and T4
polynucleotide kinase (PNK) (10 000 units/mL) were obtained from New England
Biolabs (Beverly, MA). Phosphodiesterase I (snake venom diesterase, Crotalus
adamanteus venom, EC 3.1.4.1) and alkaline phosphatase (Escherichia coli, EC 3.1.3.1)
were obtained from Worthington Biochemical Corp. (Freehold, NJ). E. coli Klenow (exo) DNA polymerase (5000 units/mL) was purchased from USB (Cleveland, OH).
Exonuclease-free T7 (exo-) DNA polymerase (13 units/ L) was either purchased from
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USB or was a gift from Dr. Smita Patel (UMDNJ, Piscataway, NJ) and was active site
titrated using the quench-flow instrument in the same lab (>75% active enzyme). DNA
polymerase , the full length clone of the human enzyme containing a C-terminal 6X
histidine tag, was a generous gift from Dr. Scott McCulloch and Dr. Thomas A. Kunkel
(Laboratories of Molecular Genetics and Structural Biology, NIEHS, NIH, Research
Triangle Park, NC).

Synthetic oligonucleotides were purchased from the Midland

Certified Reagent Company, Inc. (Midland, TX) or were synthesized in the Core
Facilities at Hunter College and further purified and desalted through a Sephadex G-25
column. Their purity was confirmed through reversed phase HPLC and negative
electrospray ionization mass spectroscopy ESI-MS (-).

2.2.2. General Methods
UV spectra and absorbance readings were recorded in a Cary 3 UV-visible
spectrophotometer. All DNA concentrations were determined by using the calculated
molar extinction coefficient (E260 (strand)) for each oligonucleotide strand and the
absorbance readings at 260 nm using the formula: c = A260/ [E260 (strand) x L] (where the
molar extinction coefficient E is expressed in M-1cm-1 and the path length of the cuvette
is L = 1.0 cm). Each E260 (strand) was calculated using formula: E260 (strand) = number
of purines x 14,000 + number of pyrimidines x 7,000, where 14,000 and 7,000 are the
averaged molar extinction coefficients for purines and for pyrimidines, respectively (1415-Chapter-1). In the case of the 2,7-DAM alkylated oligonucleotide a correction for
E260 (strand) was done by adding 5189 (E260 of 2,7-DAM) (14-15-Chapter 1). LC-MS
was performed with a Hewlett-Packard series 1100 diode array HPLC system connected
to a Hewlett-Packard series 1100 MSD mass spectrometer.

HPLC was performed in a

Beckman System Gold 125 instrument, equipped with a Beckman System Gold 168
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diode array detector. The HPLC columns used for analytical purposes were C18, 100 Å
(Microsorb MV Rainin, 5 mm x 250 mm) and C4, 300 Å (Microsorb MV Rainin, 5 mm x
250 mm) while the columns for semipreparative and preparative use were C18, 100 Å,
Dynamax (5 µm, 1 cm x 25 cm) and C4, 300 Å, Dynamax, (5 µm, 2.14 cm x 25 cm)
respectively. 18% polyacrylamide gel electrophoresis (PAGE) with 8 M urea was run in
a Sequi-Gen GT (Biorad Inc, CA) apparatus, at 2800 constant voltage for 3.5 h. The gel
was exposed to phosporimaging on a Phosphorimager 445 SI (Molecular Dynamics, now
Amersham Biosciences) and the quantitative data were produced using the software
ImageQuant 5.2.

2.2.3. Specific Methods
2.2.3.1. Synthesis of the site-specifically substituted short
oligonucleotide 10 (Scheme 3):
Scheme 3. Alkylated Oligonucleotides (10-13) and Oligonucleotide Templates
Constructed by Ligation (14-16).
5’-ACACG(MC)TCAT-3
10 (9-mer)

5’-GTGG(2,7-DAM)TACCAC-3’
11 (10-mer)

5’-CTGG(2,7-DAM)TAATTTAC-3’
12 (12-mer)

5’-CTAGTGG(2,7-DAM)TATCC-3’
13 (12-mer)

5’-ACACG(MC)TCATTAGAGATTGGTAGGG-3’
14 (24-mer)
5’-CTGG(2,7-DAM)TAATTTACTAGAGATTGGTAGGG-3’
15 (27-mer)
5’-CTAGTGG(2,7-DAM)TATCCTAGAGATTGGTA-3’
16 (24-mer)

Synthetic oligonucleotides were incubated with MC or 2,7-DAM under reductive
conditions using Na2S2O4 or catalytic hydrogenation in aqueous buffer, as described
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earlier. Specifically, 9-mer 10 and the 10-mer 11 were synthesized and characterized as
reported (14-15-Chapter 1).
2.2.3.1.1. Preparative alkylation of 120 ODS total DNA [C1 oligo (5’-A C A C G T C
A T-3’= 9 mer ) and C2 oligo (3’-T I T G C A I T-5’ = 8 mer ).
This reaction was performed using the reductive alkylation procedure of mitomycin C in
presence of substoichiometric amounts of sodium dithionate (Na2S2O4) which enable the
formation of monoaaducts as already was described elsewere (14-15-Chapter 1). The
reaction mixture contained 2.4 mM final concentration mononucleotide duplex DNA (12
µmole mononucleotide DNA duplex in 5 ml reaction mix) and 4 fold excess of
mitomycin C (9.6 mM MC) in the 5 ml reaction mix. (i.e. a total of 48 µmole total MC).
The Na2S2O4 was freshly prepared at 1/4 molar concentration of that of mitomycin C (i.e.
2.4 mM final concentration) in anaerobic conditions. Before sodium dithionate was
added to the reaction mixture, MC (stock solution in methanol), C1 and C2 oligos (both
dissolved into distilled water) were mixed together, rotavaporized to dryness and the
residuals were resuspended in 5 ml 0.1 M KH2PO4, pH=7.0 (same buffer used for sodium
dithionate preparation). The mixture was heated at 95oC for 3 minutes, and the annealing
of the two oligos was performed at room temperature for 1 hour, followed by cooling on
ice (4oC) for 30 minutes.

The DNA duplex formed after annealing is suitable for

alkylation with mitomycin C (14-15-Chapter 1):
5’-A C A C G *T C A T-3’ 9mer (C1-oligo)
3’-T I T G* C A I T-5’

8 mer (C2-oligo)

The guanine that are alkylated at NH2 position by MC are indicated with a (*).
The freshly prepared sodium dithionate (under Argon for 20 minutes) was added to the
duplex DNA + MC mixture, and reductive alkylation of the DNA duplex was performed
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on ice, in the dark, aerobically during 1 hour. The reaction mixture was further applied
on a Sephadex G-25 column (56 x 2.5 cm), and the elution of the alkylated DNA together
with the nonalkylated DNA was performed using 20 mM ammonium bicarbonate buffer.
The first peak eluted from the gel filtration column contains both alkylated and
nonalkylated DNA, while the free mitomycin C un-reacted is eluted after the DNA peak.
The first peak was further lyophilized and the presence of the alkylated DNA strands
each was determined by running the alkylated mixtures of C1 and C2 oligos on a HPLC
C4 column, using the reverse-phase buffer described in Materials and Methods.
2.2.3.1.2.

Preparative HPLC reverse phase chromatography was employed for

purification of C1= 5’-A C A C G T C A T-3’= 9 mer and C2 oligo =3’-T I T G C
A I T-5’ = 8 mer.
In order to perform the preparative HPLC, a scale-up factor was used (scale-up
factor = π r2 prep / π r2 anal), in which the ratio between the radius of the preparative
column over the radius of the analytical column is used to predict the flow rate that has to
be used for the preparative experiment such that the components of interest will eluted
with the same retention time as in the analytical run. In the preparative experiment for
the purification of C1 and C2 oligos alkylated with mitomycin C, we were using a
preparative C4, Dynamax, 300 Å-wide pore, 5 µm, 25 cm. The scale-up factor was 21.6
in this case, predicting that the flow rate would be 20 ml/min. The actual flow rate was 5
ml/min, which is 4 fold less than the flow rate that was actually predicted from the scaleup factor calculations. Thus, the time required the chromatogram was 4 fold higher, i.e.
440 minutes (110 min as for analytical runs x 4). The buffer system and the gradient
used in the reverse phase run were the same as those mentioned for the analytical run
[Buffer A: 0.1 M triethylammoniumacetate (TEAA), pH=7.0. Buffer B: 30% CH3CN in
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70 % 0.1M TEEA, pH=7.0 with the gradient, 20-60% B in 440 minutes). The individual
peaks corresponding to the alkylated oligonucleotides C1 and C2 (as determined by the
ratio of Absorption at 260 nm/Absorption at 320 nm which is between 10-14 for
alkylated oligos (14)) were collected and lyophilized.

The concentration of the

corresponding oligos was determined from UV absorption measurements. For each run a
300 µl of mixture of oligos containing around 50 ODs (as absorption units at 260 nm)
was injected into the preparative column. The Beckman HPLC system was used for the
preparative run as for analytical run.
2.2.3.1.3. HPLC reversed-phase analytical control for alkylation with MC of C1 and
C2 oligos.
The HPLC was performed using the silica based C4 analytical column (5 µm, 300 Å)
(Rainin) and the following buffer system: Buffer A: 0.1 M triethylammoniumacetate
(TEAA), pH=7.0. Buffer B: 30% CH3CN in 70 % 0.1M TEEA, pH=7.0. The gradient
applied was 20%-60% B in 110 minutes.

The peaks were monitored by fixing the

channel A at 254 nm and channel B at 320 nm. The flow rate for the analytical run was
1ml/min.

The % yield of monoalkylation of the corresponding DNA strands was

calculated from the integrated areas of the HPLC peaks corresponding to the alkylated
oligos relative to the unmodified strands. The % yield of alkylation with mitomycin C
was in all cases ~20%.

2.2.3.2.

Synthesis

of

the

site-specifically

substituted

oligonucleotides 12-13 (Sheme 3).
Preparative alkylation of 168 ODS total DNA [[5’-CTGGTAATTTAC-3’] and
[5’-AATTACCAG-3’] annealed duplex] and of 168 ODs total DNA
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[[5’CTAGTGGTATCC-3’] and [5’-GGATACCACT-3’] annealed duplex]].
The reaction of alkylation was performed in 0.1 M potassium phosphate buffer pH 5.5 in
the presence of PtO2 as catalyst, under anaerobic conditions. A total of 168 OD260 units
of oligonucleotide mixture containing either the unsubstituted oligonucleotide precursor
of 12 annealed with 3'-GACCATTAA-5' or the unsubstituted oligonucleotide precursor
of 13 annealed with 5’-GGATACCACT-3’ was mixed with 4.2 µmole 2,7-DAM and
0.841 mg PtO2 in 5 mL 0.1 M potassium phosphate buffer pH 5.5, and the mixture was
annealed by heating at 95o C for 3 min, then slowly cooling to 25o C, followed by keeping
it on ice for 30 min. After annealing, solid ferrous ammonium sulfate (0.084 mg) was
added to the mixture then purged with argon for 15 min.

The hydrogenation was

performed by purging with H2 for 17 min at room temperature. After purging with argon
for 1 h at room temperature the reaction mixture was exposed to air and was applied on
Sephadex G-25 fine column. The first UV-absorbing peak containing the unmodified
and modified oligonucleotides was collected and further purification of alkylated oligos
was performed using a semipreparative C18, column, 100 Å, and the following elution
system: eluant A: 30 mM phosphate, pH 5.4, eluant B: 30% CH3CN in 70% 30 mM
phosphate, pH 5.4. The gradient used was 10%-25% B in 10 min, 25-33% B in 60 min
and 33-100% B in 20 min, with 3 mL/min flow rate. The absorbance was recorded both
at 260 nm and 314 nm and the adducted oligos were identified from their absorption at
both wavelengths and collected as described (14-15-Chapter 1).

2.2.3.3. Characterization of adducted oligonucleotides 10-13 (Scheme3). Analytical HPLC was used establish homogeneity, using reverse phase columns
(Rainin C4 column, 300 Å (Rainin Microsorb MV, 5 x 250 mm)). ESIMS (-) confirmed
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the molecular weight of the adducted oligonucleotides.

All ESI-MS spectra were

acquired using the solvent system: 400 mM hexafluoro-2-propanol (HFIP) (5 ml water,
4.5 ml methanol, 420 µL HFIP, 12 µL triethylamine). The solvent was injected at 50
µL/min flow rate in the ion source. Digestion by snake venom phosphodiesterase and
alkaline phosphatase, followed by reverse phase HPLC of the digest confirmed the
structure of the nucleoside adducts 7 or 8, and the nucleoside and drug-nucleoside adduct
composition of 10-13 as described before (11-15-Chapter 1). Briefly, 0.3 ODs from the
purified C1-MC alkylated oligo were subjected to digestion with snake venom
phosphodiesterase (1 unit) and alkaline phosphatase (0.3 units) in 0.1 M Tris-HCl,
pH=8.2 containing 2mM MgCl2 final concentration. The reaction was left to proceed for
4 hours, at 45oC. The resulted mixture of nucleosides were tested on an analytical
column C18 (Rainin) using the phosphate buffer system (Buffer A: 30 mM phosphate
buffer, pH=5.4. Buffer B: 30% CH3CN in 70% 30 mM phosphate buffer, pH=5.4). The
gradient applied was 20-60% B in 60 minutes.

2.2.3.4. Mapping the position of the 2,7-DAM adduct in 11, 12 and 13
(Scheme-3): There are 2 guanines in oligonucleotides 11 and 12 and 3 guanines in
oligonucleotide 13 (Scheme 3). The positions of the adducts were determined as follows.
11: The oligonucleotide was 5’-labeled with [32P], heated in hot piperidine and analyzed
by PAGE along a Maxam-Gilbert G-lane of labeled unmodified control oligonucleotide.
The results showed that 11 was substituted exclusively at G(4) as described in detail
earlier (14-15-Chapter 1). Positions in 12 and 13 were determined analogously.

2.2.3.5. Construction of alkylated templates 14-16 (Scheme 3). The short
adducted oligonucleotides 10-13 (6 nmol each) were ligated to 5’-phosphorylated
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oligonucleotides (6 nmol each) by T4 DNA ligase (400 units/6 nmol duplex DNA) in the
presence of a complementary oligomer (6 nmol) which held the ligating oligomers
together, using a modified procedure described originally for other mitomycin-adducted
constructs (11-15-Chapter-1).
Specific examples of ligation experiments:

2.2.3.5.1. Ligation of the MC modified 9 mer with a 5’-phosphorylated
15 mer in the presence of a complementary 20 mer in order to obtain
the 24 mer template. The 9 mer 5’-ACACG*TCAT-3’ (3 nmol) with G* alkylated
with MC or the unmodified 9 mer (control) was annealed with the 15 mer 5’-PTAGAGATTGGTAGGG-3’

(3

nmol)

and

the

complementary

20

mer

3’-

TGTGCAGTAATCTCTAACCA-5’ (3nmol) by heating first the three oligonucleotides at
80oC and then cooling slowly to 30oC followed by a incubation at 4oC for 30 minutes.
The reaction volume was 10 µl of 50 mM Tris-HCl, pH=7.6, 10 mM MgCl2, and 10 mM
dithiothreitol (DTT). The ligation was performed using the T4 ligase (2 units) (ATP
dependent, 1mM final concentration), BSA (50 µg/ml) during 16 h at 20 oC. The
reaction was stopped by inactivation of ligase at 65oC during 10 minutes. A small aliquot
from the mixture was 5’-end
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P labeled using γ-32P-ATP, and the results of the ligase

reaction were analyzed on a 16% polyacrylamide-8M urea gel.

2.2.3.5.2.

Ligation of the 2,7-DAM modified 12 mer with a 5’-

phosphorylated 15 mer in the presence of a complementary 17 mer in
order to obtain the 27 mer template.
The 12 mer 5’- CTGG*TAATTTAC-3’ (3 nmol) with G* alkylated with 2,7-DAM or
the unmodified 12 mer (control) was annealed with the 15 mer 5’-p TAGAGATTGGTAGGG-3’

(3

nmol)

and
23

the

complementary

17

mer

3’-

24
CATTAAATGATCTCTAA-5’ (3nmol) by heating first the three oligonucleotides at
60oC (five minutes) and then cooling slowly to room temperature followed by a
incubation at 4oC for 30 minutes. The reaction volume was around 10 µl in 50 mM TrisHCl, pH=7.6, 10 mM MgCl2, and 10 mM dithiothreitol (DTT) (ligation buffer 1x). The
ligation was performed using the T4 DNA ligase (2 units) (ATP dependent, 1mM final
concentration), BSA (50 µg/ml) during 16 h at 4oC. The reaction was stopped by
inhibition of ligase during 10 minutes heating at 65oC. A small aliquot from the ligation
mix was used for
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P labeling and checking of ligation products using 18%

polyacrylamide-8M urea sequencing gel. Other specific oligonucleotide components
used for the construction of each template were the following (Scheme 3):
24 mer-template (14): 10, 5’-pTAGAGATTGGTAGGG,
5’-ACCAATCTCTAATGACGTGT.
27 mer-template (15): 12, 5’-pTAGAGATTGGTAGGG, 5’-AATCTCAGTAAATTAC.
24 mer-template (16): 13, 5’-pTAGAGATTGGTA, 5’-CCAATCTCTAGGATACCACT.
The templates were detected by UV shadowing, excised from the gel and the gel pieces
were soaked overnight at room temperature in 100 mM Tris, 0.5 M NaCl, 5 mM EDTA,
pH 8.0.

The templates were desalted by passing through a C18-Sep-Pak cartridge

(Waters). The elution buffer consisted of 0.1 M triethyl ammonium acetate (TEAA), pH
7.0 : 100% CH3OH (1:1). The alkylated templates were analyzed for the presence of the
MC or 2,7-DAM adduct by digestion with snake venom phosphodiesterase and alkaline
phosphatase followed by analysis of the digests by HPLC, as described for
characterization of the short oligonucleotides 10-13 above.
The purity of the alkylated templates was confirmed by reverse-phase HPLC, using C4
column (300 Å) and the solvent system based on 0.1 M TEAA buffer, pH 7.0 and
24
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acetonitrile (31). In addition, samples of the alkylated templates were 5’-labeled with 32P
and analyzed for purity on 18% PAGE-8 M urea high resolution sequencing gel.

2.2.3.6. 5’-Labeling (phosphorylation) of oligonucleotides with 32P. The
primer oligonucleotides were labeled using 18 pmole DNA and 20 µCi [γ-32P] ATP
(3,000 Ci/mmol) together with 20 units of T4 polynucleotide kinase (PNK) (10,000
U/ml) in a reaction mixture containing the buffer for PNK provided by the company and
BSA (100 µg/mL). The reaction of 5’-phosphorylation was performed at 37oC for 1 h and
50 min and the kinase was inactivated by incubation at 65oC for 15 minutes.

2.2.3.7.

5’-Labeling (phosphorylation) of oligonucleotides with non-

radioactive P for ligation: The oligonucleotides required to be 5’-phosphorylated
for further ligation experiments were phosphorylated using 6 nanomol DNA and 20 to 30
units of T4 PNK in a buffer used in ligation experiments at 1 mM final ATP
concentration under the same conditions as above.
2. 2.3.8. Primer extension assay. All primer extension reactions were performed
under steady state conditions. The substrates for the in vitro polymerase assay consisted
of unmodified (control) and site-specifically alkylated templates annealed with shorter
complementary
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P-labeled primers to form complexes 17, 18 and 19 (Scheme 4). The

reaction mixture contained 150-200 nM final duplex DNA concentration, primer:template
(1:1.5 molar ratio)) in buffer 1x for different DNA polymerases: 50 mM Tris-HCl, pH
7.5, 1 mM EDTA, 5 mM MgCl2, 50 mM NaCl, 1 mM DTT for T7 (exo-) DNA
polymerase; 10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 7.5 mM DTT for Klenow (exo-)
polymerase; 40 mM Tris-HCl, pH 8.0, 10mM MgCl2, 60 mM KCl, 10 mM DTT for eta
polymerase. Each buffer was containing in addition 100 µg/ml BSA final concentration.
25
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The enzymes were added to the annealed primer/template complex such that their final
concentration in the reaction mix was 15-20 nM (10 fold excess DNA substrate vs.
enzyme) except for the eta polymerase where the enzyme was 40 nM and the duplex
DNA substrate was 200 nM such that the substrate : enzyme ratio was 5:1.

The

polymerase reaction was initiated by adding to the preformed [duplex DNA/ polymerase]
complex an equimolar mixture of the four dNTPs in a range of 100 – 500 µM
concentration of each (20-25 µl final volume of reaction). Equal aliquots from the
reaction mix (5-7 µL at each time point) were withdrawn at 1, 3, 5, 10 and 30 or 60 min
and quenched with an equal volume (5-7 µL) mixture of 20 mM EDTA, pH 8.0, and
sequencing loading gel buffer containing 95% formamide and 0.05% bromphenol blue.
Fractionation of all products from the primer extension reaction was performed by PAGE
and quantified as described above.

2.2.3.9. Single nucleotide incorporation assay. Four independent reactions,
corresponding to the incorporation of dATP, dGTP, dCTP and dTTP opposite the lesions
were run at 250-500 µM dNTP concentration using the same procedure and enzymes
described for the primer extension assay using the DNA substrate constructs 20, 21 and
22 (Scheme 4).
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Scheme 4. Primer/Template Complexes Used in Primer Extension on Adducted
Templates.
(15-mer)
3’-ATCTCTAACCATCCC-5’-32P
5’-ACACG(MC.)TCATTAGAGATTGGTAGGG-3’
(24-mer)
17
3’-AATGATCTCTAACCAT-5’-32P
(16-mer)
5’-CTGG(2,7-DAM)TAATTTACTAGAGATTGGTAGGG-3’
(27-mer)
18
3’-AGGATCTCTAACCAT-5’-32P
(15-mer)
5’-CTAGTGG(2,7-DAM)TATCCTAGAGATTGGTA-3’
(24-mer)
19
3’-AGTAATCTCTAACCATCCC-5’-32P
(19-mer)
5’-ACACG(MC)TCATTAGAGATTGGTAGGG-3’
(24-mer)
20
3’-ATTAAATGATCTCTAACCATCCC-5’-32P
(23-mer)
5’-CTGG(2,7-DAM)TAATTTACTAGAGATTGGTAGGG-3’
(27-mer)
21
3’-ATAGGATCTCTAACCAT-5’-32P
(17-mer)
5’-CTAGTGG(2,7-DAM)TATCCTAGAGATTGGTA-3’
(24-mer)
22
3’-AATGATCTCTAACCAT-5’-32P
(16-mer)
5’-CTGG(2,7-DAM)2TAATTTACTAGAGATTGGTAGGG-3’
(27-mer)
23
3’-ATTAAATGATCTCTAACCATCCC-5’-32P (23-mer)
5’-CTGG(2,7-DAM)2TAATTTACTAGAGATTGGTAGGG-3’
(27-mer)
24

2.3.10. Quantitative analysis of primer extension kinetics. Quantitative
analysis of the kinetic data were performed using the Phosphorimager software Image
Quant. The total counts per each line (corresponding to each time point of the kinetic
run) was performed. The DNA polymerase reaction product was calculated by dividing
the counts for each individual DNA product (like the counts corresponding to 36 mer, 25
mer, 24 mer, 22 mer, etc.) with the total counts for the specific time point.

Thus, the

data were expressed as Fraction Product = f (time) or as the %primer remained unextended as a function of time. The data were thus normalized for the possible errors that
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could appear due to differences in the concentration of DNA applied into each wells.
%primer remained un-extended was calculated as the fraction between the primer
remained unextended at each time point and the primer counted at time ‘0’ multipled with
100.

2.3. RESULTS
2.3.1. Synthesis of the site-specifically substituted short oligonucleotides
10-13 (Scheme 3).
2.3.1.1.Synthesis

of

MC-alkylated

oligonucleotide

5’-

ACACG(MC)TCAT-3’-C1-oligo.
The short adducted oligonucleotides 10-13 were designed for ligase-mediated extension
to 24- or 27-mer template strands 14-16 (schemes 3 and 4). The alkylation reactions of
specific duplexes containing the sequence slectivity for MC or 2,7-DAM were performed
under the conditions described in Materials and Methods.

The alkylated and

nonalkylated DNA strands are separated as a single fraction by passing the reaction mix
over a Sephadex G-25 column (figure 3).

A (254 nm)

Fraction I

Apply sample

Chromatogram development

Figure 4: Analysis of oligonucleotides mixture (C1 oligo = 5’-ACACG(MC)TCAT-3’
and C2 3’-TITGCAIT-5’ = 8 mer oligo) by Sephadex-G 25 gel filtration
chromatography after alkylation with mitomycin C. 1st peak (Fraction I) contains the
mixture alkylated and non alkylated C1 and C2 oligos.

28

29
Fraction I from sephadex G-25 was further used to purify the alkylated
oligonucleotides using preparative HPLC as described in the Materials and Methods
section.

As can be seen from Figure 4 a very powerful separation of alkylated strands

from non-alkylated oligonucleotide was achieved using a gradient of 20-60% B in 440
minutes were: Buffer A: 0.1 M triethylammoniumacetate (TEAA), pH=7.0. Buffer B:
30% CH3CN in 70 % 0.1M TEEA, pH=7.0. the structural characterization of the purified
peaks eluted at 67.62 min and 99.15 min was performed using both electrospray
ionization (“-“ mode) mass spectroscopy ((ESI-)-MS) and nucleosides analysis on
analytical C18 columns, after digestion of alkylated oligonucleotides with snake
phosphodiesterase and alkaline phosphatase as described in Materials and Methods. The
alkylated oligos are having always a ratio of Absorption at 260 nm/Absorption at 320 nm
(A(260 nm)/A(320 nm)) between 10-14 (13-14-Chapter 1). As can be seen from HPLC
chromatogram in Figure 4 the alkylated DN A strands have higher absorption on channel
B (set at 320 nm) than the non-alkylated parent strands which have lower absorption on
channel B (at 320 nm). These UV characteristics for alkylated oligos allowed their
original purification from the non-alkylated (parent DNA strands) provided the gradied
performed enabled their separation as is demonstratd in the preparative HPLC run
presented in Figure 4.
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C1-MC

A (320 nm)

A (260 nm)

5’-ACACG*(MC)TCAT-3’

Time (minutes)

Figure 5. Analytical Reverse Phase HPLC of the reaction mixture containing 5’ACACG(MC)TCAT-3’ alkylated oligo. The conditions used for running the HPLC are
described in the Materials and Methods section. The peak eluted at 99.15 minutes was
identified through ESI-MS (- mode) to be the oligonucleotide C1-MC, alkylated with
mitomycin C (MC), i.e. 5’-ACACG*(MC)TCAT-3’ using the procedure described in
Materials and Methods.
The purity control of the MC alkylated oligo C1 was checked by performing
analytical reverse-phase chromatography using C4 column (Rainin), 300 angstoms,
Microsorb, and the same TEAA buffer system used for the preparative and semi
preparative work as described under Materials and Methods. The purified C1-MC
alkylated oligo has the retention time 22.78 minutes and is more than 95 % pure. This
C1-MC alkylated oligo was further used in the ligation experiments for obtaining the 24
mer template for polymerases.
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A (320 nm)

A (260 nm)

31

Time (minutes)
Figure 6. The reversed phase HPLC control of purity for: 5’-A C A C G *(MC) T
C A T-3’ alkylated oligo. The appearance of a double signal (both at 254 nm and at 320
nm) is an indication of the presence of a mitomycin C alkylated guanine as described in
Materials and Methods. The peak eleuted at 22.78 minutes was characterized by ESI(-)
mass spectroscopy and by analytical analysis of the base composition as being the 5’-A C
A C G *(MC) T C A T-3’ oligo containing one single guanine alkylated with MC
(underlined) (see Materials and Methods, Section2.3.1.).
The structural identification of the alkylated guanine at the NH2 position in C1
oligo was performed by running reverse phase HPLC of the corresponding alkylated
oligo after digestion with snake venom phosphodiesterase and alkaline phosphatase as
described earlier (15-Chapter 1) and under Materials and Methods. In a parallel control
run, the non alkylated C1 oligo was digested in the same conditions with the two
enzymes (snake venom phosphodiesterase and alkaline phosphatase), to determine the
retention time for each individual nucleoside (dA, dT, dC and dG). The chromatogram in
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figure 6 (A) support the purity of the alkylated C1 oligo since after digestion with snake
venom phosphodiesterase and alkaline phosphatase, there is no free dG eluted (the
retention time for dG is around 5 minutes). All the dG is shifted at higher retention time
(19.4 minutes) due to the presence of the MC drug covalently bound to NH2 exocyclic
position. The structure of the monoadduct of guanine with mitomycin C at NH2 position
was confirmed by taken the scan of the peak at 19.44 minutes between 200 and 400 nm.
The presence of the monoadduct is confirmed by the appearance of the UV
characteristics at 252 nm and at 315 nm. The ratio 215nm/352nm is 2.3 in the case of

A (320 nm)

A (260 nm)

monoadducts (15-Chapter 1). The spectra of the monoadduct is presented in figure 6 (B).

Time (minutes)
Figure 7 (A-B). The reverse-phase HPLC analytical run of the mixture of
nucleosides containing the alkylated guanine from the C1-5’-A C A C G *(MC) T C
A T-3’ oligo, after snake venom phosphodiesterase and alkaline phosphatase
treatment. The monoadduct of guanine with mitomycin C at N2 position (adduct 7 in
Figure 1) has the peak shifted at 19.44 minutes as it was identified using authentic
standard of this monoadduct (see Materials and Methods Sections 2.3.1-2.3.
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Figure 6 (B). The UV spectrum of guanine N2-MC-monoadduct 7 (Figure 1).
The spectrum of the alkylated dG-nucleoside eluted at 19.4 min in the reversed-phase
HPLC (Figure 6(A)) was recorded using the photodiode array detector of the HPLC
system. The UV-spectrum shows the spectral characteristics described already in the
literature for this monoadduct (11-15-Chapter 1).
The expected adduct and nt compositions of C1-5’-A C A C G *(MC) T C A T3’ oligo were verified by ESI-MS (-) as described in Materials and Methods. For
comparison the MS scan of the control non-alkylated oligonucleotide was also recorded
(see figures 7 (A) and 7 (B)).
Table 1 summarizes the theoretically predicted molecular weights (MW) and the
experimentally determined MW for the oligonucleotides C1 and C1-MC. The MW for
the oligonucleotide C1-MC (5’-ACACG(MC)*TCAT-3’) was calculated from the MW
of the parent oligonucleotide C1 (not alkylated) using the folowing formula: MW of
alkylated C1 oligonucleotide = theoretical MW of non-alkylated C1 oligo (2683 Da) to
which the MW of the drug mitomycin C was added (MW for MC is 334 Da) after which
the MW of the methanol (MW=32.0 Da) was substracted, since when the guanine is
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alkylated with MC it looses methanol = 2683Da+334Da-32Da=2985Da predicted MW
for the oligonucleotide 5’-ACACG(MC)*TCAT-3’.

Figure 8-A. ESI-(-) MS spectrum acquired for the control, parent oligonucleotide
5’-ACACGTCAT-3’ (see Materials and Methods). The peaks were deconvoluted and
fitted to the molecular ion mass of 5’-ACACGTCAT-3’ (Table 1).

Figure 7 (B). MS spectrum acquired for the alkylated 5’-ACACG(MC)*TCAT-3’
oligonucleotide (see Materials and Methods). The peaks were deconvoluted and fitted
to the molecular ion mass of 5’-ACACG (MC) TCAT-3’ (Table 1).
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Table 1: The molecular masses of the parent and alkylated 5’-ACACGTCAT-3’
oligonucleotides as determined from ESI-MS (-) (Materials and Methods).
Oligonucleotide

Theoretically

Experimentally

predicted MW (Da)

determined MW (Da)

5’-ACACGTCAT-3’

2683

2682.13

5’- ACACG(mc)TCAT

2985

2984.48

In conclusion, the structural investigations (reversed-phase HPLC and ESI_MS) support
the fact that the oligonucleotide 5’- ACACG(MC)TCAT-3’ (C1-MC) incorporated one
single drug molecule at the specific guanine residue.

2.3.1.2. Synthesis and structural characterization of C6 oligonucleotide
5’-CTGG(2,7-DAM)TAATTTAC-3’.
As for the case of MC-alkylated oligonucleotides the alkylated and non-alkylated
DNA strands are separated as a single fractiopn by passing the reaction mixture over a
Sephadex G-25 column (figure 8).

The alkylation of DNA duplex 5'-

CTGG*TAATTTAC-3' (C6 oligonucleotide/ 3'-GACC ATTAA-5' (C7 oligonucleotide)
was performed nder reductive conditions as described in Materials and Methods.
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Chromatogram development

Fraction I (contains mixture of alkylated and
non-alkylated oligonucleotides)

Figure 9: Separation of the C6 oligonucleotide (5'-CTGG*TAATTTAC-3') and C7
oligonucleotide (3'-GACC ATTAA-5') from the alkylation reaction mixture by gelfiltration chromatography on Sephadex G-25 column.

Fraction-I peak collected from Sephadex G-25 was further purified for the
alkylated oligonucleotide using reversed phase HPLC. In figure 9, the reverse-phase
HPLC semi-preparative Fraction-I collected from gel-filtration chromatography is
presented. The buffer system used was: Buffer A: 30 mM phosphate buffer, pH=5.4.
Buffer B: 30% CH3CN in 70% 30 mM phosphate buffer, pH=5.4). The gradient: 10%25%B in 10 minutes, 25-33%B in 60 minutes and 33-100%B in 20 minutes. The column
was a semipreparative, Dynamax C18 column. 50 ODs from the reaction mixture (C62,7-DAM +parent C6 +parent C7) was applied to the column and run at 3 ml/min. The
absorbance recordings were at 260 nm (channel A) and 320 nm (channel B) as indicated
on the HPLC chromatogram.
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A (320 nm)

A (260 nm)

N7-dG5’-CTGG*TAATTTTaC-3’
37.7-40.5 min

Time (minutes)
Figure 10. Reversed-phase HPLC semipreparative purification of C6-5'-CTGG*
(2,7-DAM)TAATTTAC-3'alkylated oligo on semipreparative C18 column
(conditions for running the HPLC are described in Materials and Methods). The
alkylated oligonucleotides are eluted later than the non-alkylated parent oligonucleotides.
The structural identity of the alkylated oligonucleotide (indicated with the arrow) was
determined by ESI(-)-MS) as described in materials and methods and presented in figure
12 (B) and table2.

Figure 9 shows that there are many peaks that absorb both at 260 and at 320 nm
suggesting that adducts other than N7-2,7-DAM monoadduct were formed. In most cases
the 2,7-DAM-G-N7 monoadducted-oligonucleotide eluted immediately after the parent
oligonuleotide. As can be seen in figure 9 the C6-oligo alkylated with 2,7-DAM was
eluted after parent oligo at 37.7-40.5 minutes.

This individual peak was collected,

lyophilized and subjected to further purification using semi-preparative HPLC methods
described in Materials and Methods. In addition the analytical reversed-phase HPLC was
used to test the purity of the 2,7-DAM alkylated oligonucleotide. In figure 10 the HPLC
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trace for the analytical control of the purity of the N7-G-2,7-DAM monalkylated
oligonucleotide 5'-CTGG* (2,7-DAM)TAATTTAC-3' is presented.

A (260 nm)

A (320 nm)

(5'-CTGG* (2,7-DAM)TAATTTAC-3')

Time (minutes)
Figure 11. Analytical HPLC reverse phase control of purity of C6-5'-CTGG*(2,7DAM) TAATTTAC-3’ oligonucleotide. The structural identity of the alkylated
oligonucleotide was determined by ESI-MS (-) mode as described in Materials and
Methods.
As can be seen from the analysis of the chromatogram from figure 10, the C6-2,7DAM oligo is pure (>95%) and elutes at 40.68 minutes in the HPLC reversed system
used: C18 analytical column, run at 1ml/min with the following gradient: 10-25% B in 10
minutes, 25%-33% B in 60 minutes and 33%-100% B in 20 minutes. Buffer A: 30 mM
KH2PO4, pH=5.5; Buffer B: 30% acetonitrile into 70% 30 mM KH2PO4, pH=5.5.
The structural identity of the G-N7-2,7-DAM monoadduct was determined by
subjection to digestion with snake venom phosphodiesterase and alkaline phosphatase of
alkylated C6-2,7-DAM oligonucleotide using the same procedure as that described for
the digestion of oligos alkylated with mitomycin C (see Materials and Methods).
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In the case of an oligonucleotide having 5’----GG----3’ tract, where the second
guanine from 5’end is chemically alkylated with 2,7-DAM at N7-position, there is a
stable structure containing the two Gs linked together, from which only one guanine
carries the 2,7-DAM drug. This structure is resistant to digestion by snake venom
phosphodiesterase and alkaline phosphatase (11-15-Chapter 1). In order to obtain just
one single N7-G-2,7-DAM it is necessary to heat the digested sample 1 hour at 90oC.
Upon depurination the N7-Guanine monoadduct with 2,7-DAM is released (adduct 8,
figure 1). Figure 11 (A) shows the analytical HPLC of the digested nonheated samples
and figure 11 (B)-the digested heated sample. The structural assignment of the N7-G*2,7-DAM monoadduct was performed by comparison with an authentic standard
described previously (see also Appendix-I-Figure 69) and by inspection of its own UV
spectrum (11-15-Chapter 1). The UV-scan of the released G-2,7-DAM monoadduct was
recorded during HPLC run using the built-in photodiode array detector. The spectral
characteristic of the N7-G monoadduct is the ratio of 1 between the absorbance at 285 nm
and the absorbance at 314 nm (figure 12). In Appendix (I) the preparation of an authentic
standard for N7-G-2,7-DAM is described together with the HPLC chromatogram used to
identify the adduct and its own UV spectrum (Figure 69).
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A) Analysis of digested C6-alkylated unheated oligo on C18 analytical column.

A (320 nm)

A (260 nm)
Time (minutes)

B) Analysis of digested C6-alkylated oligo on C18 analytical column after depurination
at 90oC for 1 hour as described earlier (15-Chapter 1).

A (320 nm)

A (260 nm)
Time (minutes)

Figure 12 (A-B). HPLC analysis of N7-2,7-DAM monoadduct present in the C6-5'CTGG*(2,7-DAM) TAATTTAC-3’oligo.
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Figure 12: The UV spectrum of guanine N7-2,7-DAM-monoadduct 8 (Figure 1).
The UV spectrum is identical with that of the standard-control shown in Figure 69 (B)
in Appendix (I).
The elution conditions for both the heated and unheated sample presented in the
HPLC chromatograms in Figure 11 (A-B) were: Column: C18, 100 angstroms, 5 µm,
Microsorb Rainin; Buffer A: 20 mM NH4Acetate, pH=5.5; Buffer B: 30% acetonitrile in
70% 20 mM NH4Acetate, pH=5.5 and the gradient applied: 20%-60% B in 60 minutes,
with a flow rate of 1 ml/min. The retention time of the N7-guanine monoadduct 8 (figure
1) is 34.05 minutes (Figure 11) (A-B). The spectral characteristics of the N7-G-2,7-DAM
monoadduct are presented in Figure 12.
The

expected

adduct

and

nt

compositions

of

5’-CTGG*(2,7-

DAM)TAATTTAC-3’ (C6-2,7-DAM) were verified by ESI-MS (-) as described in
Materials and Methods.

For comparison the MS scan of the control non-alkylated

oligonucleotide was also recorded (figures 13 (A) and 13 (B)).
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Figure 13 A. The ESI-MS spectrum for the parent oligonucleotide 5’CTGGTAATTTAC-3’.
The deconvoluted spectra shows the presence of an
oligonucleotide with a MW of 3635.06 Da as expected from theoretical calculations
(table 2) (we assumed that the oligo is ionized with (-3), (-4) or (-5) charges
corresponding to the m/z ratio of 1210.6, 907.7 and 726.0 respectively).

Figure 13 (B).
The ESI-MS spectrum for the G-N7-2,7-DAM alkylated
oligonucleotide 5’-CTGG*(2,7-DAM) TAATTTAC-3’. The deconvoluted spectra
shows the presence of an oligonucleotide with a MW of 3877.92 Da as expected from the
theoretical calculations (see Table 2) (we assumed that the oligo is ionized with (-3), (-4)
or (-5) charges corresponding to the m/z ratio of 1291.5 and 968.6 respectively).
Table 2 summarizes the theoretically predicted molecular weights and the
experimentally determined MW for the oligonucleotides C6 and C6-2,7-DAM. The MW
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for

the

oligonucleotide

C6-2,7-DAM

5’-CTGG*(2,7-DAM)TAATTTAC-3’

was

calculated from the MW of the parent oligonucleotide C6 (not alkylated) using the
following formula: MW of alkylated C6 oligonucleotide = theoretical MW of nonalkylated C6 oligo (3634 Da) to which the MW of the drug 2,7-DAM incorporated in the
oligonucleotide was added (MW for [2,7-DAM+guanine] is 394 Da and the MW of
Guanine is 151.1, such that the MW of the 2,7-DAM drug incorporated into the
oligonucleotide is 394-151.1 = 242.9 Da). Thus the MW of the C6-oligo alkylated at one
single guanine with 2,7-DAM is expected to be 3634Da + 242.9Da = 3876.9Da.
Table 2: Mass of parent and of alkylated 5’-CTGG*(2,7-DAM)TAATTTAC
oligonucleotides determined by ESIMS (-).
Theoretically

Experimentally

predicted MW

determined MW

(Da)

(Da)

Oligonucleotide

5’-CTGGTAATTTAC

3634

3634.90

5’-CTGG*(2,7-DAM)TAATTTAC

3877

3877.92

*mark the position of alkylated guanine.
All the structural investigations (reversed-phase HPLC and ESI-MS) support the identity
of the oligonucleotide 5’- CTGG*(2,7-DAM)TAATTTAC-3’ (alkylated at guanine with
2,7-diaminomitosene (2,7-DAM)). This oligonucleotide was further used in the ligation
experiments to obtain 24 and 36 mers templates for polymerases.
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2.3.2. Synthesis, purification and structural characterization of an
oligonucleotide containing a single N2-dG-2,7-DAM monoadduct; in
vitro conditions that enhanced the selective alkylation of DNA duplexes
for favoring N7-G*-2,7-DAM vs. N2-dG-2,7-DAM monoadducts.
Beside the duplex C6-(5'-CTGG*TAATTTAC-3') and C7 oligonucleotide
(3'-GACCATTAA-5'), duplex I, an independent construct, namely duplex II, 5’CTAGTGGTATCC-3’ (CI) / 3’-TCACCATAGG-5’ (CIII) was akylated with 2,7-DAM
under reductive conditions which enhanced the production of either N-7-2,7-DAM
monoadduct or N2-dG-2,7-DAM monoadduct. The N2-dG-2,7-DAM monoaadduct was
first discovered and structurally characterized using UV spectroscopy by Palom et al.
(23-Chapter-1). It was in our interest to obtain a pure oligonucleotide containing the N2dG-2,7-DAM monoadduct which can be further ligated within 24 mer templates and
subjected to primer extension in vitro reactions. Thus, an enhanced structure-activity
relationship (SAR) of N7-G-2,7-DAM and N2-dG-2,7-DAM could be performed.

2.3.2.1. Reductive conditions that enhanced the production of N7-dG2,7-DAM monoadduct using the DNA duplex (I). There was a preference
for the alkylation at N7-G-position by 2,7-DAM when the alkylating agent was
having higher percentage of decarbamoyl 2,7-DAM (>30%). The conditions for
alkylation are described below:
Alkylating agent: 2,7-DAM: 60% 2,7-DAM and 40% decarbamoyl 2,7-DAM (as
determined by HPLC).
Hydrogenation time: 25-45 minutes: the longer the hydrogenation time the higher the
yield of the N7-G-2,7-DAM monoadduct obtained.
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Argon time: 60-90 minutes; after 1 hour the N7-dG-2,7-DAM monoadduct is reaching a
plateau (figure 15). Preparative alkylation of oligos C6 (5’-C T G G*T A A T T T A C3’ = 12 mer) annealed with C7 (3’-G A C C A T T A A-5’ = 9 mer) (duplex (I)-DNA)
with 2,7-DAM was performed as described earlier in section 1.2.

N7-G *-2,7-DAM
↓
N2-dG
2,7DAM
↓
A (320 nm)

A (260 nm)
Time (minutes)

Figure 14: Snake Venom Phosphodiesterase (SVD) treatment of the oligonucleotide
mixture at 10 minutes Argon treatment after 40 minutes hydrogenation, under the
conditions described at section 1.3.1. It can be seen that the N7-dG-2,7-DAM
monoadduct is obtained in the highest yield, as compared with N2-dG-2,7-DAM
monoadduct which is obtained in lower yield in these conditions. Both monoadducts
were identified based on authentic standards and based on their UV-scans as described in
Materials and Methods.
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Figure 15: The production of N7-G-2,7-DAM monitored in time by reversed-phase
HPLC. The ratio % area of N7-dG-monoadduct and % area of N2-dG-monoadduct to %
area of dT as a function of time of alkylation reaction of duplex (I) (C6-(5'CTGG*TAATTTAC-3') and C7 oligonucleotide (3'-GACC ATTAA-5')) is plotted. The
% area for each monoadduct was calculated using the integration procedure built-in the
software for data analysis of the Beckman HPLC system. The hydrogenation time was
25 minutes while the alkylation under argon was during 1 hour, but the graph shows only
the first 20 minutes of reaction progress under argon.

The N7-G-2,7-DAM monoadduct is produced at higher yield and with faster rate
during both the hydrogenation and the argon time periods. Originally the hydrogenation
time was 15-18 minutes (14-15-Chapter 1) but figure 14 supports the fact that increasing
hydrogenation time enhances the yield of N7-G-2,7-DAM monoadduct. The N7-Gmonoadduct continues to increase in time during argon period when it reaches a plateau
before 60 minutes. The chemical mechanism responsible for enhancing the production of
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N7-G-monoadduct vs. N2-dG-monoadduct in the presence of increased amounts of
decarbamoyl 2,7-DAM (> 40%) is not known by this time and is still under investigation.

2.3.2.2. Reductive conditions enhancing the production of N7-G-2,7DAM monoadduct using the DNA duplex (II): 5’-CTAGTGGTATCC3’-(CI)-3’-TCACCATAGG-5’ (CIII).

The reductive conditions used for

alkylation of duplex (II) with 2,7-DAM are the same as those described in section 2.3.2.1.
The oligonucleotide carrying the N7-G-2,7-DAM monoadduct was purified by
semipreparative reverse phase HPLC as described in Materials and Methods and
presented in figure 16. The purified oligonucleotide was further analyzed on analytical
HPLC (nonheated sample-figure 17 (A) and heated sample for depurination-figure 17
(B)).
5’-CTAGTGG(2,7-DAM) TATCC-3’

A (320 nm)

A (260 nm)
Time (minutes)

Figure 16:
Reversed-phase HPLC semipreparative purification of C-I-5’CTAGTGG(2,7-DAM) TATCC-3’ alkylated oligo on semipreparative C18 column.
The conditions used to run the semipreparative HPLC column are described in Materials
and Methods.
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A (320 nm)

A (260 nm)
Time (minutes)

Figure 17 (A): Analytical reversed-phase HPLC control of purity for
C-I-5’-CTAGTGG(2,7-DAM) TATCC-3’ oligonucleotide- (sample not heated). The
alkylated oligo eluted at 18.05 minutes as can be seen from the absorption at both 260
and 320 nm monitored using the photodiode array system of the Beckman HPLC system.
The structural analysis of the isolated alkylated oligonucleotide was determined by ESI ()-MS and by analytical HPLC analysis of nucleosides using alkaline phosphatase and
snake venom phosphodiesterase method as described in Materials and Methods.
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Apurinic
oligonucleotide

A (320 nm)

A (260 nm)
Time (minutes)

Figure 17 (B): Analytical reversed-phase HPLC control of purity for C-I-5’CTAGTGG(2,7-DAM) TATCC-3’ oligonucleotide- (sample heated).
Through
heating for 1 hour at 90oC the depurination of N7-dG-2,7-DAM oligonucleotide takes
place releasing the apurinic oligonucleotide and the G*-N7-2,7-DAM as they are labeled
on the HPLC chromatogram. This test shows that the alkylated oligonucleotide was pure
and has the N7-G-2,7-DAM monoadduct.
In addition to the depurination of the alkylated oligonucleotide test the pure
oligonucleotide was subjected to digestion by SVD and alkaline phosphatase and the N7monoadduct was identified as described on section 2.3.2.1.

49

50

A (320 nm)

A (260 nm)
Time (minutes)

Figure 18: HPLC chromatogram of the SVD and alkaline phosphatase treated C-IN7-2,7-DAM oligonucleotide. The HPLC chromatogram supports the fact that the
oligo CI was alkylated at N7-position with 2,7-DAM by showing the N7-G-2,7-DAM
monoadduct peak eluted at 44.13 min in the analytical analysis of the nucleoside pattern
on a C18 reversed-phase HPLC. This peak was identified as being the N7-G-2,7-DAM
monoadduct by comparison with the authentic standard (Appendix I, Figure 69). The
inserted UV-spectrum (inset figure) is characteristic for the N7-2,7-DAM monoadduct as
presented earlier (figure 12).

This new 12 mer C-I-5’-CTAGTGG(2,7-DAM) TATCC-3’ was further used to
obtain the 24 mer templates through ligation experiments which were further used for
TLS with DNA polymerases.
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The ESI-(-)-MS of this oligonucleotide proved that one single drug molecule was
incorporated at N7-G position. Table 3 presents the molecular mass determination of CI-N7-2,7-DAM oligonucleotide and the theoretically calculated mass.
Table 3: Mass of parent and of alkylated 5’-CTAGTGG(2,7-DAM)TATCC-3’
oligonucleotides determined by ESIMS (-).
Oligonucleotide

Theoretically
predicted
(Da)

Experimentally

MW determined MW
(Da)

5’-CTAGTGGTACC

3636.5

3635.65

5’-CTAGTGG*(2,7-DAM)TACC (13)

3878.68

3879.68

2.3.2.3. Reductive conditions enhancing the production of N2-dG-2,7DAM monoadduct using the DNA duplex (II): 5’-CTAGTGGTATCC3’-(CI)-3’-TCACCATAGG-5’ (CIII).

This section presents experimental

evidences that support the view that increasing concentration of 2,7-DAM up to 80% vs.
decarbamoyl 2,7-DAM is enhancing the production of N2-dG-2,7-DAM. The reductive
conditions used for alkylation of DNA dduplex (II) are described below:
Alkylating agent: 2,7-DAM: 80% 2,7-DAM and 20% decarbamoyl 2,7-DAM (as
determined by HPLC).
Hydrogenation time: 25-45 minutes: the longer the hydrogenation time the higher the
yield of the N2-dG-2,7-DAM monoadduct.
Argon time: 60-90 minutes; after 1 hour the N2-dG-2,7-DAM monoadduct is reaching a
plateau .
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Adducted oligonucleotide
5’-CTAGTGG(2,7-DAM) TATCC-3’ (CI)

A (320 nm)

A (260 nm)
Time (minutes)

Figure 19. Semipreparative reversed-phase HPLC of the DNA duplex (II) 5’CTAGTGGTATCC-3’/(CI)-3’-TCACCATAGG-5’ (CIII). The alkylation with 2,7DAM was performed under conditions which allowed the synthesis of N2-dG-2,7-DAM
monoadduct. Many adducted oligonucleotides are obtained but the major
oligonucleotides adducted at N7 and N2-dG with 2,7-DAM are eluted at around 20
minutes. In most cases the N7-2,7-DAM and N2-2,7-DAM adducted oligonucleotides
are not separated during this semipreparative run.

The alkylated oligonucleotides at 20.0 minutes were collected and further purified by
HPLC.

In order to separate just the N2-2,7-DAM monoadducted C-I-5’-

CTAGTGGTATCC-3’oligonucleotide the sample was heated, depurinated to release the
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apurinic oligonucleotide, the G-N7-2,7-DAM and the N2-dG-adducted oligonucleotide
which is stable to heat (Figure 20-A-B).

A

A (320 nm)

A (260 nm)
Time (minutes)
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B

Figure 20. (A-B) Reversed-phase HPLC of a mixture of N7 and N2-dG-2,7-DAM
monoadducted C-I-5’-CTAGTGGTATCC-3’ (depurinated sample). The G-N7-2,7DAM monoadducted C-I-oligonucleotide is destroyed by depurination releasing the GN7-2,7-DAM base and the apurinic oligonucleotides. The N2-dG-alkylated C-Ioligonucleotide is stable to heat and can be further purified from this mixture. (B) UVscan of the peak eluted at 41 minutes in Figure 19 (A) shows that the N7-G-2,7-DAM
monoadduct was present in the original mixture of oligonucleotides isolated from
semipreparative HPLC (Figure 19). The UV scan in the inset on the right side of figure
20 (B) shows that the ratio of absorption at 288 nm and 314 nmis almost 1, a
characteristic for N7-G-2,7-DAM monadduct (11-15-Chapter-1).
In addition to the HPLC chromatogram of the depurinated oligonucleotide, the
SVD and alkaline phosphatase treatment of purified adducted oligonucleotides presented
in Figure 20-A showed that the original adducted oligo was a mixture of 2 different
oligonucleotides, one containing the N7-2,7-DAM monoadduct and the other containing
the N2-dG-2,7-DAM monoadduct (Figure 21 (A-C)). In Figure 21 (B) and (C) the two
UV-scan of the two known adducts of 2,7-DAM are shown the expected UV
characteristics for the 2 monoadducts dG-2,7-DAM.
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A

A (320 nm)

A (260 nm)
Time (minutes)
(B)

N7-G-2,7-DAM monoadduct-UV-scan
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(C) N2-dG-2,7-DAM monoadduct-UV-scan

Figure 21 (A-C): The SVD and alkaline phosphatase treatment of the C-Ioligonucleotide-5’-CTAGTGGTATCC-3’ containing the N7-G-2,7-DAM and N2dG-2,7-DAM monoadducts and UV scans of the isolated adducts. There are 6-7
minutes difference between the elution of N7-G-2,7-DAM base (39.45 min) and the
elution of N2-dG-2,7-DAM nucleoside (45.83 min).
The two monoadducts were
assigned by running in the same conditions (i.e.using the same HPLC machine and the
same bufferand gradient system) the authentic standards for N7-G-2,7-DAM and N2-dG2,7-DAM. (B-C): UV-scans of N7-dG-2,7-DAM and N2-dG-2,7-DAM monoadducts
are showing the expected UV characteristics (12-15-Chapter 1).

The purified N2-dG-2,7-DAM-C-(I) oligonucleotide was tested on C18 analytical
reversed phase HPLC column and further subjected to SVD treatment for nucleoside
analysis. The UV characteristics of N2-dG-2,7-DAM-monoadduct were consistent with
the published data and with authentic standards (figure 22 (A), (B) and (C)).
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(A)

A (320 nm)

A (260 nm)
Time (minutes)
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(B)

A (320 nm)

A (260 nm)
(C)

Time (minutes)

Figure 22 (A-C): Analytical reversed-phase HPLC analysis of purified N2-dG-2,7DAM adducted C-I-5’-CTAGTGGTATCC-3’- oligonucleotide (A) and SVD
treatment of the purified C-I-5’-CTAGTGGTATCC-3’- oligonucleotide and
nucleoside analysis on C18 column (B-C). The UV-scan of the adduct N2-dG-2,7DAM monoadduct (C). The N2-dG-2,7-DAM monoadduct eluted at 47 minutes in the
reversed-phase system (the conditions for running the nucleosides are described in
Materials and Methods).
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The ESI-(-)-MS of this oligonucleotide proved that one single drug molecule was
incorporated at N7-G position (Figure 23).

Table 4 presents the molecular mass

determination of C-I-dG-N2-2,7-DAM oligonucleotide and the theoretically calculated
mass.

Figure 23: ESI-MS-(-) (negative mode) of purified C-I-5’-CTAGTGGTATCC-3’oligonucleotide. The MS scan confirms that the oligonucleotide has one single 2,7DAM drug molecule covalently bound to it (Table 4) (we assumed that the oligo is
ionized with (-5) or (-6) charges corresponding to the m/z ratio of 645.5 and 553.2
respectively).
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Table 4: Mass of parent and of alkylated 5’-CTAGTGG(2,7-DAM)TATCC-3’
oligonucleotides determined by ESIMS (-).
Oligonucleotide
5’-CTAGTGGTACC

Theoretically
predicted MW
(Da)
3636.5

Experimentally
determined MW
(Da)
3635.65

3878.68

3879.68

5’-CTAGTGG*(2,7-DAM)TACC
(13)

The progress of a reaction mix during alkylation of duplex (I) under conditions
which favor the production of N2-dG-2,7-DAM monoadduct (hydrogenation time: 45
minutes and Argon: 60 minutes) is presented in Figure 24 (A-D).
In Figure 24 (A) the ratio % area of N7-dG-monoadduct and % area of N2-dGmonoadduct relative to % area of dT is presented as a function of time of alkylation
reaction.

In general the N7-G-2,7-DAM monoadduct is unstable supporting the

hypothesis that it can be decomposed under anaerobic conditions into a reactive species
of 2,7-DAM which can in turn activate the NH2 (N2) position of guanine giving rise to
N2-dG-2,7-DAM monoadduct. However, an independent pathway for producing the N2dG-monoadduct cannot be excluded. In contrast, the N2-dG-2,7-DAM monoadduct is
more stable and is formed at a slower rate than N7-2,7-DAM monoadduct. Also other
adducts labeled z, w, W are also formed in parallel with N2-dG-2,7-DAM adduct,
possibly competing with the intermediate reactive species which gives rise also to N2-dG2,7-DAM adduct (eventually they are guanine adducts-see Figure 24 (C) and their UV
scans). We are still working on additional experiments to test the above hypothesis.
In Figure 24 (B) the SVD treatment of a reaction mix at two different data points
under Argon is presented as an example for the assignment of the adducts N7-dG-2,7DAM and N2-dG-2,7-DAM. In all cases the reaction mix treated with SVD and alkaline
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phosphatase is heated to fully release the N7-dG-2,7-DAM. The assignment of the
adducts is performed based on authentic standards of N7 and N2-dG-2,7-DAM and on
their UV-characteristics (Figure 24 (C)).
In Figure 24 (D) the ratio % area N7-G*-2,7-DAM / %area N2-dG-2,7-DAM is
plotted as a function of reaction time. This graph suggests indirectly that N7-dG-2,7DAM is converted into N2-dG-2,7-DAM but there are not direct proofs for this
mechanism yet.

(A)
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(B) 40 minutes Argon (after 45 minutes hydrogenation)

A (320 nm)

A (260 nm)
Time (minutes)
60 minutes Argon (after 45 minutes hydrogenation)

A (320 nm)

A (260 nm)
Time (minutes)
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(C)

(D)

Figure 24 (A-D). Reductive conditions enhancing the production of N2-dG-2,7-DAM monoadduct
using the DNA duplex (I): C6 (5’-C T G GT A A T T T A C-3’ = 12 mer) and C7 (3’-G A C C A T T
A A-5’ = 9 mer). The reaction conditions together with the results which enhanced the production of
the C6-5’-C T G G*T A A T T T A C-3’-alkylated with 2,7-DAM at N2-position of dG are presented
in APPENDIX (II) (figure 72 (A-C)). The reductive conditions were the same as described in section
1.3.3.
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2.3.3. Mapping the position of N7-2,7-DAM adduct within the C6- 5’CTGG(4)(2,7-DAM)TAATTTAC-3’

(construct 12-scheme 3) and

within the C-I-5’-CTAGTGG(7)(2,7-DAM)TATCC-3’ (construct 13scheme-3) by Maxam Gilbert.
The positions of the 2,7-DAM-adduct 8 (see figure 1) in oligos 12-13 had to be
independently determined, since these oligonucleotides contained more than one
alkylatable target guanines, based on the known 5’…-GG-…3’ sequence selectivity of
formation of adduct 8 upon alkylation of DNA by 2,7-DAM (14-15-Chapter 1). The
alkylation is selective in general for G tracts of DNA and for the 3'-G in -NGGNsequences in duplex oligonucleotides; guanine in -NGN- sequences is essentially
unreactive (12-15-Chapter 1). Accordingly, each of the oligonucleotide substrates for
2,7-DAM alkylation was designed to contain the same -TGGTA- target sequence. The
oligonucleotide substrate for 13 contained an additional guanine in an -AGT- sequence,
which was not expected to be alkylated. The positions of the adduct in 12 and 13 were
determined experimentally by PAGE assay of their fragmentation upon treatment with
hot piperidine (18) (figure 25).
Assay of the adducted oligonucleotide 12 showed that adduct 8 was located
exclusively at nt position 4, as expected (Figure 25a). The same assay of 13, which has
three Gs, indicated that the 2,7-DAM adduct 8 was located in nt position 7 (Figure 25b).
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Figure 25: Piperidine cleavage assay of the 2,7-DAM adduct positions in the
alkylated oligonucleotides 12 and 13 (Scheme 3).
(a) Assay of 12: PAGE (top), and histogram of % relative fragment intensities in lane
5 (below). PAGE lanes: 1, control; 2, control + piperidine; 3, control + dimethyl
sulphate (DMS) + piperidine (G-lane); 4, 12; 5, 12 + piperidine.
(b) Assay of 13: PAGE (top), and fragment intensities (below). PAGE lanes: 1, 13 +
piperidine; 2, 13.
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2.3.4. Synthesis of 24 mer, 27 mer and 36 mer templates substrates for
DNA polymerases.
The templates 14-16 were designed to contain the adduct located close to the 5' terminus
in order to ensure uninhibited initial binding of the primer-template duplex substrate
(Scheme 4) to the DNA polymerases. These templates were homogeneous on HPLC and
PAGE and showed the expected composition by analysis of nucleosides using SVD
treatment of the corresponding oligonuleotides (figures 31-34, Figures 75-78 Appendix
IV). A schematical review of the major steps in the synthesis of each template construct
is presented in Scheme 5.
Scheme 5: Schematical representation of the major steps used to obtain the
templates for DNA polymerases.
(I)

Synthesis of 24-mer containing a MC guanine monoadduct

Synthesis of the 24 mer template with a guanine adduct of MC
Step 1: Synthesis of a 9 mer containing a guanine adduct of MC:
5’-ACACGTCAT-3’

MC
5’-ACACG*(MC)TCAT-3’
reductive activation
(H2, PtO4)

Step 2: Ligation to make a longer template:
5’-ACACG*(MC)TCAT-3’ + 5’-p-TAGAGATTGGTAGGG-3’
3’-TGTGCAGTAATCTCTAACCA-5’ complementary strand for annealing)
↓
Product of ligation
5’-ACACG(MC)*TCATTAGAGATTGGTAGGG-3’
24 mer template (MC)
5’-TTTGTT-3-OH + 5’-p-ACACG*(MC)TCAT-3’-OH +
5’-pGGTTGGACGGCTGCGAGGCCG-3’
3’-AAACAATGTGCAGTACCAACCTGCCGACGCTCC-5’ (complementary
strand for annealing)
↓
Product of ligation:
5’-TTTGTTACACG*(MC)TCATGGTTGGACGGCTGCGAGGCCG-3’
36-mer template (MC)
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(II)
Synthesis of the 27 mer template with a guanine 2,7-DAM adduct
Step1: Synthesis of a 12 mer containing one guanine adduct with 2,7-DAM:
5’- CTGGTAATTTAC-3’
2,7-DAM 5’- CTGG*(2,7-DAM)TAATTTAC3’
reductive activation
(H2, PtO4)
Step2: Ligation to make a longer template:
5’-CTGG*(2,7-DAM)TAATTTAC-3’ + 5’-p-TAGAGATTGGTAGGG-3’
3’-CATTAAATGATCTCTAA-5’ (complementary strand for annealing)
↓
Product of ligation:
5’-CTGG*(2,7-DAM)TAATTTACTAGAGATTGGTAGGG-3’
27 mer template (2,7-DAM)
Synthesis of the 24 mer template with a guanine 2,7-DAM adduct
Step1: Synthesis of a 12 mer containing one guanine adduct with 2,7-DAM:
5’-CTAGTGGTATCC-3’ 2,7-DAM

5’- CTAGTGG (2,7-DAM)TATCC-3 ’

reductive activation
(H2, PtO4)
Step2: Ligation to make a longer 24 mer template:
5’-CTAGTGG*(2,7-DAM) TATCC-3’ + 5’-p-TAGAGATTGGTA-3’
3’-TCACCATAGGATCTCTAACC-5’ (complementary strand for annealing)
↓
Product of ligation:
5’-CTAGTGG*(2,7-DAM) TATCCTAGAGATTGGTA-3’
24 mer template (2,7-DAM)

In order to test if the ligation reactions were successful aliquots from each
reaction mix were run on high resolution sequencing gel (20% PAGE containing 8 M
urea). The templates products of ligation reactions which contain the alkylated short
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oligonucleotides (constructs 10, 12 and 13-Scheme 3) are having slower migration rate
than the templates without the alkylated guanine-monoadducts, so that their presence in
the reaction mix can be identified (Figures 26-28, and Figures 73 and 74 from
APPENDIX III).

Figure 26: Analysis of ligation reactions involving the ligation of the 12 mer C6-2,7DAM oligo into the 24 mer template on 8M high resolution PAGE sequencing gel.
(the conditions for running the gel are described in Materials and Methods).

Figure 27: Analysis of ligation reactions involving the ligation of the 9 mer (MC)
oligo (C1-MC) into the 24 mer template on 8M high resolution PAGE sequencing
gel (the conditions for running the gel are described in Materials and Methods).
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Figure 28: Analysis of ligation reactions involving the ligation of the 9 mer (MC)
(C1-MC) oligo into 36 mer template on 8M high resolution PAGE sequencing gel
(the conditions for running the gel are described in Materials and Methods).
The ligations experiments were performed successfully for the 27 mer construct
containing one guanine alkylated with 2,7-DAM (see Figure 26), also for the 24 and 36
mer constructs containing one guanine alkylated with MC. The bands corresponding to
the template 27, 24 or 36 mer alkylated at one guanine with MC or 2,7-DAM have the
slowest electrophoretic mobility (as seen from the sequencing gels (Figure 26-28).
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Figure 29: Analysis of ligation reactions involving the ligation of the 12 mer C-I-2,7DAM oligo [5’-CTAGTGG(2,7-DAM) TATCC-3’ ] into the 24 mer template on 8M
high resolution PAGE sequencing gel. (the conditions for running the gel are described
in Materials and Methods).
1- 24 mer control template. 2- ligation reaction mix for ligation of a 12 mer adduct
alkylated at one single guanine with 2,7-DAM at (N7) position. 3- ligation reaction mix
for ligation of a 12 mer adduct alkylated at one single guanine with 2,7-DAM at (N7)
position. 4- ligation reaction mix for ligation of a 12 mer adduct alkylated at one single
guanine with 2,7-DAM at (N7) position. 5- ligation reaction mix for ligation of a 12 mer
adduct alkylated at one single guanine with 2,7-DAM at (N7) position. 6- ligation
reaction mix for ligation of a 12 mer adduct alkylated at one single guanine with 2,7DAM at (N7) position. 7- ligation reaction mix for ligation of a 12 mer adduct alkylated
at one single guanine with 2,7-DAM at 2N position. 8- ligation reaction mix for ligation
of a 12 mer adduct alkylated at one single guanine with 2,7-DAM at 2N position. 9ligation reaction mix for ligation a 12 mer adduct alkylated at two guanines with 2,7DAM at (N7) position. 10-ligation reaction mix for ligation a 12 mer adduct alkylated at
two guanines with 2,7-DAM at (N7) position. 11- ligation reaction mix for ligation a 12
mer adduct alkylated at two guanines with 2,7-DAM at (N7) position. 12-pool fractions
of ligation mix of a 12 mer adduct alkylated at one single guanine with 2,7-DAM at (N7)
position (for preparative work). 13- pool fractions of ligation mix of a 12 mer adduct
alkylated at one single guanine with 2,7-DAM at (2N) position (for preparative work).
14-pool fractions of ligation mix of a 12 mer adduct alkylated at two guanines with 2,7DAM at (N7) position. 15- purity control for the 12 mer adduct alkylated at one single
guanine with 2,7-DAM at (N7) position. 16- purity control for the 12 mer adduct
alkylated at one single guanine with 2,7-DAM at (2N) position. 17- purity control for the
12 mer adduct alkylated at two guanines with 2,7-DAM at (N7) position. 18- 15 mer
used for ligation experiments (1). 19-15 mer used for ligation experiments (2). 20-17
mer used as complementary strand during ligation experiments.
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The results show that the ligation experiments were successful for the 24 mer
construct containing one or two guanines alkylated with 2,7-DAM (as is seen on the
sequencing gel (Figure 28) the shifted band above the 24 mer control template
correspond to the alkylated 24-mer template). The alkylated template has a slower
electrophoretic mobility than the non-alkylated control template. It can be seen that part
of the new alkylated templates are depurinated, generating an independent band with the
same electrophoretic mobility as the control template (Figure 28-lanes 12-14).

2.3.5. Purification and structural characterization of the alkylated 24
mer and 36 mers templates alkylated with MC and 2,7-DAM.
2.3.5.1. Purification of templates from PAGE-urea gels.
The ligation mix was used to purify the alkylated templates (24, 27 mer and 36 mers)
from the other oligonucleotides used for ligation using preparative 16% polyacrylamide8M urea gel. The 24 or 27 mer and the 36 mer templates were excised from the gel and
desalted using a Sep-Pak cartridge (Waters) and further purified as described in Materials
and Methods (Specific Methods section).

The preparative urea gel used for the

purification of DNA templates contained as marker lanes 32P-labeled ligations mix such
that after autoradiography the positions of the required DNA bands could be determined.
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Figure 30: 16% preparative polyacrylamide gel containing 8 M urea for
purification of 24 mer-G*(MC), 24 mer-G*(2,7-DAM) and 36 mer-G*(MC).

2.3.5.2.

Structural characterization of the alkylated 24, 27 mer and 36 mer

alkylated mitomycin C or with 2,7-DAM.
Before the alkylated templates were further used in the primer extension assays, the
structural characterization of the purified DNA templates was performed to determine if
the final product of the ligation was having a single guanine alkylated with MC or with
2,7-DAM.

The structural characterization of the alkylated templates involved the

digestion of the DNA with snake venom phosphodiesterase and alkaline phosphatase,
both for the adducts with MC and with 2,7-DAM, followed by the analysis of the
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nucleosides using the reverse-phase HPLC (C18 column, 100 Å) and the buffer system as
described in the Specfic Methods section and in sections 1.1-1.2 (Figures 75-78, in
Appendix IV presents the HPLCs for the digested alkylated templates, as a proof for their
structural identity: the alkylated MC or 2,7-DAM nucleoside G is eluted at later retention
time than the nonalkylated nucleosides and were identified to be the expected
monoadducts based on HPLC analysis of authentic standards and on UV characteristics
already described in the literature (11-15-Chapter 1).
2.3.5.3. High resolution sequencing PAGE electrophoresis and reversed-phase
HPLC proofs of purity for the MC and 2,7-DAM 24, 27 mer and 36 mer alkylated
mitomycin C or with 2,7-DAM.
The purity of adducted templates 14-16 (Scheme 3) was tested by running 32P-labeled
aliquots of each template on a 18% sequencing gel, at 2800 V constant voltage for 3
hours and half. The gel was exposed and processed using a 445 SI PhosphorImager and
ImageQuant 5.2 software (as described in detsails in Materials and Methods).
As can be seen from Figures 31-34 and Figures 79-84 in APPENDIX V all the
templates are homogeneous pure. In the case of 2,7-DAM alkylated templates we were
interested to check if any depurination was taking place, since is known from the
literature that the apurinic sites are easily bypassed with incorporation of dATP opposite
the apurinic site (34-50). The PAGE test showed that the 2,7-DAM-alkylated template
was not depurinated (APPENDIX V-Figure 84).
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A

B

Figure 31. A. 18% Sequencing gel analysis of ligation reactions for obtaining the 27mer-G*-(2,7-DAM) template. 1- 27 mer-G*(2,7-DAM) template purified. 2- 24 mer
template control. 3- ligation mix for 27 mer-G*-(2,7-DAM).
B. Reverse-phase HPLC analysis of the 27-mer-G*-(2,7-DAM) template on a C4
column (300 Å) as described in “Materials and Methods”.
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B.

Figure 32: PAGE (A) and HPLC (B) analysis of alkylated 24-mer-MC template. A.
18% Sequencing gel analysis of ligation reactions for obtaining the 24-mer-G*-(MC)
template. 1- 24 mer template control. 2-24-mer-G*-(MC) template purified. B.
Reverse-phase HPLC analysis of the 24-mer-G*-(MC) template on a C4 column
(300 Å) as described in “Materials and Methods”.
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B.

Figure 33: PAGE (A) and HPLC (B) analysis of alkylated 36-mer-MC template. A.
18% polyacrylamide high resolution sequencing gel for purity check of 36 merG*(MC) template. B. Reverse-phase HPLC analysis of 36-mer-G*-(MC) template
on a C4 column (300 angstroms) (details in “Materials and Methods”).
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24 mer-G-2,7-DAM

24 mer control

Figure 34: PAGE (A) analysis of 24-mer-2,7-DAM alkylated template (construct
16 from schene 3).

2.3.6.

In vitro primer extension and single-nucleotide kinetics assay

using Klenow exo-, T7 exo-, eta and Klenow exo+ DNApolymerases.
The in vitro polymerase and single-nucleotide kinetics were performed with four
different polymerases Klenow fragment (KF) (exo-), T7 (exo-), eta and Klenow exo+
DNApolymerases. We were interested in the following major questions:
1. Is the DNA lesion containing N7-dG-2,7-DAM bypassed during primer extension
experiments?
The purpose of this experiment was to determine if there is any translesional
bypass in the case of the template containing one single guanine alkylated with 2,7-DAM
or 2 guanines alkylated with 2,7-DAM.
2. Which dNTP has the highest frequency of insertion opposite the G-2,7-DAM lesion?
In order to test the mutagenic potential of the N7-2,7-DAM lesion we we performed
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single-nucleotide incorporation kinetics, were one single dNTP was incorporated at a
time opposite the G*-containing the N7-G*-2,7-DAM lesion.
3. By comparison with N7-G-2,7-DAM lesion is the N2-dG-MC lesion bypassed or is
inhibiting the translesion synthesis (TLS) by Klenow exo-, T7 exo- and eta DNA
polymerase?
We knew from previous studies that the N2-dG-MC lesion is inhibiting primer
extension by Klenow exo- and T7 exo- DNA polymerases one nucleotide before the
lesion (17-Chapter 1). However, it was important to compare the relative rates of primer
extension for the two lesions, thus we repeated the translesion synthesis reactions for the
N2-dG-MC lesion. We run at steady state in real time the reactions of TLS not at end
point kinetics as were originally run (17), so that we could compare the rate with which
the primer is extended in time for the two lesions N2-dG-MC and N7-G-2,7-DAM.
4.

In addition to the questions raised above, how is the TLS performed by DNA

polymerase eta in the case of the two lesions N2-dG-MC and N7-G-2,7-DAM? DNA
polymerase eta is known to be error prone translesion synthesis (being part of the Y
family of DNA polymerases (3-50). The investigations of TLS using polymerase eta
presented in this dissertation research are bringing new evidences for the inhibition or the
translesion synthesis (TLS) as a function of the structure of the monoadduct (in this case
we compared the minor groove vs. major grove orientations of the two adducts N2-dGMC and N7-G-2,7-DAM respectively and their effects upon the TLS).
Footprinting experiments indicate that Klenow Fragment covers 19 and 12
nucleotides on the template and primer strands, respectively (35). Other experiments
indicates that templates 19-20 nucleotides and primers 12 nucleotides in length are
sufficient to form stable polymerase/DNA complexes (35).
78

79
We conduccted the experiments of TLS and single nucleotide incorporation
kinetics using primarily 24 mer templates alkylated at one single guanine with MC or
2,7-DAM annealed with 15 mer or 17 mer primers. Our quench flow experiments
showed that the polymerization rate for T7 exo- polymerase (kpol) is higher for the
36mer/25 mer (template/primer) constructs than for 24 mer/17 mer (template/primer) (C.
Clement –unpublished results-see Figures 85, 86-Appendix VI) suggesting that the DNA
polymerases have higher affinity for longer templates/primer constructs. However, most
of the in vitro TLS assays are conducted with 24 mer-27 mer/15mer-17-mer
(templates/primers) constructs as a first test for the abilities of different DNA
polymerases to bypass different lesions (36, 37, 38). It was reasonable to construct 24
mers and 27 mers templates primarily adducted at one guanine with MC or 2,7-DAM and
conduct the in vitro TLS with these substrates. We also succeeded to synthesize a 36 mer
template adducted at one single guanine with MC and we run in vitro TLS with this
template annealed with a 25 mer primer. The template/primer constructs used for TLS
and single nucleotide incorporation kinetics are presented in Scheme 4. The conditions
used to run all the TLS reactions are described in details in the Specific Methods section
and presented schematically in Scheme 6.
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Scheme 6: The experimental design used to run primer extension and single
nucleotide incorporation kinetics with MC and 2,7-DAM adducted templates:
Primer extension reaction mixture
Steady-State kinetics
Template (MC or 2,7-DAM adduct)
5’-32P-primer (150 nM duplex DNA)
DNA polymerase (15 nM)
dNTPs (500 µM each dNTP)
MgCl2 (10 mM)
Buffer for polymerase, pH 7.5

Kinetics of primer extension or single nucleotide incorporation and
analysis of the reaction products:
1. Incubate the reaction at room temperature (25oC).
2. Quench aliquots with EDTA/sequencing gel buffer at time points of
1, 3, 5, 10 and 20 minutes.
3. Analysis of the 1, 3, 5, 10 and 20 minutes (reaction products and 0minutes control by 18% PAGE-8 M urea sequencing gels. The
32P-labeled primer extension products are detected by
phosphorimager and their length is established by comparison
with 32P-labeled standard oligonucleotides.

2.3.6.1. Primer Extension kinetics (TLS) by T7 exo- polymerase.
T7 exo- polymerase was the first enzyme used for the primer extension assay using
different substrates constructs (scheme 4).

The results of primer extension (TLS)

performed by this DNA polymerase are presented in figures 35-41.
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Figure 35: TLS (translesion synthesis) performed with T7 exo- polymerase and 27mer-2,7-DAM template (substrate 18 in scheme 4) at 250 µM final concentration of
each dNTP. The results of TLS showed that the 2,7-DAM lesion was fully bypassed by
T7-exo- polymerase resulting in the production of fully extended primers (24 mer
products). Extra extension of the alkylated template with 4 more nucleotides maybe due
to the primer slippage during the reaction of primer extension.
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Figure 36: Quantitative measurements of TLS (translesion synthesis) performed
with T7 exo- polymerase and 27-mer-2,7-DAM template (substrate 18 in scheme 4)
at 250 µM final concentration of each dNTP. The data from figure 35 were quantified
as fraction of product (A) or % primer extended (B) using the Phosphorimager and the
Image Quant as described in Specific Methods section.

82

83

21-position
of lesion
N7-2,7DAM

Figure 37: TLS (translesion synthesis) performed with T7 exo- polymerase and 27mer-2,7-DAM template (substrate 18 in scheme 4) at 300 µM final concentration of
each dNTP. The results of TLS showed that the 2,7-DAM lesion was fully bypassed
by T7-exo- polymerase resulting in the production of fully extended primers (24 mer
products). Extra extension of the alkylated template with 4 more nucleotides may be due
to the primer slippage during the reaction of primer extension.
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Figure 38: Quantitative measurements of TLS (translesion synthesis) performed
with T7 exo- polymerase and 27-mer-2,7-DAM template (substrate 18 in scheme 4)
at 250 µM final concentration of each dNTP. The data from figure 37 were quantified
as fraction of product or % primer remaine unextended using the Phosphorimager and the
Image Quant as described in Specific Methods section.

84

85

Figure 39: TLS (translesion synthesis) performed with T7 exo- polymerase and 27mer-2,7-DAM template (substrate 18 in scheme 4) at 500 µM final concentration of
each dNTP. The results of TLS showed that the 2,7-DAM lesion was fully bypassed by
T7-exo- polymerase resulting in the production of fully extended primers (24 mer
products). Extra extension of the alkylated template with 4 more nucleotides maybe due
to the primer slippage during the reaction of primer extension.
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Figure 40: TLS (translesion synthesis) performed with T7 exo- polymerase and 27mer-2,7-DAM template (substrate 18 in scheme 4) at 500 µM final concentration of
each dNTP. The results of TLS showed that the 2,7-DAM lesion was fully bypassed by
T7-exo- polymerase resulting in the production of fully extended primers (24 mer
products). Extra extension of the alkylated template with 4 more nucleotides may be due
to the primer slippage during the reaction of primer extension. The rate of primer
utilization is slowere in the case of the alkylated template as compared with control
template, suggesting that T7 exo- polymerase has lower affinity for the alkylated
substrate as compared with the non-alkylated control template.
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Figure 41: PAGE analysis of primer extension on MC- and 2,7-DAM-adducted
templates by T7 (exo-) DNA polymerase. (a) PAGE of primer extension of MCadducted template/primer complex 17 (scheme 4). Reaction conditions: 250 µM dNTP
(each), 200 nM complex 17, 40 nM T7 (exo-) DNA polymerase; 25o C. Minutes of
incubation time are indicated above each lane. (b) Plots of results in (a): The fractions of
the expected 24-mer fully-extended control product (∇) and an aborted 19-mer product (1
nucleotide before MC lesion) ( ) are plotted as a function of incubation time. The rates
for the two products are different, the MC lesion is not bypassed and a 19-mer aborted
product (1 nucleotide before lesion) is accumulated at a slower rate than in the case of the
same reaction run with Klenow (exo-) DNA polymerase (see Fig. 43 b). (c) PAGE of
primer extension of 2,7-DAM-adducted template/primer complex 19 (scheme 4).
Reaction conditions: Same as in (a). (d) Plots of results in (c): The percent of original
primer remained un-extended during the primer extension reaction is plotted as a function
of incubation time for the complex 19 using the data presented in 41 (c). The 2,7-DAM
lesion (closed triangles) is bypassed with a slower rate than the control undamaged
template (closed circles).
87

88
The primer strand in the MC complex 17 was again elongated only to a 19-mer,
indicating a complete block of elongation one nt before the MC adduct 7 in the template
(Figure 41-a). This polymerase exhibited a low activity for elongation of the starting 15mer primer in complex 17 relative to elongation of the control, nonadducted complex and
also relative to elongation in complex 17 by Klenow (exo-) DNA polymerase. In sharp
contrast, the primer strand in the 2,7-DAM-dG-N7 complex 19 was elongated to full its
24 nt length, indicating bypass of the adduct 8 in the template, albeit at a lower efficiency
relative to the control, nonadducted template (Figure 41 b and Figure 42). A similar result
was obtained using complex 18 as the substrate for the T-7 (exo-) polymerase as shown
in figures 35-40.

This substrate yielded, in addition, products of overextension of the

primer by 1, 2, or 3 nts beyond the template terminus, most likely originating from primer
slippage. Figure 42 presents a detailed mathematical fit of the kinetics data presented in
Figure 41. Since the data were best fitted to a double exponential decay model, we
hypothesized that the primer extension reaction proceeded with a change in the
conformation of the DNA polymerase as it was binding to the template/primer substrate.
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Figure 42: Quantitative analysis of primer extension on 2,7-DAM-adducted
template of complex 18 (Scheme 4) by T7 (exo-) DNA polymerase. Doubleexponential decay fit of experimental data presented in figure 41 (d) to the equation
f=Y(0)+ a*exp(-b*x)+c*exp(-d*x). The % primer remained un-extended follows a
double exponential decay with a faster rate (d = 1.2080) for the control than for the 2,7DAM alkylated template (d= 0.0527) probably due to a lower affinity of the polymerase
for the alkylated substrate and a loss of processivity near the bulky lesion.
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2.3.6.2. Primer Extension kinetics (TLS) by Klenow exo- polymerase.
The primer strand in the 2,7-DAM complex 19 (scheme 4) containing adduct 8
was elongated past the 2,7-DAM adduct 8 (scheme 3) using DNA polymerse Klenow
exo-. This is concluded from the presence of 18-24 nt long primer products at gradually
increasing relative intensities of the fully extended 24-mer as the time of the incubation
was increased from 1 to 60 min (Figure 43 c). This extension reaction was conducted at a
5:1 stoichiometry of the duplex 19 : enzyme ratio. Another extension reaction was run at
1:1 stoichiometry, which resulted in a slightly different pattern, in which some
accumulation of intermediates between 17- and 23-mers was detected (Figure 43 d). In
any case, both results indicate that the 2,7-DAM-dG-N7 adduct 8 is bypassed by Klenow
(exo-) DNA polymerase, in contrast to the MC-dG-N2 adduct 7. It is notable, however,
that the rate of disappearance of the starting 15-mer primer is much slower than that in
the nonadducted control complex or in the MC-adducted complex 17 as can be seen from
all results of primer extension reactions presented in Figures 44-53 performed with DNA
polymerase Klenow exo- using templates constructs 18 or 21 (see scheme 4).
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Figure 43: PAGE analysis of primer extension of MC and 2,7-DAM-adducted
templates by Klenow (exo-) DNA polymerase. (a) PAGE of primer extension in MCadducted template/primer complex 17. Reaction conditions: 250 µM dNTP (each), 200
nM complex 17, 40 nM Klenow (exo-) DNA polymerase, 25oC. Minutes of incubation
time are indicated above each lane. (b) Plots of results in (a): The fraction of the expected
24-mer fully extended product (control) and aborted 19-mer product (1 nucleotide before
MC lesion) is plotted as a function of incubation time. (Closed circles: 24-mer control
product; closed squares: 19-mer abortive product.) (c) PAGE of primer extension of 2,7DAM-adducted template/primer complex 19. Reaction conditions: 250 µM dNTP (each),
200 nM complex 19, 40 nM Klenow (exo-) DNA polymerase, (S:E ratio 5:1); 25o C.
Minutes of incubation time are indicated above each lane (d) same as (c), except used 40
nM complex (S:E ratio 1:1). (e) Plots of results in (c) and (d): The percent of original
primer remained un-extended during the primer extension reaction is plotted as a function
of incubation time. The 2,7-DAM lesion (closed triangles) is bypassed with slower rate as
compared with the control undamaged template (closed circles).
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Figure 44. Translesion synthesis (TLS) using a 27-mer-G*-2,7-DAM (construct 21,
scheme 4) and Klenow exo- polymerase at 500 µM each dNTPs. (A) The primer is
less extended when is annealed with the alkylated template as compared with the control,
non-alkylated template. (B) The quantitative analysis shows the same %primer remained
un-extended kinetics as is shown in figures 40, 42 and 43 (e). The rate of primer
extension is slower in the case of alkylated template and the yield of the primer
remained-un-extended is higher than in the control non-alkylated template, suggesting
that the polymerase has a lower affinity for the alkylated template and is loosing
processivity for the DNA substrate during the primer extension reaction.
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Figure 45. Translesion synthesis (TLS) using a 27-mer-G*-2,7-DAM (construct 18,
scheme 4) and Klenow exo- polymerase at 500 µM each dNTPs. (A) The results are
showing that the primer is less extended when is annealed with the alkylated template as
compared with the control, non-alkylated template. (B) The rate of primer extension is
slower in the case of alkylated template and the yield of the primer remained-un-extended
is higher than in the control non-alkylated template.
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Figure 46. Translesion synthesis (TLS) using a 27-mer-G*-2,7-DAM (construct 18,
scheme 4) and Klenow exo- polymerase at 500 µM each dNTPs (independent
experiment). The rate of primer extension is slower in the case of alkylated template and
the yield of the primer remained-un-extended is higher than in the control non-alkylated
template.

96

97

Figure 47. Translesion synthesis (TLS) using a 27-mer-G*-2,7-DAM (construct 18,
scheme 4) and Klenow exo- polymerase at 300 µM each dNTPs (independent
experiment). The rate of primer extension is slower in the case of alkylated template and
the yield of the primer remained-un-extended is higher than in the control non-alkylated
template.
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Figure 48: Quntitative measurements of TLS (translesion synthesis) performed
with Klenow exo- polymerase and 27-mer-2,7-DAM template (substrate 18 in
scheme 4) at 250 µM final concentration of each dNTP. The data from Figure 46 were
quantified as fraction of product (A) or % primer remained (B) unextended using the
Phosphorimager and the Image Quant as described in Specific Methods section.
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Figure 49: Translesion synthesis (TLS) using a (27-mer-G*-2,7-DAM)2 (construct
24, scheme 4) and Klenow exo- polymerase at 500 µM each dNTPs. The rate of
primer extension is slower in the case of double alkylated template and the yield of the
primer remained-un-extended is higher than in the control non-alkylated template. These
results are consistent with the those obtained for the 27-mer template containing one
single G alkylated with 2,7-DAM.
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Figure 50. PAGE analysis of primer extension (TLS) on 2,7-DAM-adducted
template of complex 19 by Klenow (exo-) DNA polymerase at 37o. The increased in
the temperature had a better effect upon the TLS reaction in vitro.
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Figure 51: The primer extension reaction using a 27-mer-G*-2,7-DAM and Klenow
exo- polymerase but a different template construct (the drug is moved toward the
midle of template) (construct 18 scheme 4). The ratio substrate (primer/template):
enzyme is 6:1. The lesion with 2,7-DAM is bypassed but with slower rate with respect to
the control template. Also, at this enzyme: substrate ratio the enzyme is less efficient in
extending fully the primer (21-22 mers instead of 24 mers are the final products of the
reaction).
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Figure 52: The primer extension reaction using a 27-mer-G*-2,7-DAM (construct
(18)-scheme 4) and Klenow exo- polymerase at lower concentration of dNTPs (100
µM instead of 500 µM). At lower dNTPs concentration (i.e. below 200 µM) the lesion
with G*-2,7-DAM was not bypassed anymore, suggesting that the 2,7-DAM drug within
the template is decreasing the relative affinity for the dNTPs (i.e. the Km for dNTPs is
increased).
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Figure 53: Klenow exo- polymerase primer extension of a dG-N2-mitomycin C
alkylated 36 mer template. The reaction of primer extension is inhibited by the
presence of MC drug, after one nucleotide incorporation opposite the lesion.
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2.3.6.3. Primer Extension kinetics (TLS) by DNA polymerase eta.
The comparison between the TLS of N7-G-2,7-DAM and TLS of N2-dG-MC
were performed with the error prone DNA polymerase eta and showed that a bulky
minor groove adduct (N2-dG-MC) is completely inhibited the polymerase one nucleotide
before lesion, while the major groove adduct (N7-G-2,7-DAM) is allowing lesion bypass.

Figure 54: PAGE analysis of primer extension on MC- and 2,7-DAM-adducted
templates by DNA polymerase eta. (a) PAGE of primer extension of MC-adducted
template/primer complex 17. Reaction conditions: 250 µM dNTP (each), 200 nM
complex 17, 40 nM DNA polymerase eta, 25 oC. (b) Plots of results in (a): The percent
of original primer remained un-extended during primer remained un-extended during
prime extension reaction is plotted as a function of incubation time for the complex 17.
The MC lesion was not bypassed and a 19-mer abortive product (1 nucleotide before
lesion) is accumulated with the same rate as the 24-mer product of control template:
Closed triangles: non-alkylated control 25-mer; closed squares: adducted template/primer
aborted 19-mer. (c) PAGE of primer extension of 2,7-DAM-adducted template/primer
complex 19. Reaction conditions: as in (a). (d) Plots of results from (c): The percent of
original primer remained un-extended during the primer extension reaction is plotted as a
function of incubation time for the complex 19 using the data presented in figure 54 (c).
The 2,7-DAM lesion (open triangles) is bypassed with a slower rate as compared with the
control undamaged template (open circles).
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These results would be the basis for further structural investigations of complexes
between eta DNA polymerase and substrates containing adducted templates with these
two structurally different drugs. In advance, the molecular modeling studies using the
Dpo4 DNA polymerase (39) in complex with the constructs used for primer extension
and single nucleotide incorporation kinetics may bring new structural basis for the
observed differences in the translesion synthesis of the two studied monoadducts.

Figure 55: PAGE analysis of primer extension on 2,7-DAM-adducted template
(construct 19-scheme 4) by DNA polymerase eta. The conditions for running the
translesion synthesis (TLS) are inserted within the same figure. At smaller substrate:
enzyme ratios (such as 2:1 or 1:1) the N7-G*-2,7-DAM lesion is more easily bypassed by
polymerase eta which showed in general a lower efficiency of bypassisng this bulky
adduct (see figure 54 c).
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Figure 56: PAGE analysis of primer extension on 2,7-DAM-adducted template of
complex 19 by T7 exo-, Klenow exo- and eta DNA polymerases. The translesion
synthesis (TLS) were run at 250 µM final concentration of each dNTP, 89 nM final
duplex DNA concentration and a substrate to enzyme (S:E) ratio of 3:1 for 20 minutes.
The lower substrate: enzyme ratio increased the efficiency of N7-G-2,7-DAM adduct
bypass by all three DNA polymerases: 1- Klenow exo- polymerase; 2- T7-exopolymerase; 3- eta polymerase.
In the MC-dG-N2 complex 17, polymerase η extended the primer strand only to
19-mer, one nt before the MC adduct 7 in the template strand, at relatively low efficiency
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as compared to control primer extension (Figure 54 a). In contrast, in the 2,7-DAM-dGN7 complex 19, the primer strand was extended two nts past the 2,7-DAM adduct 8, to
20-mer, with surprisingly high efficiency. A product corresponding to the fully extended
primer is formed only to a low extent (Figure 54 b). In these reactions, a ratio of 5:1 (S:E)
was employed. In analogous studies of other bulky adducts, polymerase η showed
similarly low efficiencies of primer extension under such conditions (46-48). However,
using a lower (2:1) or 3:1 S:E ratios, we observed substantially more efficient TLS and
the extension to 23 nt length of the primer (figure 55 and figure 56 respectively).

2.3.6.4. Primer Extension kinetics (TLS) by Klenow + DNA polymerase.
The primer extension reaction of adducted N7-G-2,7-DAM templates was performed at
high concentration of dNTPs (1mM each) when the lesion was bypassed by Klenow exo+
with the production of fully extended primers (24 mers for construct 23-scheme 4).
However, we observed the degradation of the alkylated template as compared with the
control non-alkylated template suggesting that the lesion may induce improper alignment
of the primer with the template and misspaired base pairs may appear opposite the
guanine alkylated with 2,7-DAM.
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Figure 57: PAGE analysis of primer extension on 2,7-DAM-adducted template by
Klenow exo+ DNA polymerases at 1 mM final dNTPs concentration. The translesion
synthesis pass the N7-G-2,7-DAM lesion was obtained only on higher dNTP
concentration (> 1mM each dNTP). At low concentration of dNTPs (below 500 µM) we
didn’t observed any translesion synthesis (see figure 3, APPENDIX VII).
Additional primer extension reaction using all constructs presented in scheme 4
and all four DNA polymerases (T7 exo-, Klenow exo-, Klenow exo+ and eta) are
presented in APPENDIX VII-Figures 87-89.

2.3.6.5. Comparison of translesion synthesis (TLS) by Klenow exo- and
T7 exo- DNA polymerases on adducted templates containing the N7-dGand N2-dG-2,7-DAM.
The translesion synthesis (TLS) on adducted templates containing the adducts N7dG-2,7-DAM and N2-dG-2,7-DAM were performed on constructs containing the N7- dG2,7-DAM (construct 19-scheme 4) and on independent constructs containing N2-dG-2,7-
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DAM monoadduct obtained through ligation of small 12-mer oligonucleotides into 24
mer templates as described in Materials and Methods. Two polymerases were shown the
TLS: T7 exo- and Klenow exo- polymerase (figures 58-60).

TLS performed by

polymerase eta on templates adducted with N2-dG-2,7-DAM is under current
investigation. We don’t have yet the strong evidences for the position of N2-dG-2,7DAM within the templates, thus we can propose just a global interpretation for the rate of
primer extension reaction observed in the case of the templates adducted with N2-dG-2,7DAM. We have however some preliminary data supporting the fact that the adduct at
N2-dG is almost 50% distributed in between the adjacent guanines. These preliminary
results for the mapping of the N2-dG-2,7-DAM position and the results from primer
extension reactions presented in figure 58 would suggest that the N2-dG-2,7-DAM lesion
is also bypassed, but with slower rate and less efficiently than the N7-G-2,7-DAM lesion
(based on the %primer remained unextended during primer extension reaction).
(A)
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Figure 58: The primer extension reactions on templates adducted with N7-dG- and
N2-2,7-DAM by T7 exo- polymerase. The primer extension reaction was performed in
vitro using the assay described in Materials and Methods for primer extension reaction
for the construct template/primer-19 at 250 µM of each dNTP. (B) Quantification of
gels in figure 56 (A) shows that at two different time points the fraction of primer
remained un-extended in the case of N2-dG-2,7-DAM adduct is higher than in the case of
N7-dG-2,7-DAM adduct. These results suggest that N2-dG-2,7-DAM adduct is
decreasing the affinity of T7 exo- polymerase for the substrate more than the N7-dG-2,7DAM adduct does, explaining the slower rate of primer extension observed for the N2dG-2,7-DAM lesion than for the N7-G-2,7-DAM lesion .
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Figure 59: The primer extension reactions on templates adducted with N7-dG- and
N2-2,7-DAM by T7 exo- polymerase (independent experiment). The primer extension
reaction was performed in vitro using the assay described in Materials and Methods for
primer extension reaction for the construct template/primer-19 at 250 µM of each dNTP.

The fraction of primer remained un-extended in the case of N2-dG-2,7-DAM adduct is
higher than in the case of N7-dG-2,7-DAM adduct. These results suggest that N2-dG2,7-DAM adduct is decreasing the affinity of T7 exo- polymerase for the substrate more
than the N7-dG-2,7-DAM adduct does which is reflected in a less effcicient primer
extension reaction for the -dG-2,7-DAM lesion. Figure 60 shows the primer extension
reaction performed with Klenow exo- DNA polymerase were it can be seen that the N2dG-2,7-DAM lesion is even more less efficient replicated than the N7-G-2,7-DAM
lesion.
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Figure 60: The primer extension reactions on templates adducted with N7-dG- and
N2-2,7-DAM by Klenow exo- polymerase. The primer extension reaction was
performed in vitro using the assay described in Materials and Methods for primer
extension reaction for the construct template/primer-19 at 250 µM of each dNTP. The
fraction of primer remained un-extended in the case of N2-dG-2,7-DAM adduct is higher
than in the case of N7-dG-2,7-DAM adduct.
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2.3.7. Single nucleotide incorporation opposite 2,7-DAM-dG-N7 Adduct.
These experiments were designed to test the fidelity of the translesion bypass observed in
the case of the 2,7-DAM-adducted (8) (scheme 3) templates, described in scheme 4. The
alkylated primer-template complex 21 and the control nonalkylated complex were
incubated with only a single dNTP at a time at high concentration (500 M) and Klenow
(exo-) DNA polymerase.

(A)
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Figure 61: Single-nucleotide incorporation kinetics opposite the 2,7-DAM-dG-N7
lesion. dCTP was having the highest frequency of incorporation both opposite 2,7-DAM
alkylated guanine in the template. The kinetics for dCTP incorporation opposite the
lesion shows that the second dCTP incorporation opposite G beyond the lesion in the
template has a slower rate than in the case of control, non-alkylated template (B). These
results are consistent with primer extension kinetics which showed the loss of
processivity for polymerase as is approaching the lesion.

The control non-alkylated complex incorporated two C units into the primer
strand (25-mer). A small amount of primer intermediate (24-mer) incorporating one
single C unit was observed at the end of the 60-min incubation period Figure 61 (A). No
appreciable incorporation of the other 3 nucleotides was observed (data not shown). The
alkylated complex 21 incorporated two C units at a lower overall efficiency than the
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control (figure 61 (B)). The 24-mer one-C-incorporated intermediate was accumulated in
a two-fold proportion relative to the 25-mer two-C-product, during the 60 min incubation
(figure 61 B). Figure 61 (B) shows that the nucleotides A and T were not incorporated.
The base G was incorporated to a relatively low extent opposite the G(4) position of the
template.
The important conclusion of these results is that the 2,7-DAM-guanine-N7 adduct
is not mutagenic in the Klenow (exo-) DNA polymerase replication system.
As in the case of primer extension reaction, we didn’t observed any single
nucleotide incorporation events at low concentration of dNTP (100 µM) (figure 62).

Figure 62: Single nucleotide kinetics for dCTP and dGTP incorporation opposite
the N7-G-2,7-DAM lesion by Klenow exo- polymerase at lower concentration of
dNTPs (100 µM). At lower dCTP concentration (i.e. below 300 µM) there is no single
nucleotide incorporation opposite the lesion N7-G*-2,7DAM, suggesting that the 2,7DAM drug is decreasing the relative affinity for the dCTP, i.e. the Km for dCTP is
increased. In the case of dGTP, there was no incorporation of nucleotide opposite the
lesion at 100 µM.
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In Figure 63, the lesion N7-G-2,7-DAM was bypassed with lower efficiency and slower
rate than the control nonalkylated template, supporting the data presented in Figure 61
(b). The dNTP with the highest efficiency of incorporation one nucleotide beyond the
lesion was dCTP. dATP, dGTP and dTTP were not incorporated beyond the lesion with
high efficiency (data not shown) confirming the lack of mutagenicity (in vitro) of the N7G-2,7-DAM monoadduct. Altogether, the results from figures 61 (b) and 63 supports the
view that N7-G-2,7-DAM is not an easily bypassed lesion but is definitely nonmutagenic when the lesion bypass reactions are performed with replicative DNA
polymerases (such as T7exo- DNA polymerase) or with Klenow exo-.
By contrary, when the lesion bypassing experiments are performed in vitro with
DNA polymerases which are known to bypass the lesions with high error during DNA
synthesis, such as DNA polymerase eta, the N7-lesion is prone to be mutagenic, due to
the lack of high fidelity of bypass of DNA-polymerase eta. As figure 64 shows, DNA
polymerase eta incorporated with high efficiency dGTP opposite the N7-G-2,7-DAM
lesion but with lower efficiency than in the control nonalkylated template. dGTP was
incorporated opposite dGTP in the control nonalkylated template, but with lower
efficiency than dCTP, the normal expected dNTP to be incorporated opposite dGTP.
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Figure 63: Single-nucleotide incorporation of dCTP one nucleotide beyond the N7G*-2,7-DAM lesion by Klenow exo- polymerase. dCTP had the highest frequency of
incorporation beyond 2,7-DAM alkylated guanine in the template construct . The rate of
dCTP incorporation one nucleotide beyond lesion is slower than in the control, nonalkylated template, given rise to a lower yield of expected extended product (as compared
with control). No appreciable amounts of dATP, dGTP and dTTP were observed to be
incorporated in this primer/template construct.

Figure 64: Single nucleotide incorporation opposite N7-dG-2,7-DAM lesion by DNA
eta polymerase. The conditions for running the single nucleotide incorporation are
described in the insert below figure 64. The control experiment showed that polymerase
eta is error-prone in incorporation one single dNTP at a time, with the following order of
frequency of dNTPS incorporation: dCTP>> dTTP>dGTP>>>>dATP (in agreement with
other published pol eta single nucleotide incorporation experiments (40-50). However, in
the case of N7-dG-2,7-DAM adducted template the only dNTP incorporated opposite the
lesion is dGTP.
117

118

2.3.8. Single nucleotide incorporation Opposite MC-dG-N2 Adduct.
Despite the previous studies which showed that MC is non-mutagenic both in vitro and in
vivo (17-Chapter 1) our last studies of single nucleotide incorporation opposite the N2dG-MC lesion showed that at higher concentrations of dNTPs, 500 µM, there is a
nonspecific incorporation of all dNTPs opposite this lesion contained within a 36 mer
template (figure 65). At 100 µM there is no dNTP incorporated opposite the N2-dG-MC
lesion (figure 66), results which are in agreement with the translesion synthesis were the
extension of the primer is blocked o nucleotide before the lesion (figure 41).

An

independent experiment run at 100 µM of each dNTP but with a 24 mer-N2-dG-MC
lesion construct we observed a preference for dATP incorporation opposite this lesion.
The order of dNTPs incorporation in this case was dATP>dCTP>dGTP>dTTP (figure
67).

Figure 65: Single nucleotide incorporation opposite the G*-MC lesion using Klenow
exo- polymerase and 500 µM each dNTP.
The reaction of single nucleotide
incorporation were performed for 30 minutes using the conditions described in materials
and methods.
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Figure 66: Single nucleotide incorporation opposite the G*-MC lesion using Klenow
exo- polymerase and 100 µM each dNTP. The reaction of single nucleotide
incorporation were performed for 30 minutes using the conditions described in materials
and methods.

Figure 67: Single nucleotide incorporation opposite the G*-MC lesion using Klenow
exo- polymerase and 100 µM each dNTP. The reaction of single nucleotide
incorporation were performed for 30 minutes using the conditions described in Materials
and Methods.
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Since we always obtained double-2,7-DAM alkylated (at 2 Gs) 12 mer constructs
(see scheme 3) we generated trhough standard ligation experiments 27-mer templates
(see scheme 4) containing 2 Gs alkylated at N7 position with 2,7-DAM. The presence of
the double alkylated 12 mer was determined by ESI-MS (-) mode and by Maxam Gilbert
hot piperideine treatment for G-line as explained in Materials and Methods (Section
2.2.3.4). We conducted single nucleotide kinetics of dNTP incorporation opposite the
double alkylated lesion (see constructs in scheme 3 and in figure 68) and we determined
that the double adduct N7-G-N7G-(2,7-DAM)2 is mutagenic. The frequency of each
dNTP incorporation opposite the double (N7-2,7 DAM-G-)2 lesion was: dTTP > dCTP
> dGTP>>> dATP (figure 68 (A) and (B) (independent experiment)).

(A)
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(B)

Figure 68: Single-nucleotide incorporation kinetics opposite the (G*-N7-2,7-DAM)2
lesion (construct 24)using Klenow exo- polymerase and 500 µM each dNTP. The
frequency of incorporation opposite the double (N7-2,7 DAM-G-)2 lesion was:
dTTP > dCTP > dGTP>>> dATP (A) and (B) (independent experiment).
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DISCUSSION
The major goal of the research addressed the relationship between the structure of
Mitomycin C (MC) and 2,7-Diaminomitosene (2,7-DAM) monoadducts and their
interaction with polymerases in an in vitro polymerase assay system.

Specifically, we

investigated the effect of MC and 2,7-DAM adducted DNA template upon the kinetics of
DNA polymerases in an in vitro system. Initial cell biology experiments showed higher
rate of survival for the cells treated with 2,7-DAM as compared with the cells treated
with MC, suggesting that mitomycin C (MC) was a very cytotoxic drug while 2,7-DAM
is non cytotoxic (1-20-Chapter 1) .
Based on these experimental evidences we initially hypothesized that a primer
extension reaction performed in vitro just in the presence of the alkylated DNA
templates/primer substrates and the DNA polymerase (no other proteins from the
replication machinery involved) is expected to result in a translesion bypass of the 2,7DAM lesion and a stop of the polymerase before the lesion containing guanine alkylated
with mitomycin C.
Initially, during the first stages of this research, steady-state kinetics were
performed using 10 fold molar excess of DNA substrates (annealed primer/template) vs.
enzyme concentration and 500 µM of each dNTP in order to determine if the lesion in the
template containing 2,7DAM is bypassed by the DNA polymerases. Primer extension
experiments were conducted with 27 mer and 24 mer construct templates having one
guanine (G) alkylated either with MC or with 2,7-DAM were used together with control
non-alkylated templates.

In addition, templates containing 2 guanines both alkylated

with 2,7 DAM were also used to investigate the lesion bypass by polymerases.
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We investigated first the translesion synthesis of the N7-G-2,7-DAM and N2-dG2,7-DAM adducted templates by DNA replicative polymerases T7 exo- and Klenow exoafter we confirmed that the templates were homogeneosly pure by PAGE analysis (see
Figures 31-34). We showed for the first time that both T7 exo- and Klenow exo- DNA
polymerase are bypassing the N7-G-2,7-DAM bulky lesion (figures 35-52).

The

quantitative analysis of primer extended showed that the rate of bypass was slower in the
case of templates containing alkylated guanines as compared with the non-alkylated
templates. The results showed that in the case of templates containing N7-G-2,7-DAM
there is an accumulation of shorter length DNA products during the primer extension and
translesion bypass. 17, 18, 20, 21, and 22 mers are accumulated in the reaction such that
the final yield for the expected product (24 mer+/-25 mer) is just 5-10 % in the case of
the 24 mer templates (figures 36, 38, 40, 41, 48).

These shorter DNA products

correspond to the positions one nucleotide before lesion, one nucleotide opposite the
lesion and one and two nucleotides beyond the lesion. We are proposing that the DNA
polymerases are losing the processivity as they are approaching the lesion, a phenomenon
that may explain the accumulation of shorter length DNA products (also reported in other
primer extension reactions of bulky DNA-adducts (1-50).
In addition, the primer extension reaction for the 27 template was accompanied by
over-extension with 5 more nucleotides beyond the expected length of 27 mer, suggesting
that there may be a slippage of the primer during the extension reaction, primarily due to
the presence of the drug very near the 5’-end of the alkylated template (figures 37-42).
It is important to mention that both replicative DNA polymerases had very good
kinetics of primer extension with control substrates, suggesting that there was no error in
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the polymerase assay. In most cases the % primer extension was between (75-85)% in
the case of control in all of the in vitro assays for primer extension.
All the primer extension kinetics were performed in high excess of each dNTP
(300 µM and 500 µM) and there was no primer extension at lower dNTPs concentration
(100 µM dNTPs). Since the Km for each dNTP is around 50 µM if normal (nonalkylated) templates are used in all polymerase reactions (2-5), the above results suggest
that Km for the dNTPs is highly increased in the case of the N7-2,7-DAM (G)-alkylated
template, thus the DNA polymerases have lower affinity for these chemically alkylated
substrates. For most replicative DNA polymerases, the loss in affinity for the substrates
is correlated many cases with the lost of processivity (1-20).
The mitomycin C (MC) monoadducts are in general not bypassed as was the case
of both 24 mer-G*(MC) and 36 mer-G*(MC) adducted templates. Thus DNA polymerase
(Klenow fragment (exo-) was blocked one nucleotide before the alkylated G*(MC) in the
case of 24 mer-G*(MC) template, producing high yield (80%) of abortive product 19 mer
(the mitomycin C lesion has the 20th position) (figure 41). In the case of the 36 merG(MC) the DNA polymerase (Klenow fragment, exo-) was blocked after it incorporated
1 nucleotide opposite the G-N2-alkylated guanine and the rate of incorporation of one
single nucleotide opposite the lesion was also higher than in the case of the control (nonalkylated) template (figure 53). Independently than Klenow exo-, T7 exo- polymerase
was also inhibited in bypassing the N2-dG-MC lesion 1 nucleotide before lesion, but at a
slower rate than in the control experiments (figure 41).

Thus the mitomycin C

monoadducts are a strong block for the replication, a result consistent with already
published data which are shown the highly cytotoxic effect of mitomycin C (in
mammalian cancer cells) (10, 11-Chapter 1). The mitomycin G-2N-monoadduct was
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shown independently to be a block of replication in an in vitro system using
primer/mitomycin C-2N-G-alkylated template substrates and T7 and Klenow exopolymerases by other group of researchers (17-Chapter 1).
In the case of the templates containing one single G-N2-alkylated with mitomycin
C quantitative analysis of %primer extension data supports the idea that in the case of
mitomycin C monoadducts, the rate of primer extension is the same for both the nonalkylated and the alkylated templates. In some cases, the rate for the extension of the Gmitomycin C alkylated template was higher than for the non-alkylated template
suggesting a possible higher affinity of DNA polymerase for the alkylated template,
making the mitomycin C monoadduct to behave like a “suicide” substrate (figure 41).
The primer extension reaction conducted with DNA polymerase eta showed for
the first time that DNA polymerase eta is performs the translesion synthesis of N7-dG2,7-DAM lesion is true with less efficiency than T7 exo- and Klenow exo-DNA
polymerases. Although the structural details and biological function of the translesion
bypass type DNA polymerase η differ from those of the T7 and Klenow fragment
polymerases (40-48), the observed differential extent of the bypass of the 2,7-DAM-dGN7 and MC-dG-N2 adducts in the cell free system (figures 54-56) follows the same
adduct structure-activity pattern obtained using the other two DNA polymerases (9Chapter 1).
It is known (40-65) that pol eta is an error-prone polymerase, thus it was
important to perform single nucleotide incorporation at end-point kinetics opposite N7dG-2,7-DAM monoadduct to test the mutagenicity of this lesion as it is bypassed by
DNA polymerase eta . The control experiment showed that polymerase eta is error-prone
in incorporation one single dNTP at a time, with the following order of frequency of
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dNTPS incorporation: dCTP>> dTTP>dGTP>>>>dATP (in agreement with other
published pol eta single nucleotide incorporation experiments (46)). However, in the
case of N7-dG-2,7-DAM adducted template, the only dNTP observed as being
incorporated opposite the lesion is dGTP, with a lower efficiency than in the control
template, probably due to the presence of the drug in the G-template opposite the
incoming dNTP which could allow favorable hydrogen-bonds or electrostatic interactions
between the drug and the incoming dNTP (10-15).
An interesting case was the translesion bypass obtained with Klenow exo +
polymerase during TLS of (N7-dG-2,7-DAM)2 monoadducts. At lower concentration of
dNTP (< 1 mM) the polymerase was not bypassing the lesion. In addition, extended
primers were degraded in shorter DNA fragments, suggesting that the extended primer
does not form the right hydrogen bonding between the incoming dNTP and the base
alkylated in the template. This misspaired primer-template substrate would allow dNTP
missincorporation events which are detected by the Klenow exo+ editing function
resulting in degradation of the wrong extended primer (figure 89, APPENDIX VII). At
high concentration of dNTP (1 mM) we observed that the lesion N7-dG-2,7-DAM was
bypassed resulting in fully extended primer (figure 57). The Klenow exo+ activity
toward substrates containing N7-2,7-DAM alkylated templates suggests structural
deficiencies in annealed primer/template complex such as nucleotide missincorporation
events at the end of the extended primer during the replication or the slippage of primer.
Each of the four polymerases had a different extension efficiency: Klenow exohad the highest efficiency of bypassing the N7-G-2,7-DAM lesion followed by T7 exoand eta polymerases, with the lowest efficiency being observed for Klenow exo+. In all
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cases substrate: enzyme ratios (S:E) of 1: 1, 2:1 and 3:1 were allowing a higher efficiency
for translesion synthesis of both bulky adducts than S:E ratios of 5:1 or higher.
Additional single-nucleotide kinetics using 32(P)-primers with the free 3’-OH end
stopping one nucleotide before the lesion or having at the 3’-OH a cytosine base-pairing
with the opposite guanine-2,7-DAM lesion in the template were used to investigate the
frequency of single nucleotide incorporation opposite the lesion and the frequency of
single nucleotide incorporation one nucleotide beyond the lesion. In both cases dCTP
had the highest frequency of incorporation opposite 2,7-DAM alkylated guanine in the
template.

Very low (<1%) frequency of dGTP incorporation opposite the lesion

containing 2,7-DAM was also observed. It is important to mention that the singlenucleotide kinetics experiments were performed with Klenow exo- polymerase which has
intrinsically the tendency to incorporate dGTP opposite G in the control non-alkylated
template at high dGTP concentrations (>250 µM). No detectable levels for incorporation
of dATP or dTTP opposite the 2,7-DAM alkylated guanine in the template were observed
during all the single-nucleotide kinetics experiments (figure 61). These results suggest a
lack of depurination of the 2,7-DAM (G) alkylated template during the single-nucleotide
kinetics. Thus, we can argue that the lesion bypass during primer extension experiments
was allowed strictly by the presence of 2,7-DAM in the template and was not due to the
presence of an apurinic site. The presence of apurinic sites due to the depurination events
(a phenomenon encountered primarily for the lesions containing alkylated guanine at N7
position in the purine ring (50-57)) is totally excluded both in the case of primer
extension and single nucleotide kinetics experiments since the apurinic sites are
characterized by a high frequency of dATP incorporation opposite the apurinic site,
which did not our system (50-57).
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In contrast with the single 2,7-DAM-monoadducted template the double 2,7DAM-monoadduct template (construct 24) showed translesion synthesis, i.e. the double
adduct was bypassed but with the accumulation of overextended products of extension,
suggesting that the double adduct impared the right alignment and hydrogen bonding
between the template and the primer. The DNA polymerase fidelity of bypassing the
double adduct is lower than for the single N7-G-2,7-DAM monoadduct.

In single

nucleotide incorporation events opposite the double lesion (figure 68) we observed dTTP
with the highest frequency of incorporation opposite the lesion suggesting the mutagenic
potential of this lesion. The dNTP frequency of incorporation opposite the double (N72,7 DAM-G-)2 lesion was: dTTP > dCTP > dGTP>>> dATP .
In the case of kinetics of lesion bypass experiment, a

32

(P)-primer having at the

3’-OH a cytosine base-pairing with the opposite guanine-2,7-DAM in the template was
annealed with the 27 mer template, and the kinetics for the next dCTP incorporation
beyond this lesion was determined.

The results suggest a very slow rate for the

incorporation of dCTP opposite the next G after the alkylated-G in the template (see
figure 63).
In contrast, the G-MC-adducted templates were shown in some cases (see figures
65 and 67) the potential for being mutagenic with the following order of frequency of
incorporation of dNTPs opposite the lesion: dATP > dCTP >> dGTP>>> dTTP a result
which is in contrast with earlier findings were the T7exo- and Klenow exo- DNA
polymerases were used in single nucleotide incorporation assays (17-Chapter 1).
In the field of DNA damage bypass these are one of the few examples which
show that the dG-N2-monoadducts fully inhibit the translesion bypass while the dG-N7monoadducts are bypassed by the DNA polymerase eta. These results are opening new
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questions related to the structure of primer/damaged template and their molecular
recognition by eta polymerase.
In order to propose a model that could explain the molecular mechanism of action
of mitomycin C and its derivative 2,7-DAM, computation modeling can be performed to
allow the docking of the primer / (G*) MC or 2,7-DAM alkylated template into the active
site of Klenow fragment, T7 exo- and Dpo4 DNA polymerases (an error-prone
translesion synthesis DNA polymerase proposed to be structurally similar with eta
polymerase). Since both the N7-G-2,7-DAM and N2-dG-2,7-DAM monoadducts are
bulky, it is of interest to perform the first docking experiments using the Dpo4, which is
part of Y family of polymerases, known to be error-prone during translesion synthesis.
Y-family DNA polymerases are believed to replace replicative DNA polymerases that are
stalled at sites of bulky lesions such as those caused by the binding of polycyclic
aromatic hydrocarbon (PAH) metabolites to DNA (46-48). Such adducts, if not repaired,
largely block primer extension by replicative DNA polymerases (47- 49) but can be
bypassed by the Y-family polymerases (50). Most of members of this latter family lack
an intrinsic proofreading exonuclease, exhibit low processivity, and replicate undamaged
DNA with low efficiency and fidelity (48-49). Translesion synthesis by Y-family DNA
polymerases can be error-prone and may result in mutations, which, if present in critical
cell cycle control genes such as oncogenes and tumor suppressor genes, can lead to
cancer initiation (46-49). A bulky DNA adduct at the active site is bypassed more easily
by the Y-family DNA polymerases, and the spacious active site results in a relaxed
geometric selection for the incoming 2'-deoxynucleotide 5'-triphosphate (dNTP) (48, 49),
thus compromising the efficiency and fidelity of DNA replication. The lesion bypass
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ability, accuracy, and efficiency of these polymerases vary significantly and depend on
the type of DNA lesion (46-65).
Crystal structures of Dpo4 with unmodified DNA and the incoming nucleotide
cocrystallized with the protein provide excellent models for investigating the structural
features that determine lesion bypass efficiency and fidelity (41). These structures solved
for Dpo4 showed two modes of entry for a dNTP (45, 46). They can be used to perform
docking experiments of the primer/adducted MC and 2,7-DAM-templates using
molecular dynamics simulation and AMBER 6.0 force-field as used by others to study
details of the interactions between the alkylated templates and the Dpo4-DNA
polymerase which could explain the different translesion synthesis observed in
biochemical assays (41-45).
The translesion synthesis (TLS) on adducted templates containing the adducts N7dG-2,7-DAM and N2-dG-2,7-DAM were performed on constructs containing the N7- dG2,7-DAM (construct 19-scheme 4) and on templates constructs containing N2-dG-2,7DAM monoadduct. Two polymerases were shown the TLS of the N2-dG-2,7-DAM
monoadduct: T7 exo- and Klenow exo- polymerase (figures 60-63). We assumed that
N2-dG-2,7-DAM monoadduct can be located on either of the three guanines in the
template. The ESI-MS (-) data showed the incorporation of one single drug within the
structure. The degree of primer extension for the template adducted with N2-dG-2,7DAM was less efficient than for the templates adducted with N7-dG-2,7-DAM adduct
both with Klenow exo- and T7 exo- polymerase (figures 60-63).

Klenow exo-

polymerase was less efficient than T7 exo- in performing the primer extension reaction
on templates adducted with N2-dG-2,7-DAM lesion. It is important to mention that these
are just global observations with respect to the primer extension reaction and we cannot
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say anything about the bypass of N2-dG-2,7-DAM lesion since we don’t have yet
evidence for the position of the monoadduct within the template.
Further experiments are going on to compare the TLS of N7-dG-2,7-DAM and
N2-dG-2,7-DAM adducted templates using in vitro primer extension and single
nucleotide incorporation performed by DNA polymerase eta (η).

CONCLUSION
In conclusion, the lesion with N7-G-2,7-DAM guanine is bypassed by four DNA
polymerases we have investigated, Klenow exo-, T7exo-, eta, Klenow exo+ and is not
mutagenic. All four DNA polymerases lost thir processivity when it encounters the
lesion during the primer extension reactions as reflected in the accumulation of abortive
products in addition to the fully extended primer product. Thus, the lesion containing one
or two G-alkylated with 2,7-DAM is clearly affecting the normal rate of primer
extension. However, the N7-G-2,7-DAM lesion is bypassed resulting in lower yield for
the final products of primer extension. The results from the in vitro assay of primer
extension are partially in agreement with the “in vivo” experiments which showed the
lack of cytotoxicity of 2,7-DAM monoadducts (9-Chapter 1).
The results from single-nucleotide kinetics experiments suggest a lack of
mutagenicity for the (N7)-2,7-DAM monoadduct since the highest frequency of single
nucleotide incorporation was obtained with dCTP, the normal nucleotide expected to be
incorporated opposite G. This lack of mutagenicity of the N7-G--2,7-DAM monoadduct
is consistent with the new findings which showed that the adduct was only weakly toxic
and generated ~50% progeny as compared to control when it was inserted into an M13
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plasmid and its replication was screened in repair-competent Escherichia coli (9-Chapter
1). No mutant was isolated after analysis of more than 4000 progeny phages from SOSinduced or uninduced host cells; therefore, it was estimated that the mutation frequency
of 2,7-DAM-dG-N7 was less than 2 × 10-4 in E. coli. In addition, to determine if N7-G-2,7-DAM might be mutagenic in mammalian cells, it was incorporated into a singlestranded shuttle phagemid vector, pMS2, and replicated in simian kidney (COS-7) cells.
Analysis of the progeny showed that mutational frequency of a site specific 2,7-DAMdG-N7 was not higher than the spontaneous mutation frequency in simian kidney cells
(9-Chapter 1). Thus, our in vitro experiments of primer extension and single nucleotide
incorporation opposite the N7-G-2,7-DAM lesion are in agreement with these in vivo
findings which are supporting the non-mutagenic potential of this lesion and its lack of
cytotoxicity.
We do not have X-Ray data or molecular models of the MC and 2,7-DAM
adducted templates annealed with primers and any DNA polymerases investigated.
These in vitro biochemical studies raised structural questions related to the structural
factors that may be responsible for the observed differences between the 2,7-DAM-dGN7 adduct 8 and the MC-dG-N2 adduct 7 as replication blocks. The three-dimensional
solution structure of the G-N7 adduct 8 in duplex DNA (18-Chapter 1) indicated that the
drug moiety is not intercalated and lies in the major groove of a relatively nonaltered BDNA structure. In contrast, the mitomycin drug moiety of the G-N2 adduct 7 lies snugly
in the minor groove of duplex DNA (19-Chapter 1). Although solution structures of
primer-template

junctions

at

mitomycin

adducts

have

not

been

determined

experimentally, it was speculated based on the adducted duplex DNA structures above
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that at this junction the Watson-Crick H-bonding interface of the G-N7 adduct in the
template and the incoming dNTP is unobstructed; furthermore, the drug moiety of the
adduct has no tendency to stack with the incoming dNTP and the guanine when this
basepair is formed (9-Chapter 1). Rather, the drug moiety stays out of the way in the
incipient major groove during the TLS step at the active site. In contrast, the H-bonding
interface of the G-N2 adduct in the template is directly obstructed by the bound drug
moiety and formation of the closed conformation of the DNA polymerase is sterically
prevented (9-Chapter 1).
A similar scenario was proposed for earlier precedent, which is analogous to the
present findings (38): The ethylene dibromide-derived bulky glutathione adducts at the
N7- and N2-positions of guanine differ considerably in their behavior in TLS systems of
all four DNA polymerases tested in their system (38). The N7 adduct allowed relatively
efficient full primer extension and selective incorporation of dCTP opposite the adduct,
while the N2 adduct strongly blocked replication and only dATP was incorporated
opposite to the adduct. The authors suggested a similar explanation to what we proposed
above and speculated that the weak blocking effect of the G-N7 adduct is due to direct
interaction of the bulky glutathione residue with the polymerases. On the basis of these
considerations and our present results, it appears that bulky G-N7 adducts, which
intercalate in duplex DNA, inhibit DNA replication and its fidelity while groove-binding
G-N7 adducts are less inhibitory (19-Chapter 1).
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APPENDIX I
1. Synthesis of an internal N7-2,7-DAM monoadduct standard by chemical
reductive alkylation of dG with 2,7-DAM. In order to confirm the structural identity
of the N7-2,7-DAM monoadduct of Guanine, the nucleoside dG (commercially available
) was also alkylated with 2,7-DAM, under the same experimental conditions described
for the oligonucleotide duplex (I) (C6/C7) (see Materials and Methods). In figure 1 the
HPLC reverse chromatography on a C18 analytical column presents the pattern of elution
for the major adducts that are obtained by alkylation of dG with 2,7-DAM, under
reductive conditions. The reverse HPLC was run with an analytically C18 column, 100
angstroms, Microsorb, and the buffer system was: Buffer A: 0.02 M NH4Acetate,
pH=5.5, Buffer B:30% acetonitrile in 70% 0.02 M NH4Acetate. The gradient applied
was 20-60% in 60 minutes, with a flow rate of 1ml/min.

Figure 69 . The reverse-phase HPLC of reaction mixture containing dG alkylated
with 2,7-DAM and free excess of drug. A parallel control was run in which the drug
itself was injected in the column (data not shown), in order to identify the peaks that are
corresponding to the drug.
As can be seen from figure 1, many adducts are formed, the major peaks being eluted at
31.30 minutes, 33.22 minutes, 35.88 minutes and 40.07 minutes. The peaks at 25 and
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49.51 minutes were assigned to the drug itself.

An inspection of the spectral

characteristics showed that the peak at 35 minutes correspond to the N7-G monoadduct
while the peak at 40.07 minutes correspond to another adduct of guanine with 2,7 DAM,
originally identified by Y. Palom as being the N2-guanine monoadduct (23-Chapter 1).
The structure of N7-2,7-DAM monoadduct is presented below (figure 1 (B)) together
with the spectral characteristics that were obtained from the scan (between 200-400 nm)
of the peak at 35 minutes.

Structure and UV-scan of N7-G-2,7-DAM monoadduct at 35.5 min retention time.

(B) The structure and the spectrum of the N7-G monoadduct with 2,7-DAM.
The spectral characteristic of the N7-G monoadduct is the ratio of 1 between the
absorbance at 285 nm and the absorbance at 314 nm. It is important to mention that the
N7-guanine monoadduct have specific characteristics, i.e. by heating it depurinates,
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releasing the dG which has the 2,7-DAM drug covalently linked to the N-7 position in the
guanine ring.

2.

Alkylation

of

duplex

(II)-

5’-CTAGTGGTATCC-3’/(CI)-3’-

TCACCATAGG-5’ (CIII) by 2,7-DAM in the conditions that favors the
production of N7-dG-2,7-DAM and N2-dG-2,7-DAM monoadducts.
5’-CTAGTGG-(2,7-DAM)TATCC-3’-(CI)

F
Figure 70: Semipreparative run of the duplex (II)- 5’-CTAGTGGTATCC-3’/(CI)-3’TCACCATAGG-5’ (CIII) alkylated with 2,7-DAM: hydrogenation: 25 minutes; argon:
90 minutes.
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(B)
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(C)

Figure 71: The purified N2-dG-2,7-DAM adducted C-I-5’-CTAGTGGTATCC3’oligonucleotide analysis by reversed-phase HPLC (A). SVD treatment of pure C-I5’-CTAGTGGTATCC-3’ oligonucleotide for nucleoside analysis. The adduct eluted at
42.56 minutes in (B) shows the UV-characteristics of N2-dG-2,7-DAM monoadduct (C).

138

139

APPENDIX II
In Figure 72 (A) the % adduct area of N7-G-2,7-DAM monoadduct and % of N2dG-2,7-DAM relative to the % of dT is presented as a function of alkylation reaction
time. In general the N7-G-2,7-DAM monoadduct is instable supporting the hypothesis
that it can be decomposed under anaerobic conditions into a reactive species of 2,7-DAM
which can in turn activate the NH2 (N2) position of guanine giving rise to N2-dG-2,7DAM monoadduct.

However, and independent pathway for producing the N2-dG-

monoadduct cannot be excluded. In contrast, the N2-dG-2,7-DAM monoadduct is more
stable and is formed at a slower rate than N7-2,7-DAM monoadduct. Also it can be seen
that other adducts (eventually of guanine-see figure 23 (C) their UV scans) labeled z, w,
W are also formed in parallel with N2-dG-2,7-DAM adduct, possibly competing with the
intermediate reactive species which gives rise also to N2-dG-2,7-DAM adduct.
In Figure 72 (B-C) the SVD treatment of a reaction mix at two different data
points under Argon is presented as an example for the assignment of the adducts N7-dG2,7-DAM and N2-dG-2,7-DAM. In all cases the reaction mix treated with SVD and
alkaline phosphatase is heated to fully release the N7-dG-2,7-DAM. The assignment of
the adducts is performed based on authentic standards of N7 and N2-dG-2,7-DAM and
on their UV-characteristics (figures 20-23 ).
In figure 72 (D) the ratio N7/N2-dG-2,7-DAM is plotted as a function of
alkylation reaction time.

This graph suggests indirectly that N7-dG-2,7-DAM is

converted into N2-dG-2,7-DAM but there are not direct proofs for this mechanism yet.
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(A)

(B)
80 minutes Argon (after 25 minutes hydrogenation)

90 minutes Argon (after 25 minutes hydrogenation)

140

141

(C)

(D)

Figure 72: The progress of a reaction mix during alkylation of DNA duplex (I): 5'CTGG*TAATTTAC-3' (C6 oligonucleotide) / 3'-GACCATTAA-5' (C7
oligonucleotide) under conditions which favor the production of N2-dG-2,7-DAM
monoadduct; hydrogenation time: 25 minutes and Argon: 90 minutes.
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APPENDIX III

Figure 73. Sequencing gel analysis of ligation mix for ligation of a 12 mer
containing 2 guanines alkylated with 2,7-DAM into a 27 mer template (27-merG*G*-(2,7DAM)2) (scheme 4-II).
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[ 5’-CTAGTGG*(2,7-DAM) TATCCTAGAGATTGGTA-3’]
1

2

3

4

5

6

7

8

9

Figure 74. Sequencing gel analysis of ligation products from reactions involving the
ligation of 12 mer adduct alkylated at one guanine with 2,7-DAM at (N7) position
(scheme 4-II).
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APPENDIX IV

Figure 75: Reversed-phase HPLC analytical run for the alkylated 24 mer-G*MC
oligonucleotide digested with snake venom phosphodiesterase and alkaline
phosphatase. The peak at 19.4 minutes corresponds to the nucleoside N2-dGmitomycin C monoadduct which has the structure shown in the inserted UV scan.

Figure 76: Reversed-phase HPLC analytical run for the depurinated alkylated 24
mer-G*-2,7-DAM oligonucleotide digested with snake venom phosphodiesterase and
alkaline phosphatase. The peak at 44.13 minutes corresponds to the nucleoside N7-G2,7-DAM monoadduct (8-figure 1) which has the structure shown in the inserted UV
scan.
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Figure 77: Reversed-phase HPLC analytical run for the alkylated 36 mer-G*MC
oligonucleotide digested with snake venom phosphodiesterase and alkaline
phosphatase. The peak at 21.4 minutes corresponds to the nucleoside N2-dG-mitomycin
C monoadduct which has the expected structure as is shown in figure 75-Appendix IV.

Adducted templates oligonucleotides were digested with snake venom phosphodiesterase
(SVD) and alkaline phosphatase and subjected to HPLC analysis of nucleoside pattern as
described in Materials and Methods (section 2.2.3.3.).
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Figure 78: Analytical Reversed-phase HPLC for the alkylated 24 mer-G*MC
oligonucleotide digested with snake venom phosphodiesterase and alkaline
phosphatase. The peak at 21.2 minutes corresponds to the nucleoside N2-dG-mitomycin
C monoadduct which has the expected structure as is shown in figure 1-Appendix IV.

146

147

APPENDIX V

27 mer-G-2,7-DAM

27 mer control

Figure 79: PAGE analysis of the construct template (15) (scheme 3).

Figure 80: Purity control for the 27 mer-G*(2,7-DAM) and 24-mer–G*(MC) using
PAGE analysis.
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Figure 81. Purity control for the template 27-mer-G*G*-(2,7-DAM)2 [the template
containing 2 guanines each alkylated at 7N position with 2,7-DAM).

Figure 82: Purity control for the template 27-mer-G*G*-(2,7-DAM)2 [the template
containing 2 guanines each alkylated at 7N position with 2,7-DAM]-independent
experiment).
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Figure 83: Purity control for the template 27-mer-G*-(2,7-DAM)2-template
containing 1 guanine each alkylated at 7N position with 2,7-DAM-independent
experiment.

Figure 84: Depurination control for the template 27-mer-G*-2,7-DAM monitored by
high resolution sequencing PAGE analysis. In order to test if the 2,7-DAM alkylated is
depurinated an aliquot of the template was subjected to depurination by heating at 90oC
1 hour and 30 minutes. The sequencing gel presents the original 27 mer-G*-2,7 DAM
template and the depurinated template. It can be seen that the depurinated template
(which lost a G-2,7-DAM) migrated faster than the control template (containing the 2,7DAM drug). This result showed that the template which was subjected to primer
extension and single-nucleotide kinetics assay was not depurinated.
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APPENDIX VI

Figure 85: Pre-steady state kinetics for active site titration of T7 exo- DNA
polymerase (quench flow).
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Figure 86: Pre-steady state kinetics for active site titration of T7 exo- DNA
polymerase (quench flow) (independent experiment).
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APPENDIX VII

Figure 87: PAGE analysis of primer extension on 2,7-DAM-adducted template of
complex 23 by Klenow (exo-) DNA polymerase.

Figure 88: PAGE analysis of primer extension on 2,7-DAM-adducted template of
complex 23 by Klenow (exo-) DNA polymerase.
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Figure 89: PAGE analysis of primer extension on (2,7-DAM-adducted)2 template
of complex 23 by Klenow (exo+) DNA polymerase 250 µM dNTP. At low
concentration of each dNTP the N7-G*-2,7-DAM lesion is not bypassed by Klenow
exo+. Klenow exo- has a higher efficiency of lesion bypass than T7 exo- DNA
polymerase.
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CHAPTER 3
Thermal melting and thermodynamic analysis of stability of a DNA
duplex containing the 2,7-DAM-G-monoadduct
3.1. INTRODUCTION
In order to study the stability of chemically modified deoxyoligonucleotides
spectroscopical methods are primarily used either to gain details of high structural
resolutions, as is the case of nuclear magnetic resonance (NMR) (1-4), either to analyze
the thermodynamic parameters, such as enthalpy, entropy and free energy for the folded
state of the chemically modified DNA duplex (5-21).

We use UV spectroscopy to

investigate the stability of a self-complementary DNA duplex d(G-T-G-G(2,7-DAM)-TA-T-A-C-C-A-C) chemically alkylated with 2,7-DAM in order to determine its
thermodynamic stability by performing reversible melting experiments. It is well known
from other studies of DNA interaction with different drugs, (which are binding either
reversible or chemically to specific bases) that the drug has primarily a destabilizing effect
upon the DNA duplex, most of the time due to the decrease in the level of stacking
interactions (1-10). Since we have already determined the NMR structure of the selcomplementary duplex d(G-T-G-G(2,7-DAM)-T-A-T-A-C-C-A-C) and we knew that the
drug is oriented in the major groove, but without being intercalated within the DNA bases
(19-Chapter 1) it was interesting to perform melting studies which could reveal the
stability of the DNA duplex.

This chapter presents the original contribution to the

thermodynamic analysis of melting of a DNA duplex containing 2,7-DAM alkylated on
N7-guanine. The duplex containing alkylated guanine had lower thermal stability and a
160
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more favorable enthalpy but much less favorable entropy in the duplex state, relative to the
nonadducted parent duplexes.

3.2. MATERIALS AND METHODS
3.2.1. UV Spectroscopy and Melting Studies.
Oligonucleotide concentrations were determined using formula: 260(strand) = number of
purines × 14 000 + number of pyrimidines × 7000. In the case of the alkylated
oligonucleotide a correction for 260(strand) was done by adding 5189 ( 260 of 2,7DAM). 260(duplex) was assumed as equal to 2 × 260(strand). The

260

for the duplex of

the nonalkylated oligonucleotide was 252,000 M-1 cm-1 while the 260 for the alkylated
duplex was 262, 378 M-1 cm-1. The concentration of the oligonucleotide (strand) was 2.2
M in all melting experiments. The synthesis of the alkylated DNA self-complementary
duplex used in melting studies was performed according to published data (18-Chapter
1).

Thermal melting curves at 260 nm were determined using a Cary-3

spectrophotometer. Temperature control was obtained through a jacketed cell holder
connected to a water bath and controlled by the software of the Cary-3. The samples were
heated gradually in stoppered cuvettes of 1 cm path length. The temperature range was
20-85

C. The data were acquired with 0.8 C increments/min at each 15 s, such that a

total of 260 data points were acquired for each sample. The melting curve data were fitted
by sigma plot nonlinear regression analysis to a sigmoid curve. Three independent
experiments were carried out on each sample, and the resulting Tms were averaged.
Immediately prior to analysis the samples were incubated at 60
slowly cooled at room temperature to provide the annealing.
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C for 3 min and then
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3.2.2. Thermodynamic Analysis of the Melting Curves. Melting temperature
Tm and the thermodynamic parameters that characterize the helix-coil transition of the
DNA duplexes were determined by employing the built-in Cary-3 software. The method
of choice for the calculation of the thermodynamic parameters was direct application of
the van't Hoff equation (21).
Our chosen method for the analysis was the direct application of the van’t Hoff equation
(22, 23). Using this analysis of the melting curves, an important assumption was made,
that for a dodecamer duplex the melting process is bimolecular, corresponding to the
duplex-coil melting transition. The Cary-3 software is creating first the curve α(T) (the
fraction of the duplex that remains in the initial state, in this case in the duplex form, at
temperature T. The plot α(T) versus T is generated using the slopes (m) and intercepts
(b) from the fitted baselines as follows:
α(T) = [Au(T)-A(T)]/[Au(T)-AL(T)]=[muT+bu-A(T)]/[(mu-mL)T+bu-bL]
where Au(T)= muT+bu and AL(T) = mLT + bL
The Tm is defined as the temperature at which α=0.5. The association constant K(T) is
calculated using the formula K(T) = α(T)/nCn-1[1-α(T)]n; were C represents the total
concentration of the duplex (in this case for the self-complementary duplex was 1.1 µM
for both free and the alkylated oligonucleotide. A plot of lnK(T) versus 1/T is used to
determine ∆H0 = -RδlnK(T)/ δ(1/T). The free energy change associated with the melting
transitions is also determined from the van’t Hoff equation using the formula:
∆G0 = ∆H0 / R (1/T-1/Tm) + (n-1)ln(nC/2).

The values for the entropy change is

determined using the formula ∆G0 = ∆H0 - Tm∆S. In these equations “n” represents the
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number of molecules (strands) in equilibrium with the duplex.

In the case of the

bimolecular process, n=2.
Independent of the built-in software, the Nonlinear Regression analysis of the
Sigma-Plot software was used to fit the melting curves to a sigmoid curve with 4
parameters [f=Y(0) + a/[1+exp(-(X-X(0))/b] where the independent and the dependent
variables are as follows:
X(0)= the value of X for the Y value 50% of the distance from the minimum to the
maximum of smoothed data for the sigmoid shaped curve.
Y(0) = min (Y) =minimum of Y of the smoothed data for the sigmoid shaped curve.
A = max (y) – min (y) = the distance from the minimum to the maximum of smoothed
data for the sigmoid shaped curve.
b = X(75)-X(25) = the region of the sigmoid curve where Y varies linearly with X.
X(75)= the X value for the Y value 75% of the distance from the minimum to the
maximum of smoothed data for a sigmoid curve.
X(25) = the X value for the Y value 25% of the distance from the minimum to the
maximum of smoothed data for a sigmoid curve.
The statistical analysis of Sigma Plot was used to assess the goodness of the fit.
Each independent fit was used to determine Tm.

The Tm values determined from

Nonlinear Rgression of the melting curves were within 1% errorwith those determined
using the software provided by Cary-UV spectrophotometer assuming a two-state
transition model for the melting curves.
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3.4. RESULTS
3.4.1. Synthesis of 2,7-Diaminomitosene Adducts with d(G-T-G-G-T-AT-A-C-C-A-C) for melting studies.
We synthesized the 2,7-diaminomitosene adduct with d(G-T-GG(4)-T-A-T-A-CC-A-C) (duplex III) and purified it using reverse-phase C18-HPLC. The G4-position as
the adduct site was established as described in the Materials and Methods section 3.2 (see
Appendix VIII for HPLC analysis of oligonucleotide d(G-T-G-G(4)-T-A-T-A-C-C-A-C))
. This adduct complemented with itself as observed by imino proton resonances in the
NMR spectrum run in H2O (19-Chapter 1). The self-complementary duplex was used in
the melting studies.

3.4.2. Melting Studies and Thermodynamic Analysis of the Melting
Curves. One potential problem that arises in the case of guanyl-N7 adducts is
sensitivity toward thermal depurination (1-18, 28). To minimize the experimental
artifacts due to this effect, melting experiments were conducted such that the temperature
increase was relatively fast (0.80

C min-1) to avoid excessive incubation at each

temperature step, although in a range acceptable for short oligonucleotide duplexes.
Figure 1 presents the melting curves of the control duplex and 2,7-DAM-adducted duplex
III. Depurination was not significant, as seen by their complete reversibility and by
HPLC analysis of the melted sample (data not shown). The melting temperatures are
lower for the alkylated duplex III (two adducts per duplex) as compared with the control,
with

Tm = 8.90 ± 0.70

C. The reduction in the thermal stability of other

nonintercalating N7-guanyl adducts is in the range of ~11

C (27), which is not far from

that found for the 2,7-DAM adduct. The hyperchromicity for the nonadducted duplex was
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15.5% while that for the adducted duplex III was 7.6%. The lower hyperchromicity of the
adducted duplex could be due to helical perturbations centered about the adducted bases.
The shape of the melting curves is compatible with a two-state cooperative transition
between the helix and the coil states both for the nonalkylated and for the adducted
duplexes.

The results of van't Hoff analysis of the melting curves based on this

assumption are presented in Table 1. The transition enthalpy for the adducted duplex III
facilitates duplex formation by -29.4 kcal/mol over that of the parent counterpart, while
the transition entropy is less favorable, as a difference of -98 cal mol-1 K-1 was observed.
In the case of other major groove-located guanyl-N7 adducts the thermodynamic analysis
of melting curves also showed that enthalpy of the alkylated duplex is more favorable,
while the entropy is less favorable, suggesting that the decrease in the thermal stability of
the adducted duplex is due to the entropic component (27, 28). It has been also speculated
that the more favorable coil-to-helix transition enthalpy of the adducted duplex may be
due to the positive charge imposed on the imidazole ring by N7-guanine alkylation (28).
The

G of the coil-to-helix transition of the adducted duplex is only slightly lower than

that of the parent duplex (

G

25

C

= -0.3 kcal/mol); this is also analogous to the other

G-N7 alkylated oligonucleotides (27, 28).
Table 5: Effect of the 2,7-DAM-Guanine-N7 Adduct 4 in the Self-Complementary
d(GTGGTATACCAC) Adduct Duplex 5 on Thermal and Thermodynamical Duplex Stability,
Spectroscopically Determined Tm, and Calculated Changes of the van't Hoff Transition Enthalpy
( H ), Entropy ( S ), and Free Energy ( G25 ) for the Coil-to-Helix Transitiona

Oligonucleotide

Tm ( C)

d(GTGGTATACCAC)

H

(kcal/mol)

S (cal
mol-1 K-1)

G

25

C

(kcal/mol)

51.0 ± 0.4

-49.2 ± 2.0

-125.7 ± 5.9

-11.7 ± 0.2

d(GTG[M]GTATACCAC)
42.1 ± 0.4
(III)

-78.6 ± 6.1

-223.2 ± 1.9

-12.1 ± 0.3

b
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a

The thermodynamic parameters were extracted from the melting curves (figure 1) by
direct application of the van't Hoff equation (21) using the Cary-3 software.b [M]G
denotes the adducted guanine residue (see also Appendix IX for details of
thermodynamic analysis using the built-in software provided by Cary-UV-Visible
spectrophotemer).

Figure 90: The melting curves for the parent and the alkylated (G-T-G-G(2,7DAM)-T-A-T-A-C-C-A-C). The details for running of melting studies are described in
specific methods section (see also Appendix IX for thermodynamic analysis of melting
curves using the Cary-UV-Visible built-in software).

3.5. DISCUSSIONS AND CONCLUSION
This original study of thermal stability of the 2,7-DAM-DNA duplex III (Figure 67 and
Table 5) reveals properties of adduct duplex III strikingly similar to those of duplexes
containing simpler nonintercalating guanine-N7 alkyl groups: lower thermal stability and a
more favorable enthalpy but much less favorable entropy in the duplex state, relative to the
nonadducted parent duplexes (28). On the other hand, the guanine-N7-aflatoxin B1 adduct,
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in which the drug moiety is intercalated, shows increased thermal stability, characteristic
of intercalated adducts (29). A structural feature of the adduct duplex III, namely,
confinement of the G-N7 (+) electrostatic interaction in the groove of the duplex (see
reference 18 and figure 2 in Chapter 1), is consistent with the observed decrease of
transition entropy resulting in decreased thermal stability over that of the parent duplex.
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A (260 nm)

A (320 nm)

APPENDIX VIII

Time (minutes)

Figure 91. HPLC analysis of self-complementary oligonucleotide
d(G-T-G-G(4)-T-A-T-A-C-C-A-C)) used in thermal melting studies
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APPENDIX IX
Table 6: Thermodynamic analysis of melting curves using the Cary-UV-Visible
built-in software. (Tm is the melting temperature for the nonalkylated (nonalk) or
for the alkylated DNA (alk)).
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PART II
Structure-based design, synthesis, structure-conformation and
structure-activity relationships studies of
D-Phe-Pro-D-Arg-P1’-CONH2 tetrapeptides with
inhibitory activity for thrombin
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ABSTRACT
This original research part II of the thesis presents the structure-activity relationship
(SAR) of tetrapetides from series D-Phe-Pro-DArg-P1’-CONH2 with reversible
inhibitory activity toward thrombin. The P1’ position was varied with D and L amino
acids. The significant differences between the inhibitory constants (Kis) of tetrapeptides
from the series D-Phe-Pro-D-Arg-P1’-CONH2 suggest that the interaction between the
amino acid at P1’ position and the S1’ subpocket in thrombin is very specific. There is a
2 to 500 fold experimentally determined difference between the Kis of different peptide
inhibitors and our in vitro inhibition assay for thrombin proved that the P1’ position
requires small hydrophobics and polar amino-acids. In addition, there is a significant
change in the affinity for interaction with thrombin as the configuration for the same
amino-acid in P1’ position is changing from L to D. Specifically, a switch from L-Thr
into D-Thr in P1’ was correlated with a 13 fold increase in the inhibitory activity.
Similarly, a switch from L-Ala to D-Ala in P1’ was increasing the affinity 8 fold. These
differences in the binding affinities upon switching from L into D of amino-acids in P1’
were confirmed both kinetically and through isothermal titration calorimetry (ITC). In
the case of ITC the heat released upon binding to thrombin for peptides with L-Ala in P1’
is lower,1.2 kcal/mole of injectant, than the heat released during the titration of the same
peptide into thrombin but with D-Ala in P1’, 6.5 kcal/mole of injectant. The structural
basis for this favorable switch in the affinity was further investigated through molecular
modeling of docked peptides into the thrombin template 1ABJ.pdb. The results from
molecular modeling suggest that the D-Thr in P1’ forms different hydrogen bonds with
specific amino-acids from the insertion loop and the S1’ subpocket of thrombin which are
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lacking in the analog peptide containing L-Thr in P1’.

The extra hydrogen bonds

between the peptide ligand and the amino acids side chains from the active site of
thrombin might be responsible for the observed increased affinity for peptide containing
D-amino acids in P1’. These results strongly support our original structure-based design
of peptides as reversible inhibitors for thrombin and provides a new lead peptide
inhibitors which can be used to design further more potent anticoagulants.
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INTRODUCTION
The vascular system, in the healthy state, is under the strict homeostatic control of the
coagulation system. The soluble component of the coagulation system, known as the
coagulation cascade, is comprised of a series of soluble proteases and their regulatory
cofactors (Figure 92). Alpha-thrombin is the last enzyme of this cascade that converts
fibrinogen to fibrin I and fibrin II by limited proteolysis. Alpha-thrombin is generated by
the proteolytic cleavage of prothrombin by the prothrombinase complex which includes
factor V, a phospholipid surface, and factor Xa, the serine-protease immediately
preceding thrombin in the coagulation cascade. In the presence of Ca2+, alpha-thrombin
is also involved in the activation of factor XIII to generate factor XIIIa. Factor XIIa
stabilizes the blood clot by cross-linking fibrin through Nε -(γ-glutamyl)lysine transamide
bridges.

The polymerized fibrin forms the general scaffold for the growth of the

thrombus.
The enzymatic activity of thrombin is known to be crucial not only for the arrest of
blood flow but also for the ensuing growth of the thrombus. Therefore, the inhibition of
the enzymatic activity of alpha-thrombin is considered a viable mechanistic approach for
the development of anticoagulant inhibitors (figure 92, (1-13)).
Alpha-thrombin is a prolate ellipsoidal glycoprotein molecule made up of a short A
chain (36 residues) and a long B chain (259 residues) cross-linked by one disulfide bond.
Amino acids Ser195, His57, and Asp102 (chymotrypsin numbering system) form a
catalytic triad, which is integral to the catalytic activity of all serine proteases. These
residues are located at the entrance to the substrate binding pocket, and their geometry is
stabilized by hydrogen bonds.

Serine proteases hydrolyze peptide bonds via the

formation of tetrahedral state intermediates.
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Stabilization of the transition state

177
intermediate occurs through the formation of hydrogen bonds between the oxyanion
intermediate and the amido groups of residues Gly193 and Ser195. The substrate binding
sites in the enzyme involved in precise interactions are referred to as Sn, …S3, S2, S1,
S1’, S2’, S3’, …Sn’ sites, and the amino acid residues of the substrate or inhibitor that
occupy these sites are referred to as Pn, …P3, P2, P1, P1’, P2’, P3’,…Pn’, respectively.
These complementary sites were shown through many X-Ray structures of thrombin with
peptide-derived inhibitors to allow the specific alignment of the substrate/inhibitor with
the catalytic triad and the oxyanion hole for enzymatic specificity (14, 15). In trypsinlike serine proteases, Asp189 is at the bottom of the primary S1 susbstrate binding site,
and forms a salt bridge with the guanidino group of P1 Arg residues in the
substrate/inhibitor.

Thrombin is a serine-protease with Arg-Xxxx or Lys-Xxxx

specificity at P1 position within the substrate sequence H2N…-P3-P2-P1-P1’-P2’-P3’…COOH with preference for arginine (were P1-P1’ represents the scissile bond). The
molecular basis for the enhanced affinity for arginine has been elucidated by Bode et al.
(14). A large majority of the active site-directed synthetic inhibitors contain guanidino or
an amidino groups to mimic the interaction of the natural substrate with the enzyme (1520). The charged guanidine or amidino groups form strong ionic interactions with the
carboxylate group of Asp189 in the specificity pocket of the enzyme (S1) (14, 17-20).
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Figure 92: The coagulation cascade showing the intrinsic and the extrinsic pathways
together with the most important serine-proteases involved in blood clotting (5).
As can be seen from Figure 92 thrombin is the last in a cascade of trypsin-like plasma
serine-proteases, which by catalyzing the conversion of fibrinogen to fibrin, activation of
FXIII and inducing platelets aggregation is a key enzyme in haemostasis and thrombus
formation.
It has been a long term goal in antithrombotic therapy to design and discover drugs
that could inhibit thrombin directly and could provide better efficacy and safety as
compared with other antithrombotic drugs such as heparin and coumarins (16). Potent
and selective inhibitors of thrombin were originally designed based on the D-Phe-ProArg sequence. Two major small molecular weigh inhibitors were emerging as lead in the
structure-activity relationship for thrombin. The first is of the argatroban and NAPAP
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type (Scheme 7). The reactivity of thrombin toward peptides of arginine chloromethyl
ketone and peptide substrates is also highly dependent on the nature of the amino acids
residues in the flanking peptide sequence (P2 and P3 binding sites). The most effective
inhibitor of thrombin in the chloromethyl ketone series is H-(D)Phe-Pro-ArgCH2Cl,
which, when compared with other arginine chloromethyl ketones, indicates differences in
reactivity greater than 4 orders in magnitude obtained by variations in amino acid
residues in the P2 and P3 residues. In the above mentioned sequence ((D)Phe-Pro-Arg)
the P1=Arg, P2=Pro, and P3=D(Phe) (15-20).
Another well known class of inhibitors of alpha-thrombin are peptides containing αaminoboronic acids with neutral side chains. These boronic acid based inhibitors are
highly effective, slow binding, having association constants in the order of pM range.
One of the most known boronic acid derivative with anti-coagulant activities is Ac(D)Phe-Pro-boroArg-OH.

The mechanism of inhibition by boronic acids has been

already elucidated, and involves the formation of tetrahedral complex with the active site
serine in a manner analogous to that expected for the tetrahedral intermediate formed
during normal substrate hydrolysis. However, the synthesis of boronic acids peptides
requires a complex procedure, and only few laboratories in the world are involved in this
synthesis, making the cost of these anti-coagulant drugs being high (21-26).

Also,

clinical administration of these drugs have shown secondary effects, like severe
hypotension in some cases and respiratory depression (21).
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Scheme 7: Major types of thrombin inhibitors (14-19).

One of the most recently developments in the field of rational drug design with anticoagulant activities involves the molecular design of peptides or small molecules that can
reversibly bind to the active site of thrombin or other coagulation factors (mostly targeted
being factors VIIa, IXa, Xa) and thus can have a competitive type of inhibition (27-29).
The struggle is for designing and development of reversible inhibitors with nanomolar
and even picomolar association binding constants. These peptides which mimics the
natural substrate have the advantage that are soluble in H2O and thus can pass different
physiological barriers, as compared with mostly small organic molecules or other small
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derivatives of peptides with anti-coagulant properties (like chloromethyl ketones) which
are less soluble in H2O and thus their utilization is limited (28-31).
One of the most powerful tool in finding small peptides (less then 15-20 amino
acids) as possible reversible inhibitors of thrombin or other targeted coagulation factors is
the commercialized phage display libraries. The advantage of using the commercialized
kit of the phage display is that multiple libraries can be screen fast such that the
probability of finding a sequence of amino acids with effective inhibition toward these
class of serine proteases is increased (32-38). One very important aspect of this approach
is that if no specific selection is applied, the probability of finding active-site directed
binding peptides is decreased (38-40).
The disadvantage of using such phage-display libraries is that no D-amino acids
can be incorporated in these peptides naturally displayed by the phage, so the sequence
“space” that can be actively involved in the inhibition process is limited. Thus, Phage
Display Libraries can be used in parallel with the molecular design or structure-based
design (SBD) strategies that are using docking experiments coupled with combinatorial
chemistry approaches (41-45).

Using synthetic methods the amino acids sequences

containing D-amino acids can be further explored for their potential anti-coagulant
activities (46-53).
The Structure-Activity-Relationship (SAR) for designing and development of
peptides with anti-coagulant activities can be presented schematically in the Figure 93.
The major goal of this research was focused on designing and development of new
peptides reversible inhibitors for thrombin. Our major experimental approach involved a
combination between computational modeling (using the docking software “SCULPT”),
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combinatorial chemistry applied to solid phase synthesis of peptide libraries and in vitro
screening of peptides for their inhibitory activity toward thrombin.

Figure 93: Strategy employed for finding peptides inhibitors of thrombin.
Based on the strategy of discovering of peptides inhibitors presented in figure 2
molecular modeling provides the information for chemical synthesis of peptides and
experimental evaluation of the inhibitory constant. Initially, a defined criteria (such as
the predicted free energy of interaction between thrombin and different peptides) was
used to generate “leading compounds” groups from molecular docking experiments. This
process can work in parallel with the selection of phage display libraries from where a
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specific peptide sequence can be chosen to increase the reliability of the computational
modeling. This sequence is supposed to prove a very good inhibitory potential (lower
µM – nM range).

The major criteria for selection of leading compounds from

computational modeling is the based on the predicted free energy (∆G) of interaction
between the designed peptides and the enzyme of interest (like thrombin or other
coagulation factors). The free energy criteria assumed that energies which are below “–
50 kcal/mol” are predicting a very tight interaction between the docked ligand and the
protein of interest (in the order of nM and pM range) (54-58). However, a critique
evaluation of these values of the predicted free energies of interaction should be
considered since the accuracy of this prediction varies from one software to another and
depends on the type of force-field is implemented in the docking software (54-65). It is
well known from the field of structure-based design (SBD) that the initial docking
experiments are based on the sterical fitness between the ligand and the active site of the
targeted enzymes. Thus, the van der Waals and Lenard Jones potentials dominate the
free energy functions which are used to describe the binding of ligands to the protein
targets during first stages of “crude” docking (55, 57, 60).
The X-Ray crystallographic studies of human alpha-thrombin complexed with
hirudin and synthetic peptide inhibitors have revealed many details of thrombin-inhibitor
interactions at the molecular level. For example hirudin, produced in the salivary glands
of the blood sucking leech Hirudo medicinalis, prevents the clotting of ingested blood
and is the most potent natural thrombin inhibitor with a Kd reported as low as 20fM.
Hirugen and hirulogs are examples of peptide inhibitors designed to mimic thrombinhirudin interactions. The crystal structure of an enzyme / ligand complex is a very good
target for the design of new inhibitors. However, the possible lack of correspondence
183

184
between the crystal structure and the dynamic structure of the interacting species in
solution, at the same time scale as the biochemical reactions is a major concern in
inhibitor design (41, 42, 47, 57, 59).
It is important to use more than one single software in docking experiments till
the validation of new leading group compounds is reliable (60). As an alternative, if one
single docking software is used in the beginning of the in silico screening of a large
number of compounds then the docking experiments have to be performed by using
independent templates having high atomic resolution of their X-Ray solved structures (<
2.5 Å) (55, 59, 61).
This original research thesis presents the structure-based design rational of small
peptides reversible inhibitors for thrombin together with the structure-activity
relationship derived from in vitro kinetics of thrombin inhibition, thermodynamic
analysis of binding of lead peptide to protein target and from more advanced structural
investigations such as 2-D-transferred NOESY experiments.

We used the docking

software SCULPT provided by MDL (66) to perform all the docking experiments and we
assessed the free energy of interaction between the peptides and thrombin using the builtin advanced molecular mechanics force-field (MMFF) (56, 58). The docking of all
peptides of well defined sequences was done using the same template protein with known
3D structure, 1ABJ.pdb. However, it was assumed that the active site can have minor
perturbation in the conformation from one 3D structure to another.

Thus, in later

experiments more than one template was used in docking experiments (such as 1AI8.pdb,
1HAI.pdb). All the templates used in docking experiments were characterized by high
atomic resolution of their X-Ray structures (<2.5 Å) and by less than 0.5 Å rsmd (root
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mean square deviation) between the backbone and the side chains of the most important
amino acids involved in ligand binding.
As presented in figure 93 a feedback from combinatorial chemistry and in vitro
screening of lead compounds for their inhibitory activity against thrombin increased the
accuracy of SAR for the predicted models from docking experiments and speed the SAR
at specific variable positions P1’, P2’ and P3’ within the original designed peptide
sequence (1)-D-Phe-Pro-Arg (P1)-D-Pro(P1’)-P2’-P3’-CONH2.

Originally a well

defined SAR was found for the two sequence spaces which were investigated (1)-D-PhePro-Arg (P1)-D-Pro(P1’)-P2’-P3’-CONH2 and (2)-D-Phe-Pro-D-Arg(P1)-P1’-P2’-P3’CONH2 as derived from the in vitro kinetics of thrombin inhibition.

Both peptide

sequences showed inhibition of thrombin activity in an in vitro assay using the S2238 (HD-Phe-Pip-Arg-pNA) as substrate. New lead compounds emerged from these two major
sequences and new peptide libraries were designed by maintaining constant the tripeptide
D-Phe-Pro-D-Arg- and varying P1’ position with amino acids analogs of Phe.
Synthesis of individual peptides and libraries of peptides was performed using Fmoc manual synthesis of amide-tetrapeptide libraries on a Rink-Amide resin
incorporating phenylalanine (Phe) or Phe analogs in the P3 position such as trans/(cis)
cinnamic, dihydrocinnamic acids, D-Naphthylalanine (D-Nal), Phe constrained analog
1,2,3,4- (D)-tetrahydroisoquinoline-3-carboxylic acid [(D) Tic], 3-amino-2-naphtoic acid,
D-3,3-diphenylalanine, D-3,5-difluorophenylalanine, D-3-benzothienylalanine, (R, S)-3amino-3(1-naphtyl)-propionic acid and 1,2,3,4-tetrahydronorharman-3-carboxylic acid.
The libraries were obtained using the partition-mixing procedure coupled with parallel
synthesis. Ten variation in the P1' position were performed using natural and un-natural
amino-acids that were shown very good inhibitory activity for thrombin in the sequence
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space DPhe (P3)–Pro (P2)–DArg-P1', i.e. P1' = D-Ser, D-Cys, D-Ala, L/D-Thi, D-3benzothienylalanine, D-His, D-Pro, D-Thr, D-Asn and D-Gln. The trans-isomers of the
cinnamoyl-tetrapeptides were at least five fold more active than the cis-cinnamoyl
isomers while the release of double bond constrain through dihydrocinnamic acid had at
least two fold better activity than the cis-isomers but less activity than the trans-isomers.
In addition the L-Thi was used to scan positions P2 and P1’. The new inhibitor D-PhePro-DArg-(L)Thi has a Ki of 8.6 µM and was discovered as being a new lead compound
in the series D-Phe-Pro-D-Arg-P1’, containing an unnatural amino acid analog in the P1’
position. The order of activity for the peptides containing analogs of Phe in the P3
position is D-Nal > D-Phe > Dihydrocinnamics > Transcinnamic > D-Tic > L-Tic >
ciscinnamics >>tetrahydroharman acid-compounds with conserved residues at P2=Pro
and P1=D-Arg and variable L/D- amino-acids at P1'.

Lead compounds having the

experimentally determined inhibitory constant (Ki) between 16.5 –0.9 µM are potential
competitive inhibitors for thrombin. In order to predict if the peptides with constrained
conformation are more potent inhibitors the advanced MM3 force-field was used to
minimize individual tetrapeptides and the backbone dihedral angles phi and psi were
predicted to favor in most cases beta turns and beta hairpin conformation.

Circular

dichroism investigations suggests that the D-Arg- in i+2 position followed by D-amino
acids (polar and neutral like D-Thr, D-Gln, D-Ser and D-Ala) or L-Pro in i+3 position
favor beta turn or alpha helix structures in solution at low and neutral pH. Replacement
of D- with L-amino acids in i+3 position was accompanied by a significant lost in the
beta turn or alpha helix structure with a shift toward a disorganized structure. Also, the
aromatics (L-Phe, L-Tyr and L-Trp) in i+3 position are disturbing the beta structure
while the replacement of D-Phe with L/D-Tic is accompanied by a shift toward beta186
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strand-like structure. SAR (structure-activity relationship) suggests that tetrapeptides
which adopt beta turn - beta hairpin or alpha helix conformation in solution are more
active toward inhibiting thrombin.
In addition, isothermal titration calorimetry (ITC) was used to determine the
thermodynamic of binding of peptide inhibitors to thrombin. Both enthalpic and entropic
factors are predicted to be important contributors for the free energy of binding between
the peptides and thrombin as determined from ITC data suggesting that the hydrophobic
interactions together with hydrogen bonding are governing the ligand affinity for
thrombin. The ITC results were in agreement with the kinetics of thrombin inhibition
with respect to the experimentally determined association constant, mostly in the order of
10-0.8 µM for the best inhibitors.
2D-transferred NOESY experiments were used to further assed if the peptide
inhibitors are binding to the active site. Binary complexes between the peptides D-PhePro-D-Arg-Gly-CONH2, D-Phe-Pro-D-Arg-Ala-CONH2 and thrombin and ternary
complexes between these peptides-thrombin-thromstop (low nM inhibitor) were showing
building-up of negative NOEs in complexes between thrombin-peptides while the
presence of thromstop inhibitor decreased the negative NOEs in ternary complexes.
These results are the first structural evidence for peptides binding more than 80% to the
active

site

of

thrombin

in

the

absence

of

any

X-Ray

data.

The original SAR presented at P1’ position in the sequence space D-Phe-(P3)–Pro-(P2)–
DArg-P1'-CONH2 is the first independent evidence for the a specific amino acids
requirements in P1’, such as polar (L-Ser, L-Thr, L-Cys), small (Gly, Ala, Val) or bulky
hydrophobics (L-Ile, L-Thi).

An independent group of investigations (67) showed

through X-Ray experiments that the P1’ position can be occupied by bulkier groups (such
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as L-Ile and L-Thi) than expected from the natural substrates for thrombin (i.e. Gly, Ala,
Val, Ser or Thr) since the side chain of Lys60F, which defines the S1’s subpocket is
displaced significantly and is forming a large nonpolar S1’ subsite to accommodate the
bulky P1’ residue (67).

Our SAR studies for the P1’ position showed that there are

significant differences in the binding affinity for thrombin of tetrapeptides from the series
D-Phe-Pro-D-Arg-P1’-CONH2 (ranging from 5-500 fold) suggesting that the interaction
between the amino acid at P1’ position and the S1’ pocket in thrombin is very specific
tolerating only a limited type of amino acids as described above (67). In addition, there
was a significant change in the affinity for interaction with thrombin as the configuration
for the same amino-acid in P1’ position is changing from L to D. Specifically, a switch
from L-Thr into D-Thr in P1’ was correlated with a 13 fold increase in the inhibitory
activity. The structural basis for this favorable switch in the affinity was further
investigated through molecular docking and modeling. We found that D-configuration,
at least in the case of D-Thr at P1’ position allows more favorable hydrogen bonding
networks to be established between the peptide-ligand and side-chains within the the
active site of thrombin. This research study is presenting molecular docking experiments
which support the hypothesis that tetrapeptides differing in one single amino acid at P1'
position adopt different conformations into active site of thrombin which may be part of
the factors determining the significant differences between their inhibitory potential.
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Chapter 1
Molecular docking and structure-based design of peptides with
potential inhibitory activity against thrombin
1.1. Rational selection of thrombin-templates for docking
Our major goal was to design new peptide inhibitors directed toward the active site of
thrombin, such that a competitive inhibition could be obtained. The availability of many
crystallographically determined complexes of thrombin with the modified tripeptide
PPACK (D-Phe-Pro-Arg-chloromethylketone) provided the 3D structure as target for
docking of new peptide inhibitors, a process known in the field of drug design and
discovery as Structure-Based-Design (SBD) (41-55). The major structural features of the
active site of thrombin are conserved in between many crystallographically determined
complexes thrombin/inhibitors. These major structural features refer to the aryl binding
pocket (S3 pocket) largely defined by Trp 215, Leu99, Ile174, Tyr60A and Trp60D. In
all PPACK/thrombin complexes the amino acid from the P3 position (D-Phe) is docked
into the S3 pocket. The P2 fragment (Pro) is inserted into the hydrophobic pocket (S2
pocket) defiend by the Leu59-Asn62 insertion loop of the enzyme. The side chain of the
P1 group (Arg) is inserted into the specificity pocket (S1 pocket) and forms the salt
linkages with Asp189 of the enzyme. The S1 pocket of alpha-thrombin is known to be
very similar to that of trypsin-like enzymes. The pocket is enclosed on one side by
residues Gly 216-Gly 219 in a twisted beta-strand arrangement in relation to the arginine
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side chain of the inhibitor. The pocket is closed off at the bottom by the Asp 189 which
is involved in salt bridges to the guanidine group of the P1 arginine residue. This latter
interaction provides a significant fraction of the binding energy for the inhibitor. The
pocket is closed on the other side by residues 190-193, forming an irregular strand. Gln
193 folds over the P1 side chain and closes the pocket in the front. The back part of the
pocket is enclosed by the side-chains of Tyr 228, Leu 160, Val 138, and Ala 190.
Thrombin has also the unique insertion loops B (Tyr60-A-Ile60-I) and C (Thr149-AAla149-E), contributing to the specificity of substrate binding (68-70).

It was already

shown earlier that Lys60F side chain excludes bulky amino acids at the P1’ position
(mutagenesis studies revealed that the replacement of Lys-60-F with Ala enhanced the
affinity of the bulky amino acids such as Leu at P1’) (83). The P2’ position in the natural
substrates and peptide inhibitors for thrombin is very diverse tolerating Phe, leu, Val, Ile,
Pro, Gly, His, Glu and Asn; however, the kcat/Km of synthetic substrates showed a
preference for bulky hydrophobic P2’ residues such as Phe and Trp with a total exclusion
of acidic amino acids such as Glu and Asp (80-86). P3’ position in substrates and
inhibitors is very diverse, tolerating Arg, Asn, His, Leu, Gly and Asp; however the higher
catalytic efficiency of thrombin (highest kcat/Km) was determined for basic and bulky
hydrophobic amino acids, while the acidic amino acids Asp and Glu were excluded from
P3’ position (70-75).
Originally the PDB (Protein Data Bank) (Brookhaven) was searched for X-ray
complexes between thrombin and different small peptide or non-peptidic derived
inhibitors and more than 300 solved structures were retrieved (including NMR
structures).
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The selection of thrombin templates used in the docking experiments was determined by
the accuracy of the X-Ray structures based on screening of the structural data through
PROCHECK data base (PROCHECK v.3.5.40). This data base is presenting the main
structural features of the X-ray structure as specific plots such as Ramachandran plot,
Ramachandran plots by residue type, Chi1-Chi2 plots, main-chain parameters, side-chain
parameters, residue properties, main-chain bond length distributions, main-chain bond
angle distributions, RMS distances from planarity, distorted geometry plots. The main
parameters checked by PROCHECK for each input of X-ray data are: covalent geometry,
planarity, dihedral angles, chirality, non-bonded interactions, main-chain hydrogen
bonds, disulphide bonds, stereochemical parameters, parameter comparisons, residue-byresidue analysis. For docking experiments we used 3-5 protein templates based on their
overall atomic resolution (below 2.5 Å) and their specific structural accuracy of thrombin
active site subpockets S1’, S2’, S3’ (73). The subpockets S3, S2, S1 of thrombin are well
solved at atomic resolution in most the structures containing small peptides or nonpeptides inhibitors which are occupaying just these subpockets. However, the S1’, S2’
and S3’ subpockets are not solved at high atomic resolution in some thrombin complexes
with small molecules inhibitors (68-86).

The complexes of thrombin with bivalent

inhibitors are the best templates for those docking experiments which require testing of
additional binding sites for the inhibitor at S1’, S2’ and S3’, i.e. were the specificity of
residues at P1’, P2’ and P3’ in the peptide inhibitor is the major subject in SAR studies.
In these complexes of thrombin and bivalent inhibitors the ligands are derived from
PPACK and are blocking the S3, S2, S1 pockets within the active site but contain in
addition a –(Gly)n –linker covalently linked to a peptide segment blocking the S1’, S2’
and S3’ pockets within the fibrinogen recognition exosite (73).
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One of the most important questions raised during molecular docking is related to the
conformation of the active site of the protein, which is used as template for all docking
experiments. The issue of having the same conformation of the active site for all known
3D structures is an open question. In the case of thrombin and thrombin complexes with
different inhibitors it has been shown that the structure of the hirulog 1-thrombin
complex, with an N-terminal D-Phe-Pro-Arg targeted to bind in the active site, has
practically identical interactions with that of the PPACK (D-Phe-Pro-Arg-chloromethyl
ketone) -thrombin complex in the active site (73-86).

Since the structure of an

enzyme/ligand complex is a valuable basis for the design of novel inhibitors, a
preliminary comparison of the crystallographically determined structures of different
enzyme/ligand complexes is necessary before starting any docking experiments. In the
case of alpha-thrombin/inhibitor complexes, the geometries of the enzyme active site
among these complexes are similar as already described by others (73). The difference in
thrombin conformation between thrombin/hirudin and thrombin/PPACK complexes is
limited to the short autolysis loop spanning residues Lys 145-Gly 150 (68-86). In the
case of the specificity pocket of alpha-thrombin (the S1 pocket), the geometry of this
pocket was shown to be essentially invariant in the crystal structures of these complexes
whether or not the pocket is occupied (73). Therefore, this specificity pocket in alphathrombin was one of the targets for designing of novel inhibitors (80-86).
Other structural feature important for high affinity of interaction between
thrombin- ligand inhibitor requires a dual hydrogen bond (H-bond) (usually antiparallel)
made between inhibitors and Gly216 at the S3 site in thrombin. Loss of the H-bond
between Gly216-CO and inhibitor-NH can result in a loss of 3-100 fold in affinity while

192

193
loss of the Gly216-NH H-bond interaction with inhibitor-CO can reduce activity by up to
10,000-fold (69, 75). An additional important structural features of thrombin active site
is Glu192. Thrombin shares this acidic residue with only the serine protease Protein C,
whereas the majority of trypsin-like serine proteases have a glutamine at this position.
This residue is a major determinant for thrombin specificity since a thrombin mutant
Glu192→Gln had the decreased ability to activate Factor Xa (80-85). It was showing
later through molecular modeling studies that some amino acids at P1’ position in the
peptide inhibitors derived from substrates [P3-P2-P1-P1’-CONH2] are establishing
important hydrogen bonds with their side chains and the O atoms from the carboxylate
side chain of Glu192 making this amino acid in the active site of thrombin a significant
determinant for the affinity of binding of peptides inhibitors (68-86). In figure 94 the
details of the active site of thrombin template 1ABJ in complex with PPACK are
presented. The pdb structure was downloaded from PDB data bank and the modeling
was performed using the software SCULPT-from MDL.
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1ABJ.pdb

Figure 94. The active site details of the template 1ABJ.pdb (thrombin in complex
with PPACK) (73). The pdb coordinates were downloaded from PDB and the complex
was modeled using the software SCULPT from MDL (66). The amino acids located
within the major subpockets of thrombin are labeled as presented in the original reference
(73).
Aryl pocket (S3) Trp215, Leu99, Ile174,
Tyr60A, Trp60D; dPhe (P3) docked into S3(1)
Hydrophobic pocket (S2)
Leu59-Asn62 insertion loop; Pro (P2) docked into S2(1)
Specificity pocket (S1) Gly216-Gly219
194

195
Asp189: salt bridge with Arg (P1); Arg (P1) docked into S1; Residues192-193, Tyr228,
Leu160, Val138 and Ala190 (1)
The structure 1ABJ was checked for the accuracy of X-Ray data using the software
PROCKECK (figure 95).
1. Ramachandran Plot statistics
No. of
residues
-----Most favoured regions
[A,B,L]
203
Additional allowed regions [a,b,l,p]
41
Generously allowed regions [~a,~b,~l,~p]
0
Disallowed regions
[XX]
0
---Non-glycine and non-proline residues
244
End-residues (excl. Gly and Pro)
Glycine residues
Proline residues

%-tage
-----83.2%*
16.8%
0.0%
0.0%
-----100.0%

6
23
16
---289

Total number of residues

Based on an analysis of 118 structures of resolution of at
least 2.0 Angstroms and R-factor no greater than 20.0 a good
quality model would be expected to have over 90% in the most
favoured regions [A,B,L].
2. G-Factors
Parameter
--------Dihedral angles:Phi-psi distribution
Chi1-chi2 distribution
Chi1 only
Chi3 & chi4
Omega

Score
-----

Average
Score
-----

-0.56*
-0.54*
-0.49
0.33
0.14
-0.22

Main-chain covalent forces:Main-chain bond lengths
Main-chain bond angles

-0.09
-2.32**
-1.38**

OVERALL AVERAGE

-0.59*
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Figure 95: Summary of PROCKECK (87) analysis of 1ABJ.pdb. G-factors provide
a measure of how unusual, or out-of-the-ordinary, a property is (Values below -0.5*
- unusual; Values below -1.0** - highly unusual).
It is important to mention that the main-chain bond-lengths and bond angles are
compared with the Engh & Huber (1998) (87) ideal values derived from small-molecule
data. Therefore, structures refined using different restraints may show apparently large
deviations from normality, as is the case for the structure 1ABJ.pdb. However, the
template 1 ABJ.pdb used in original docking experiments and development of lead
peptide compounds has 2.4 Å resolution with very well solved S1’, S2’ pockets within
the active site of thrombin. Thus, this structure was passing the structural criteria for
being suitable in designing inhibitors were the peptide requires well defined P1’ and P2’
positions within the sequence space [P3-P2-P1-P1’-P2’-CONH2].
Some models of X-Ray structures of thrombin complexes with PPACK or other
small molecule inhibitors used as templates for docking experiments are presented in
Figure 96. Additional X-Ray structures were used in docking experiments and tested for
their atomic resolution and structural accuracy at the required pockets within active site
of thrombin (S3, S2, S1, S1’, S2’ and S1’). The X-ray structures together with their
references are presented in Table 1.
1ABJ.pdb

1HAI.pdb
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1AD8.pdb

1H8I.pdb

Figure 96: Models of X-Ray structures of thrombin complexes with PPACK or
other small molecule inhibitors used as templates for docking experiments. All
structures were downloaded from PDB and modeled using the software Rasmol
(88).

The superposition of more than 2 templates used in docking experiments showed
some degree of deviation of some side-chains in the active site of thrombin, however they
were not significant (less than 0.5 Å-quantitative) (data not shown) supporting the fact
that structure-based design in the case of thrombin was accurate enough if more than 2
templates for docking experiments are used. However, the predicted free energies for the
interaction between thrombin and peptides were slightly different (5-8 kcal/mol
difference) when docking of the same peptide was done into each of the active site of the
two independent templates (see table 8).

These differences in the free energy are

relatively significant if we consider the accuracy of the software SCULPT which is within
+ 5-8 kcal/mol, suggesting that is always a good control to perform docking within
different X-ray known structures for the same target (thrombin in our case).
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1.2. In silico screening of peptides with potential anti-thrombin activity
using the docking software “SCULPT”.
The strategy of designing new peptides with potential inhibitory activity against thrombin
was based on discovering original leading compounds characterized by a high affinity of
interaction with thrombin. The free energy of interaction between thrombin and each
ligand was calculated with the built-in molecular mechanics force-field (MMFF)
provided by the docking software SCULPT. These new leading compounds with a
specific sequence were further developed by adding extra natural or unnatural amino
acids in the next position (from N to C terminus), such that residues with different
chemistry of the side chain were screened (aromatics, hydrophobic, acidic, basic, polar).
After each round of minimization of the structure of the complex between thrombin and
the new lead compound new sequences were developed. In the original experimental
investigations we focused on those complexes that were characterized by a free energy of
interaction between thrombin and the new peptides below “-50 kcal/mol”. This is not a
real free energy for what might be a complex between thrombin and an inhibitor peptide,
since for an dissociation constant in the range of nM-pM we expect free energy of
interaction in the order of (-10kcal/mol) – (-20kcal/mol)”. Therefore, a free energy of “50 kcal/mol” correspond to a dissociation constant far lower than the pM range and thus
is not a reliable value as generated by the software SCULPT which is employing
molecular force-field 94 (MMFF94) for predicting the free energy of interaction between
protein target and the ligand. We still considered leading group compounds those with
lower free energy, i.e. below “-50 kcal/mol” since we assumed that this free energy of
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interaction might qualitatively represent a very stable complex between inhibitor and
thrombin.
Since the structure of an enzyme/ligand complex is a valuable basis for the design
of novel inhibitors, a preliminary comparison of the crystallographically determined
structures of different enzyme/ligand complexes is necessary before starting any docking
experiments (41-50). In the case of alpha-thrombin/inhibitor complexes, the geometries
of the enzyme active site among these complexes are similar as already described by
others (68-86).

In the PDB (Protein Data Bank) there are more than 300 structures

thrombin/inhibitors solved by X-ray diffraction, thus making it difficult to choose a
template for docking experiments. Based on these structural data, we used 3-5 X-Ray
solved structures of thrombin in complex with PPACK or other small molecule ligand
inhibitors (such as benzamidine compounds (42)) to generate an in silico combinatorial
peptide libraries with potential inhibitory activity for thrombin (see section 1.1).
In SCULPT, the force-field is provided with potential energies that are used to
model: explicit hydrogen bonds; variable dihedral angles; van der Waals interactions;
electrostatic interactions; user-applied tugs (springs). Van der Waals interactions are
modeled with a modified Lennard-Jones function between atoms within 6Å of each other.
Electrostatic interactions are modeled with a Coulomb model using a distance-dependent
dielectric interaction between atoms within 10 Å of each atom. In addition to van der
Waals interactions the free energy of interaction between the designed peptides and
thrombin was including the electrostatic forces in the late steps of docking when a refined
structure between thrombin and the inhibitor peptide was generated.
In addition to this initial criteria new scoring functions for the evaluation of lead
compounds were developed based on the structural complementarity between the peptide
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ligand and the the thrombin active site such as the normalized complementarity between
the ligand and thrombin, as determined from ligand-protein contact analysis performed
with the Ligand Protein Contacts (LPC) software developed originally by Sobolev (8993) and provided by the server running at Weizmann Institute (Israel).

1.3. Peptide sequences used to generate new candidate inhibitors for
thrombin.
During the first stages of docking experiments the structural details of some very well
known peptides and peptido-mimetic inhibitors of thrombin were chosen as a starting
point for developing further candidate compounds. As shown in Figure 97 (A-E), the XRay data show specific interactions between the peptido-mimetic compounds in the
active site of thrombin. The salt bridge between D189 of thrombin binding pocket and
the R (Arg) at the P1 position of peptidomimetic inhibitors was proposed to make a large
contribution to the free energy of interaction of the thrombin-inhibitor complex, and thus
is a structural requirement for the major classes of peptides derived inhibitors for
thrombin (27-31).

As mentioned earlier other structural feature important for high

affinity of interaction between thrombin and ligand inhibitor require a dual hydrogen
bond (H-bond) (usually antiparallel) between inhibitors and Gly216 at the S3 site in
thrombin. Loss of the H-bond between Gly216-CO and inhibitor-NH can result in a loss
of 3-100 fold in affinity while loss of the Gly216-NH H-bond interaction with inhibitorCO can reduce activity by up to 10,000-fold (27-31).
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Figure 97 (A-E): The major structural features characterizing peptides inhibitors
interaction with thrombin (27, 28, 80,81).

During the initial docking experiments specific criteria were used to generate “lead
compounds” using the software “SCULPT”. The major criteria for selecting of lead
compounds from docking experiments was based on the predicted free energy (∆G) of
interaction between the designed peptides and thrombin as described in section 1.2.
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-P1------P1’Figure 98: Peptide sequence around the cleavage site of the thrombin-susceptible
bonds (-P1-P1’-) in proteins from human plasma (67).

The strategy of designing new peptides inhibitors for thrombin was based on the
substrate specificity of thrombin, which requires that the carboxyl side of the scissile
bond to have the amino acids Arg or Lys (see Figure 98). In the following amino acid
sequence…N-P4-P3-P2-P1-P1’-P2’-P3’-P4’-C…, -P1-P1’- is the scissile bond (P1 has
to be Arg or Lys). The two sequences used for designing peptide inhibitors are shown
below:
Peptide sequence (1) 2HN-X-D-Phe-Pro-Arg-D-Pro-P2’-P3’-…CONH2
Peptide sequence (2) 2HN -X-D-Phe-Pro-D-Arg-P1’-P2’-P3’…. CONH2
Peptides with D-Pro in the P1’ position and D-Arg instead of Arg in the P1 position
are expected to inhibit the hydrolysis of peptide, allowing these sequences to function as
potential inhibitors. Variations in positions P1’, P2’, P3’ and P4’ with a selection of the
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20 naturally encoded amino acids in the L- and D- forms were used to generate the in
silico library of peptides with potential inhibitory activity against thrombin.

1.4. MATERIALS AND METHODS
1.4.1. MATERIALS
The software SCULPT used in docking experiments was purchased from MDL (66). The
structures were draw with ISIS Draw 2.2.1 from MDL and the molecular models were
generated with Rasmol (88) and SPDBViewer (94). All softwares were operated on the
PC machine with Windows XP operating system.

1.4.2. METHODS
Docking and structure-based design. Molecular Modeling.

Molecular

docking was carried out using the SCULPT software package provided by MDL. The
strategy of designing new peptides inhibitors consist in drawing the polypeptides within
ISIS DRAW 2.2.1 and then importing them into three-dimensional presentation using
SCULPT for docking and minimization.

The procedure for the docking process is

described below:
1. The initial initial “.pdb” file of interest containing the atomic coordinates was
downloaded from PDB , such as the “PPACK/thrombin” complex template
(1ABJ.pdb) for docking of new peptides into active of thrombin.
2. The file was opened within SCULPT and all the water molecules were removed from
it.

The file was resaved.

The minimization process was done using just the

command for Van der Waals forces and the lowest free energy for the
inhibitor/protein complex was recorded.

This is the control free energy of

interaction between the inhibitor and the protein templates with known 3D structure.
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3. The inhibitor was deleted from the new file in SCULPT and saved separately, as
“protein.sc3” file (for example “thrombin.sc3”). This contained just the template
protein which is used later for docking experiments.
4. The initial file containing the protein/inhibitor complex was opened and the protein
was deleted , leaving just the inhibitor. This new file containing just the inhibitor
alone was saved separately either as ”.mol” or “.sc3 “ file formats.
5. The new peptides sequences were drawn as single peptide chain in ISIS DRAW,
using the amino acid templates. These new designed peptides were copied and then
opened individually each on top of the initial peptide inhibitor used as templates in
SCULPT program. The function “Paste Align” of the software SCULPT was used
to superimpose the new designed inhibitor over the old inhibitor template. After this
superposition was done the old inhibitor was deleted; thus, the new inhibitor was left
in the same position as the old inhibitor within the active site of protein template.
The protein file (protein.sc3) containing the template protein was then opened
together with the new inhibitor using the merge file box provided by SCULPT
software.
6. The protein was “freezed” while the inhibitor was “thawed” (i.e. allowed
conformational freedom) using the corresponding functions from the SCULPT
software. This ensured the flexible conformational search for the ligand in the active
site but limited the conformational states of the protein itself (rigid docking
experiments). The minimization procedures were using Van der Waals interactions
for finding the best fit of the ligand into the active. In additional the electrostatic
interactions provided by the MMFF force field from SCULPT were used together
with the Van der Waals force-field to assess the interaction between the peptides and
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the template-thrombin. The rounds of minimization were performed till the free
energy (∆G) of interaction between the ligand and the target protein remained
constant.
7. The new complex between the protein template – new inhibitor was saved as an
“.sc3” file. This predicted free energy of interaction between protein and the new
peptide inhibitor was further recorded and used as a criteria for selection of major
lead compounds.
In most cases the electrostatic force was applied during minimization procedure after the
crude docking model was obtained using just the van der Waals interactions in assessing
the free energy of interaction between thrombin template and the peptide ligands.
The new theoretical model of the protein/new inhibitor complex was saved as “.pdb” file
separately and opened in any program that accept pdb files, such as Rasmol and SPDV
Viewer.

1.5. RESULTS

1.5.1. Molecular docking and structure-based design of peptide libraries
as potential inhibitors for thrombin.
Initial molecular docking experiments were used to generate a candidate group of
compounds (with both L- and D- amino acids) that were characterized by a predicted free
energy (∆G), based on Van der Waals interactions with thrombin in the range from -20 to
-50 kcal/mol. The thrombin template used in all molecular docking experiments was the
X-Ray determined structure of thrombin in complex with the irreversible inhibitor
PPACK (D-Phenyl-Prolyl-D-Arginyl-chloromethylketone) (PDB code: 1ABJ.pdb).
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Several compounds having a Gly at the P1’ position (in the series dPhe-Pro-dArg-Gly)
have a predicted ∆G below “-20 kcal/mol. These were further used to generate
pentapeptides and hexapeptides having variable P2’and the P3’ positions, and a constant
P1’ position. The X-position was also varied but the peptides show lower affinity for
thrombin. The peptides were docked into active site of thrombin by taking the X-ray
coordinates of the protein template from the “.pdb” file and deleting the initial inhibitor
PPACK. The results from strategy of docking experiments are shown on Figure 99.
Figure 99: Docking experiments: experimental design and in silico SAR (Structure
Activity Relationship) of peptides reversible inhibitors for thrombin.
Strategy used for docking experiments using software “Sculpt”
1. PDB: Imported coordinates for Thrombin/PPACK
1ABJ.pdb in “SCULPT”.
2. Minimized Thrombin/PPACK

using “SCULPT” (molecular –mechanics algorithm).

3. Deleted inhibitor and preserve the X-Ray
coordinates of protein template THROMBIN.

4. Deleted the protein in a separate file and maintain the coordinates of initial
INHIBITOR (PPACK).sc3
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5. Drew the structure of new peptide inhibitor using the software “ISIS DRAW 2.2.1”.
and save the files with the “.skc” extension.
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In addition to D-Phe, other Phe analogs were used to perform trials for new peptides
with inhibitory activity for thrombin (figure 100).
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Figure 100: Phe-analogs used as trials for the P3 position within the D-Phe-Pro-DArg-P1’-CONH2 peptide. Other Phe analogs used in P3, P2 or P1’ positions are
described in Materials and Methods and presented in section . These peptides containing
natural or unnatural amino acids were minimized using the advanced molecular
mechanics force field (MMFF) provided by SCULPT and their final conformation
assessed by inspection of their dihedral angles (phi and psi) (data not shown). Based on
dihedral angles analysis (data not shown) we classified the conformation of the new
compounds as being beta turns, beta sheet or alpha helix (68-86).
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6. Superimposed the new inhibitor peptide over the old inhibitor (PPACK) using the
function “Paste and Align” from “SCULPT”. Deleted the old inhibitor and generated a
new file for new inhibitor: [New Inhibitor.sc3]
Example of new designed peptides inhibitors superimposed over the old inhibitor,
PPACK (the skeleton of the old inhibitor is presented in grey colors) are shown below:

D-Phe-Pro-D-Arg-Tyr-CONH2

D-Phe-Pro-D-Arg-Ala -CONH2

D-Phe-Pro-Arg-D-Pro-D-Arg-CONH2

D-Phe-Pro-D-Arg-Gly-Asp-CONH2

211

D-Phe-Pro-D-Arg-Met -CONH2

212

7. Superimposed the template file [THROMBIN.sc3] over the [New Inhibitor.sc3]
using the MERGE FILE option from “SCULPT”. Used the options FREEZE for
protein and THAW for inhibitor to further perform the MINIMIZATION procedure
which predicted the free energy of interaction ∆G (kcal/mol) between thrombin and
new peptide inhibitor (molecular mechanics (MM) algorithm). Example of
computer generated complexes between the new designed peptide inhibitors in
complex with thrombin are shown together with the active site surface of thrombin
(within 12 Å of ligand).
D-Phe-Pro-D-Arg-Gly-Asp-Met -CONH2

212

12 Å surface within ligand

213

D-Phe-Pro-D-Arg-Ala-CONH2
∆G =- 69.4 [kcal/mol]

All peptide compounds containing other amino-acids analogs at P3, P2 and P1’ positions
were docked into active site of thrombin using the same software “SCULPT” and the free
energy of interaction with thrombin was assessed using the same strategy described
above.

Tabel 7 shows the original peptide libraries and the scoring functions used to

determine the best lead compounds based on free energy of interaction with thrombin as
is predicted by “SCULPT”.
Table 7: the original peptide libraries generated in silico through docking
experiments using SCULPT and the free energy of interaction between ligand and
target protein as predicted by the docking software. The free energy was predicted
based on the van der Waals interactions between each peptide and thrombin and is
reflecting the relative sterical fitness between each ligand and thrombin.

Inhibitor tried (from N to C terminus)
original: ppack (d-phe-pro-arg)
d-phe pro Arg
Pro
d-phe pro Arg
Phe
d-phe pro Arg
Ala
d-phe pro Arg
Gly
d-phe pro Arg
d-pro
d-phe pro Arg
d-pro
d-tyr
pro Arg
d-pro
d-phe ala Arg
d-pro

Free Energy
of interaction
Trp

d-tyr
d-phe
d-tyr
d-tyr

213

124.4
243.4
-44.5
-54.1
-68.3
-61.8
-61.5
-59.2
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Leu
acetyl

d-phe
d-phe
d-phe
d-leu
d-phe
d-lys
d-phe
Lys
d-phe
formyl
d-phe
d-phe
d-phe
Z
d-phe
Arg
d-phe
d-arg
d-phe
Phe
d-phe
carbamino d-phe
d-phe
d-phe
d-phe
phe
Gly
d-phe
d-phe
d-phe
Bz
d-phe

pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro

Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg
Arg

d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro
d-pro

d-tyr
d-tyr
d-trp
d-tyr
d-tyr
d-tyr
d-tyr
d-tyr
d-tyr
d-tyr
d-tyr
d-tyr
d-tyr
phe
Trp
d-tyr
d-tyr
Tyr
d-tyr
d-tyr

d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe
d-phe

pro
val
val
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro
pro

d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg
d-arg

gly
gly
gly
gly
gly
gly
gly
gly
gly
gly
gly
ala
d-ala
val
gly
gly
gly
gly
gly
gly
gly
gly
gly
phe
glu
arg

asp
phe
asp
Arg
Val
asn
d-asp
Glu
ser
Cys
asp
asp
asp
asp
asp
asp
asp
asp
asp
asp
asp
asp
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Gly

Ala
Met
Lys
Gly
Ile
d-ala
Cys
Glu
Phe

-59.1
-58.2
-57
-54.7
-52.7
-51.6
-51.4
-51.4
-50.7
-50
-49.4
-47.2
-46.2
-41.1
-40.1
-39
-30
-28.5
16.2
666.4
-29.6
-32.5
-23
-43.1
-52.1
-43.7
-37.8
-51.6
-38.9
-20
-47.2
-45
-51.9
-45.2
-39.2
-58.9
-56.3
-55.4
-51.5
-46.9
-46.5
-45.3
-44.3
-30.4
-42.7
-28.5
-34.5
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d-phe
d-phe
d-phe
d-phe
d-phe
d-phe

pro
pro
pro
pro
pro
pro

d-arg
d-arg
d-arg
d-arg
d-arg
d-arg

Tyr
Trp
Tyr
Tyr
d-tyr
Tyr

phe
Arg
Ala

-47.9
-44.6
-53.2
-45.6
-36.5
-52.2

The in silico SAR was further extended to peptides containing amino acids
analogs at P3 position, or unnatural amino acids analogs at P1’ position. The docking
experiments were performed as described in Materials and Methods for each variation in
P3 or P1’ with different amino acids analogs and the free energy of interaction between
peptides and thrombin was assessed based on van der Waals interactions (sterical fitness)
or based on both van der Waals and electrostatic interactions (Tables 8 and 9).

Table 8: The predicted free energy of interaction between thrombin and different
peptides with amino-acids analogs determined from docking experiments performed
with the software “SCULPT”. The free energy was predicted based on the van der
Waals interactions and is reflecting the relative sterical fitness between ligand and the
target protein 1ABJ.pdb.
∆G

Sequence N Æ C

(Kcal/mol)
1

α

-71

2

Transcinnamic-Pro-D-Arg-Ser-CONH2

-80.0

3

L-Tic-Pro-D-Arg-Cys-CONH2

-88.9

4

L-Thi-Pro-D-Arg-Gly-CONH2

-79.3

5

L-Tic-L-Thi-D-Arg-CONH2

-68.3

6

DPhe-Pro-D-Arg-DThr-CONH2

-90.6

7

L-Tic-Pro-D-Arg-DAla-CONH2

-85.4

8

D-Phe-Pro-D-Arg-DCys-CONH2

-88.8

9

Transcinnamic-Pro-D-Arg-Cys-CONH2

-85.8

10

D-Phe-Pro-D-Arg-Met-CONH2

-110.0

N-CBZ-Pro-D-Arg-Gly-CONH2
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11

L-Tic-Pro-D-Arg-Thi-CONH2

-85.2

12

Transcinnamic-Pro-D-Arg-Ile-CONH2

-84.6

13

D-Phe-Pro-D-Arg-D-Ser-CONH2

-92.0

14

D-Phe-Pro-D-Arg-D-Gln-CONH2

-84.7

15

L-Tic-Pro-D-Arg-Gly-CONH2

-83

16

D-Phe-Pro-D-Arg-Thi-CONH2

-98.2

17

D-Phe-Pro-D-Arg-Thr-CONH2

-80.2

18

α

-114.3

19

L-Tic-Pro-D-Arg-CONH2

-56.7

20

α

-73.2

21

α

+16,163

22

α

+ 559.7

23

α

-71

24

D-Phe-Pro-D-Arg-CONH2

-56.6

25

Transcinnamic-Pro-D-Arg-CONH2

-63.3

26

α

-116.4

27

α

-81.7

28

α

-114.3

29

Dnaphthylalanine-Pro-D-Arg-Gly-CONH2

-81.8

30

Dnaphthylalanine-Pro-D-Arg-DAla-CONH2

-82.6

31

D-tetrahydroharman(Tpi)-Pro-D-Arg-DAla-

-80.0

32

D-tetrahydroharman(Tpi)-Pro-D-Arg-Ile

-71.3

33

Transcinnamic-Pro-D-Arg-D-Ala-CONH2

-78.3

34

Ciscinnamic-Pro-D-Arg-Gly-CONH2

-74.3

35

Ciscinnamic-Pro-D-Arg-Ile-CONH2

-86.4

36

Ciscinnamic-Pro-D-Arg-DAla-CONH2

-74.0

37

Ciscinnamic-Pro-D-Arg-Ser -CONH2

-82.7

38

Ciscinnamic-Pro-D-Arg-CONH2

-67.0

39

Dihydrocinnamic-Pro-D-Arg-Gly-CONH2

-73.3

40

Dihydrocinnamic-Pro-D-Arg-Cys-CONH2

-80.3

N-CBZ-Tyr-Pro-Arg-D-Pro-CONH2
N-CBZ-Pro-D-Arg-Ala-CONH2
N-CBZ-Pro-Arg-D-Pro -CONH2
N-CBZ-Pro-Arg-D-Pro-Gly-CONH2
N-CBZ-Pro-D-Arg -Gly-CONH2

N-CBZ-Phe-Pro-Arg-D-Pro-CONH2
N-CBZ-Pro-D-Arg-D-Ala-CONH2
N-CBZ-Tyr-Pro-Arg-D-Pro-CONH2
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41

D-Tic-Pro-D-Arg-Gly-CONH2

-83.0

42

D-Tic-Pro-D-Arg-Cys-CONH2

-83.8

Table 9:The predicted free energy of interaction between thrombin and different
peptides transcinnamic and dihydrocinamic analogs of Phe (P3) determined from
docking experiments performed with the software “SCULPT”. The free energy was
predicted based on the van der Waals and electrostatic interactions between ligand and
the target protein 1ABJ.pdb.

Inhibitor ( Tetrapeptides)
Trans-cinnamoyl-Pro- D-Arg-D-Pro
Trans-cinnamoyl-Pro-D-Arg-D-His
Trans-cinnamoyl-Pro-D-Arg-D-Ala
Trans-cinnamoyl-Pro-D-Arg-D-Ser
Trans-cinnamoyl-Pro-D-Arg-D-Cys
Trans-cinnamoyl-Pro-D-Arg-D-Thr
Trans-cinnamoyl-Pro-D-Arg-L-Thi
Trans-cinnamoyl-Pro-D-Arg-D-Tic
Trans-cinnamoyl-Pro-D-Arg-D-Asn
Trans-cinnamoyl-Pro-D-Arg-D-Gln
Trans-cinnamoyl-Pro-D-Arg-D-3Benzothienylalanine
Trans-cinnamoyl-Pro-D-Arg-D-3,5DifluoroPhenylalanine
Trans-cinnamoyl-Pro-D-Arg-Gly
Dihyrocinnamoyl-Pro-D-Arg-D-Pro
Dihyrocinnamoyl-Pro-D-Arg-D-His
Dihyrocinnamoyl-Pro-D-Arg-D-Ala
Dihyrocinnamoyl-Pro-D-Arg-D-Ser
Dihyrocinnamoyl-Pro-D-Arg-D-Cys
Dihyrocinnamoyl-Pro-D-Arg-D-Thr
Dihyrocinnamoyl-Pro-D-Arg-L-Thi
Dihyrocinnamoyl-Pro-D-Arg-D-Tic
Dihyrocinnamoyl-Pro-D-Arg-D-Asn
Dihyrocinnamoyl-Pro-D-Arg-D-Gln
Dihyrocinnamoyl-Pro-D-Arg-D-3Benzothienylalanine
Dihyrocinnamoyl-Pro-D-Arg-Gly
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Binding Energy
(van der Waals +
Electrostatics
(kcal/mol)
-138.0
-148.3
-120.5
-172.0
-110.0
-151.3
-165.5
-115.0
-132.9
-148.5
-163.9
-166.5
-132.0
-183.5
-164.7
-152.2
-165.1
-114.7
-167.3
-183.2
-146.7
-157.4
-195.7
-167.8
-122.9
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We were interested to validate the accuracy of the proposed models peptidesthrombin complexes by performing an independent docking experiment using another
template 1AI8.pdb which was also checked through PROCHECK for its structural
accuracy (see section 1.2). The results from table 10 are showing that overall there are
relatively low differences between the predicted free energy of interaction between
peptides docked in 1ABJ.pdb and 1AI8.pdb.
Table 10: The comparison between the predicted free energy of interaction between
two different thrombin templates (1ABj.pdb and 1AI8.pdb) and lead peptide
inhibitors. The docking experiments were performed with the software “SCULPT”.
The free energy was predicted based on the van der Waals interactions and is reflecting
the relative sterical fitness between ligand and the target protein 1ABJ.pdb (+ 5-10kcal/mol is within the sensitivity of software SCULPT).
∆G

Sequence N Æ C

(Kcal/mol)
(1ABJ.pdb
template)

∆G
(Kcal/mol)
(1AI8.pdb
template)

D-Phe-Pro-D-Arg-Ala-CONH2

-77.3

-77.2

D-Phe-Pro-D-Arg-D-Ala- CONH2

-80.3

-75.2

D-Phe-Pro-D-Arg- Gly-CONH2

-76.6

-75.0

D-Phe-Pro-D-Arg-L-Arg- CONH2

-87.2

-83.2

D-Phe-Pro-D-Arg-l-Glu- CONH2

-87.8

-73.1

D-Phe-Pro-D-Arg-L-His- CONH2

-88.2

83.4

D-Phe-Pro-D-Arg-L-Phe- CONH2

-87.1

-78.6
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D-Phe-Pro-D-Arg-L-Pro CONH2

-76.4

-78.8

D-Phe-Pro-D-Arg-D-Pro- CONH2

-70.0

-76.0

D-Phe-Pro-D-Arg-L-Trp- CONH2

-86.4

-96.8

D-Phe-Pro-D-Arg-L-Tyr- CONH2

-73.9

-80.1

D-Phe-Pro-D-Arg-L-Val- CONH2

-83.3

-82.4

D-Phe-Pro-D-Arg-L-Thr- CONH2

-78.6

-79.6

D-Phe-Pro-D-Arg-D-Thr- CONH2

-90.4

-79.5

D-Phe-Pro-D-Arg-L-Ser- CONH2

-90.8

-82.5

D-Phe-Pro-D-Arg-D-Ser-CONH2

-99.4

-80.4

D-Phe-Pro-D-Arg-L-Cys- CONH2

-88.0

-80.8

D-Phe-Pro-D-Arg-D-Cys- CONH2

-104.5

-77.6

D-Phe-Pro-D-Arg-L-Gln- CONH2

-94.2

84.5

D-Phe-Pro-D-Arg-D-Gln- CONH2

-104.6

-87.1

D-Phe-Pro-D-Arg-Ile- CONH2

-83.0

86.1

D-Phe-Pro-D-Arg-L-Thi- CONH2

-98.0

-91.2

D-Phe-Pro-D-Arg-L-Met- CONH2

-109.0

-107.0

In order to visualize the environment of each ligand within the active site of thrombin, the
pdb files from docking experiments were analyzed with the software SCULPT. In figure
10 the details of the active site of thrombin within 10 Å of some of the designed peptide
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inhibitors are presented as molecular models performed with the software SPDB Viewer.
The main hydrogen bonding between peptide and amino acids within the subpockets S3,
S2, S1 and S1’ in the active site of thrombin are presented as dashed lines. It can be seen
that the most important hydrogen bonds such as between Asp 189 in the S1 pocket of
thrombin and guanidinium group of D-Arg in the ligand is conserved through different
classes of inhibitors. Of importance to note is the difference in the hydrogen patterning
between these two keys groups as the amino acid in P1’ position in the peptide is
changing from L to D, such as is the case of L-Thr and D-Thr (figure 101 A, B, C and D).
L-Thr in P1’ is predicted to have less favorable hydrogen bonds than D-Thr, i.e. 2
hydrogen bonds instead of three (compare figure 101 A with 101 C and 101 D and 101E).
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Figure 101 (A) D-Phe-Pro-D-Arg-D-Thr-CONH2 (depicted in green color)
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Figure 101 (B) D-Phe-Pro-D-Arg-D-Thr-CONH2 (Van der Waals representation of
peptide ligand as colored in green).
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Figure 101 (C) D-Phe-Pro-D-Arg-L-Thr-CONH2 (blue color).
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Figure 101 (D) (the experimentally determined Kis (inhibitory constants) are
indicated for each peptide in uM (micromolar).
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Figure 101 (E): superimposed L-Thr (P1’) and D-Thr (P1’) tetrapeptides from 10
(D) showing the different conformation adopted by each tetrapeptide as the
configuration of the amino acid at P1’ position is shifted from L to D.

Figure 101 (A-E): Molecular modeling of peptides docked into active site of
thrombin 1ABJ.pdb. The models were generated with SPDB-Viewer using the pdb
files generated by the software SCULPT during docking experiments.
Additional docking experiments were performed with unnatural amino acids scanning P3,
P2 and P1’ positions as presented in Tables 8-9. A very promising amino acid analog at
P1’ was L-thienylalanine (L-Thi) which was predicted to occupy the S1’ subpocket of
thrombin’s active site with a free energy of interaction of -95 kcal/mol (based on
SCULPT docking experiments using the Van der Waals force-field) (Figure 11). This
amino-acid analog of phenylalanine was scanned by others (67) but within different
sequence space and was found to be very well fitted sterically in the small hydrophobic
pocket S1’ (based on X-ray diffraction of complexes between the peptide inhibitor
containing L-Thi at P1’ position and thrombin (67).
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Figure 102.
Molecular modeling of a new peptide inhibitor containing L-Thi
(thienylalanine) docked into active site of thrombin 1ABJ.pdb. The models were
generated with SPDB-Viewer using the pdb files generated by the software SCULPT.
Other examples of computer generated complexes between the new designed
peptide inhibitors in complex with thrombin are presented in figure 103 (A), (B), (C) and
figure 104 (A-F). The electrostatic surface within 10-12 Å of the ligand was generated
with the software “SCULPT”. The amino acids from active site of thrombin which were
found within 10-12 Å of the ligand are those corresponding to the S3, S2, S1, S1’
subpockets of the thrombin as they were described in many X-ray structures (67-81).
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(A)
D-Phe-Pro-D-Arg-Gly-Asn-CONH2

Active-site
Electrostatic Surface within
10 Å from the ligand

Within 10

B)

C)

D-Phe-Pro-DArg-Ala-CONH2
∆G =- 69.4 [kcal/mol] G = - 70.5

D-Phe-Pro-D-Arg-Gly-CONH2
∆G = - 70.5 [kcal/mol]
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Figure 103. Electrostatic surface representation (within 10-12 Å of the docked
peptide ligand within the active site of thrombin). The electrostatic potential was
generated with the docking software SCULPT using the built-in MMFF94 force-field.
(A)

(B)
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(C)

(D)

(E)
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(F)

104: Molecular models of tetrapeptides with transcinnamic and
dihydrocinnamic acids at P3 position in the ligand peptide docked into active site of
thrombin. (A) Trans-cinnamoyl-Pro-Arg-D-Pro-CONH2 (B) Dihydrocinnamoyl-ProArg-D-Pro-CONH2
(C) Dihydrocinnamoyl-Pro-Arg-D-Tic-CONH2 (D) Transcinnamoyl-Pro-Arg-D-Tic-CONH2 (E) Dihydrocinnamoyl-Pro-Arg-D-Gln-CONH2 (F)
Trans-cinnamoyl-Pro-Arg-D-Gln-CONH2 (C and D) has one of the lowest binding
energies; (E and F) has one of the highest binding energies (table 9).
Figure

In order to assess the validity of the predicted free energy, we performed “positive
control” type of docking experiments in which a well known competitive inhibitor for
thrombin (“Thromstop”) was docked into the active site of thrombin. We expected a
negative free energy as predicted by SCULPT. Figure 105 showed that this was indeed a
good control experiment, since the software SCULPT predicted a favourable free energy
of interaction between thrombin and the inhibitor. Also, we performed control docking
experiments to assess the selectivity of peptide inhibitors for thrombin as compared with
other serine-proteases from coagulation cascade (like Factor X-a). In these type of
experiments the peptide inhibitor specific for thrombin, with a very good predicted free
energy of interaction with thrombin (< -50 kcal/mol) was docked into the active site of
factor Xa. We expected a lower affinity between these peptides and Factor Xa. This
would be predicted as higher free energy of interaction between the peptide and Factor X-
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a (toward more positive values, i.e. less favorable sterical fitness between ligand and
protein template) (table 11).

SO2 H
2
N C
H
HN
H2N

O

NH
C HC
H2

O
N

Figure 105. The “SCULPT” presentation of the model of ‘Thromstop’ (Ki = 25 nM
for bovine thrombin) docked into active site of thrombin. The commercially available
inhibitor “Thromstop” (N-α-NAPAP) was docked into active site of thrombin, using the
same thrombin template as for the other peptide inhibitors, i.e. 1ABJ.pdb.
In Table 11 all peptides docked in 1ABJ.pdb and 1AI8.pdb presented in table 5
were docked within the active site of Factor X-a and the free energy of their interaction
with Factor X-a was predicted as described in Materials and Methods. These results are
confirming that the designed peptides are more selective for thrombin than for Factor Xa, since their free energy of interaction with thrombin has lower negative values than
energy predicted for their interaction with Factor X-a. It can be seen that there no
positive values but the free energy is raising toward more positive values with 15-20
kcal/mol (compare tables 10 and 11). Altogether, the results from docking experiments
are supporting “SCULPT” as a reliable docking software in predicting at least a favorable
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(negative) vs. a non-favorable (toward more positive) free energy of interaction between
the ligand and the target protein.
Table 11: Docking-control experiment for selectivity of peptides designed as
inhibitors for thrombin. The predicted free energy of interaction between Factor X-a
(1FAX.pdb) and lead peptide inhibitors is presented in kcal/mol. The docking
experiments were performed with the software “SCULPT”. The free energy was
predicted based on the van der Waals interactions and is reflecting the relative sterical
fitness between ligand and the target protein 1FAX.pdb (+ 5 kcal/mol is within the
accuracy of software SCULPT).

∆G

Sequence N Æ C

(Kcal/mol)
(1FAX.pdb
template)
D-Phe-Pro-D-Arg-Ala-CONH2

-56.1

D-Phe-Pro-D-Arg-D-Ala- CONH2

-58.5

D-Phe-Pro-D-Arg- Gly-CONH2

-59.2

D-Phe-Pro-D-Arg-L-Arg- CONH2

--75

D-Phe-Pro-D-Arg-l-Glu- CONH2

-78.8

D-Phe-Pro-D-Arg-L-His- CONH2

-83.4

D-Phe-Pro-D-Arg-L-Phe- CONH2

-72.9

D-Phe-Pro-D-Arg-L-Pro CONH2

-65.8

D-Phe-Pro-D-Arg-D-Pro- CONH2

-63.3

D-Phe-Pro-D-Arg-L-Trp- CONH2

-70.0

D-Phe-Pro-D-Arg-L-Tyr- CONH2

-68.4
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D-Phe-Pro-D-Arg-L-Val- CONH2

-67.5

D-Phe-Pro-D-Arg-L-Thr- CONH2

-64.8

D-Phe-Pro-D-Arg-D-Thr- CONH2

-71.6

D-Phe-Pro-D-Arg-L-Ser- CONH2

-76.5

D-Phe-Pro-D-Arg-D-Ser-CONH2

-77.3

D-Phe-Pro-D-Arg-L-Cys- CONH2

-66.5

D-Phe-Pro-D-Arg-D-Cys- CONH2

-69.7

D-Phe-Pro-D-Arg-L-Gln- CONH2

-80.7

D-Phe-Pro-D-Arg-D-Gln- CONH2

-78.4

D-Phe-Pro-D-Arg-Ile- CONH2

-68.4

D-Phe-Pro-D-Arg-L-Thi- CONH2

-75.7

D-Phe-Pro-D-Arg-L-Met- CONH2

-62.7

1.5. Scoring Functions for discovery of lead peptides inhibitors
for thrombin.
Scoring Function (I): In order to have a quantitative value for the docked
structures the free energy of interaction between different peptides and thrombin was
considered as the first scoring function to rank the peptides inhibitors. Thus, the initial in
silico library of peptides contained compounds characterized by a free energy of
interaction with thrombin template of less than “-10 kcal/mol”. Compounds with positive
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free energy of interaction were discarded, but for validation reasons some of them were
chemically synthesized and their activity was tested. This free energy (∆G) (kcal/mol)
for the interaction between peptides and thrombin was calculated primarily based on Van
der Waals interactions between ligands and thrombin.
Since specific contacts between ligand and protein are known from solved X-ray
structures (68-86 and figures 94 and 101), new scoring functions were developed by
assessing the structural details of the peptides docked into the active site.
Scoring Function (II): It is already known that the salt bridge between Asp 189
(from the specificity pocket in the active site of thrombin) and the Arg in the P1 position
of the inhibitors contributes to a big fraction from the energy of interaction between
thrombin and different inhibitors (41-53). Based on these structural data we proposed the
distances between (D/L) Arg (at P1 position) in the peptides and the Asp 189 in the
specificity pocket S1 of thrombin as an important parameter for predicting the structural
fitness of the peptide ligand into the active site of thrombin (this was the second scoring
function criteria for discovery of lead compounds).

Figure 106: Scoring function II (the interatomic distance between Asp 189 in
thrombin and D-Arg at P1 position in peptide).
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As can be seen from Figure 106 the majority of tetrapeptides are predicted to have
very similar distances between Asp (189) from thrombin (OD1 and OD2 of the carboxyl
group) and D-Arg from peptide inhibitor (N1 and N2 of the guanidinium group) as
compared with similar distances from the control inhibitor, PPACK.

However, the

tetrapeptide D-Phe-Pro-D-Arg-Tyr is predicted to have higher than 5 Å interatomic
distance (Asp 189-D-arg (in P1-peptide) so this peptide is predicted to have less binding
interaction with thrombin. This was a successful prediction performed with SCULPT
since the experimental results demonstrated the aromatic amino acids in P1’ position are
having at least 10 fold less inhibitory activity (and thus less affinity) toward thrombin as
compared with Gly or other polar amino acids at P1’ (see section 3.2 and Table 18). Two
heaxapeptides D-Phe-Pro-dArg-Gly-Asn-Leu and D-Phe-Pro-D-Arg-Gly-Asn-Lys have
more than 7.0 Å interatomic distance between the above mentioned atoms (the distances
between OD1 and OD2 of the carboxyl group from Asp 189 and N1 and N2 of the
guanidinium group from the D-Arg) suggesting that he hexapeptides are less potent in
binding thrombin, again a result which was supported by experimental data (table 13 and
section 3.2). All hexappetides studied were at least 50 fold less effective than the
tetrapeptides in inhibiting thrombin.

Based on these good correlations between

computation docking models and the experimental results, the salt bridges with 3-4 Å
interatomic distance between Asp 189-thrombin and-D-Arg (P1-peptide) were proposed
to predict a good affinity between ligand and thrombin and were used as a reliable
scoring function in assesing the lead compounds.
Scoring Function (III): Another scoring function was developed using the analysis
of the structural details of the docked peptides with respect to the % favorable contacts
and normalized complementarity between the ligand (peptide inhibitor) and thrombin
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active site. The % favorable contacts and normalized complementarity were analyzed
using the algorithm developed by Sobolev V., Wade R.C., Vriend G. and Edelman M
(88-91). The complementarity function is defined as CF=Sl-Si-E where Sl is the sum of
all surface areas of legitimate atomic contacts between ligand and receptor, Si is the sum
of all surface areas of illegitimate atomic contacts, and E is a repulsion term. Legitimacy
depends on the hydrophobic-hydrophilic properties of the contacting atoms. In order to
define it, for each inter-atomic contact, eight atom classes have been introduced (88-91):
I Hydrophilic

- N and O that can donate and accept hydrogen bonds

(e.g., oxygen of hydroxyl group of Ser. or Thr)
II Acceptor
- N or O that can only accept a hydrogen bond
III Donor

- N that can only donate a hydrogen bond

IV Hydrophobic
- Cl, Br, I and all C atoms that are not in aromatic rings and do not
have a covalent bond to
a N or O atom
V Aromatic
atom

- C in aromatic rings irrespective of any other bonds formed by the

VI Neutral
- C atoms that have a covalent bond to at least one atom of class I or
two or more atoms from class II or III; atoms; S, F, P, and metal atoms in all cases
VII Neutral-donor

- C atoms that have a covalent bond with only one atom of class III

VIII Neutral-acceptor - C atoms that have a covalent bond with only one atom of class II
For

each

pair

of

contacts

the

state

of

legitimacy

is

shown

below:

+,legitimate
-, illegitimate (88-91).
All the lead compounds having predicted free energy of interaction with thrombin
less than “-50 kcal/mol) were analysed using the above mentioned scoring functions, by
sending ONLINE the “pdb” files of the peptides docked into active site of thrombin to the
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server located at Weizmann Institute (Israel) which is providing the structural analysis of
the ligand-protein. Figure 107 presents the results from LPC analysis of peptidesthrombin complexes in the case of control PPACK-thrombin (A) and three different
peptides inhibitors: D-Phe-Pro-D-Arg-Ala-CONH2 (B) D-Phe-Pro-D-Arg-Gly-CONH2
(C) and D-Phe-Pro-Arg-D-Pro-D-Arg-CONH2 (D).

Figure 107 (A): control experiment (A): ligand (PPACK) in complex with thrombin
(1ABJ.PDB) entry.
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Figure 107 (B): Structural complementarity for peptide inhibitor
D-Phe-Pro-D-Arg-Gly-CONH2.
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Figure 107 (C): Structural complementarity for peptide inhibitor
D-Phe-Pro-D-Arg-Ala-CONH2.
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107-(D): Structural complementarity for peptide inhibitor
D-Phe-Pro-Arg-D-Pro-D-Arg-CONH2
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In addition to the quantitative analysis of ligand-protein interactions presented in Figure
107, Figure 108 presents the molecular models containing the predicted favorable and
disturbing contacts for some of the peptide-thrombin complexes analyzed through LPC.
(A)
D-Phe-Pro-Arg-chloromethylketone
(PPACK) (original template 1ABJ.pdb)

(B)

Color code:
Non-favorable contacts: blue-cyan
Favorable contacts: yellow
Catalytic important residues: dark-blue
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C) D-Phe-Pro-D-Arg-Ala-CONH2
∆G =- 69.4 [kcal/mol]
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D-Phe-Pro-D-Arg-Gly-CONH2
∆G = - 70.5 [kcal/mol]

Figure 108: Molecular model for some peptide-thrombin complexes showing details
of the active site and of favorable and unfavorable contacts as determined from
LPC (ligand-protein-contact) analysis of each ligand-thrombin complex.
As can be seen from the figure 108 (A, B, C and D) the tetrapeptides D-Phe-ProD-Arg-Gly-CONH2 and D-Phe-Pro-D-Arg-Ala-CONH2 are predicted to have almost the
same normalized complementarity with the control (around 0.58) suggesting that they can
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be lead compounds.

By contrary the pentapeptide D-Phe-Pro-Arg-D-Pro-D-Arg-

CONH2 was predicted to have a low normalized complementarity (0.35<0.57 (control)),
suggesting that this is a less active compound.
It is important to mention that all the above peptides were predicted to have
negative free energy of interaction (favorable) with thrombin. These results suggests that
the scoring functions based on structural fitness between ligand and target protein,
especially based on normalized complementarity between ligand and the protein target as
predicted by LPC analysis are important in assessing the overall potential of a peptide
inhibitor.

1.5.3. Analysis of different conformations adopted by peptide inhibitors
docked into active site of thrombin.
The thrombin template used in docking experiments was 1ABJ.pdb. The peptides
were docked into active site of thrombin using the software “Sculpt” and further
minimized using the molecular mechanics (MM) force–field provided by the same
software. The template was further deleted and the individual peptides were save as
individual .pdb files, preserving their conformation adopted in the active site of thrombin
after docking and minimization. The software SPDB Viewer was used to superimpose
different peptides differing in one single amino acid position in the sequence space, thus
allowing the visualization of different conformations adopted in the active site of
thrombin by peptide inhibitors with similar sequence space.

A structure-activity

relationship (SAR) for tetrapetide, pentapeptide and hexapeptide libraries was performed.
In figure 109 (A, B, C and D) tetrapeptides from series D-Phe-Pro-D-Arg-P1’-CONH2 are
compared with respect to their conformations adopted in the active site of thrombin (P1’
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was varied with different amino acid combinations) together with the experimentally
determined inhibitory constant (Ki) as described later in Section 3.2 and table 8.
Figure 109 (A)

D-Phe-Pro-D-Arg-Val-CONH2------red
Ki = 56.32 + 9.59 µM
D-Phe-Pro-D-Arg-Ala-CONH2-----yellow Ki = 16.64 + 0.01 µM
D-Phe-Pro-D-Arg-Arg-CONH2-----violet Ki = 91.09 + 21.99 µM
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Figure 109 (B)

D-Phe-Pro-D-Arg-Ala-CONH2…red
D-Phe-Pro-D-Arg-Gly-CONH2…green
D-Phe-Pro-D-Arg-Ile-CONH2…blue

Ki = 16.64 + 0.01 µM
Ki = 5.89 + 0.33 µM
Ki = 6.33 + 0.03 µM

Figure 109 (C)

Transcinnamic-Pro-D-Arg-Gly-CONH2…blue-violet Ki = 6.6 µM
Ciscinnamic-Pro-D-Arg-Gly-CONH2….red
Ki = 32.5 µM
Dihydrocinnamic-Pro-D-Arg-Gly-CONH2….yellow Ki = 102.5 µM
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Figure 109 (D)

DPhe-Pro-DArg-Gly-CONH2… blue
DPhe-Pro-DArg-Val-CONH2… yellow
DPhe-Pro-DArg-Tyr-CONH2…. red

Ki = 5.89 + 0.33 µM
Ki = 56.32 + 9.59 µM
Ki = 50.5 + 5.0 µM

Figure 109 (A, B, C and D): Modeled conformations adopted by different peptides
into active site of 1ABJ.pdb together with the experimentally determined inhibitory
constant (Ki) as described later in Section 3 and table 13.

1.6. DISCUSSIONS
The analysis of the structural models together with the Ki values obtained
experimentally suggest that the tetrapeptides differing in one single amino acid at the P1’
position are adopting different conformations into the active site of thrombin, and these
different conformations might be related to significant differences in their inhibitory
potential, as revealed by their Ki values (Figure109). These findings suggest that P1’
position has a significant contribution to the binding energies for the tetrapeptides having
the sequence D-Phe-Pro-D-Arg-P1’-CONH2. Also, significant differences between the
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Kis of tetrapeptides of the series D-Phe-Pro-D-Arg-P1’-CONH2 (varying from 500 fold)
(section 3) suggest that the interaction between the amino acid at the P1’ position and the
S1’ pocket in thrombin is very specific. These results are consistent with the X-Ray data,
which showed that S1’ pocket of thrombin is a small cavity lined by amino acids from the
back side of the apolar S2 pocket (His57, Tyr60A and Trp60D) and the side chain of
Lys60F (11). The S1’ pocket can accommodate small polar amino acid side chains as
revealed by P1’ amino acids in a number of natural thrombin substrates (P1’ in most
physiological substrates is occupied by Gly, Ser, Thr, Ile, Leu and Val).

The

computational model of the active-site docked tetrapeptides from the series D-Phe-ProDArg-P1’ and their experimentally determined Ki values (see further table 13) support
the X-Ray data since the best inhibitors are having L/D amino acids with small side chain
(like Gly) or with apolar side-chain (like Cys, Ser, Thr) or more bulky amino acids such
as Ile or analogs of phenylalanine like thienylalanine (L-Thi).

Independent studies

performed by (67) showed that P1’ can accommodate bulky hydrophobics even though in
natural substrates these residues are found only when the substrate is complexed with
another co-factor (68-86).

This cofactors are proposed to induce a conformational

change in thrombin such that the small pocket P1’ will become larger than is in the
uncomplexed state (based on X-Ray studies (70-75) and will accommodate bulkier
residues such as Ile, Leu, Norleucine (Nle) and Val beside the most usual encountered
residues at P1’ which are Thr, Ser, Ala or Gly (see also section 1.1). The computation
models of trans/cis and dihydrocinnamic derivatives (in P3) support in most cases the
prediction that peptides with trans-cinnamic in P3 position better fit to the active site than
peptides with cis-cinnamic acid while dihydrocinnamic acid in P3 position adopt a
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favorable conformation depending on the amino acid in P1’ (better than transcinnamics
peptides with the same amino acids in P1’) (see Tables 9 and 14).
We have thus proposed and validated with our own experimental data new
scoring functions for discovery of new peptides inhibitors for thrombin one of them being
based on quantitative analysis of ligand-protein interaction, namely the % normalized
complementarity between the ligand peptide and the thrombin target (based on LPC
analysis of docked peptides). The comparison between the predicted computation models
and the experimental results showed that in some cases (like in the case of peptide DPhe-Pro-D-Arg-Tyr-CONH2)

a

good

correlation

between

a

weak

normalized

complementarity and the experimental results (Ki> 50 µM). Also, the peptides from the
series D-Phe-Pro-Arg-D-Pro-P1’-CONH2 show a relative good correlation between the
experimental data of Ki>100 µM and their low normalized complementarity (<0.4) as
compared with control normalized complementarity (>0.5) (Table 12).
Table 12: Correlation between the predicted % favorable contacts, normalized
complementarity and the experimental determined inhibitory activity for some
peptides (see table 13 for details about Ki).

Peptides

dPhe-Pro-dArg-Gly-CONH2
dPhe-Pro-dArg-Ala-CONH2
dPhe-Pro-Arg-dPro
-dArg-CONH2
dPhe-Pro-Arg dPro

% favorable contacts

48% FAVORABLE
46% FAVORABLE
22% “FAVORABLE

35%

FAVORABLE

-dPheCONH2
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normalized
complementarity

Ki (µM)

0.59

5.89 + 0.33

0.57

16.64 + 0.01

0.35

980.8

0.44

2, 362
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Another proposed scoring function was the distance between Asp 189 in thrombin
and D-Arg in peptide inhibitors (figure 96). Taken just by itself, the distance between
Asp189 (specificity pocket of thrombin) and Arg (P1 position from the peptide) is not
sufficient to predict possible lead compounds.

We are proposing that all possible

interactions between the peptide and the thrombin would be investigated and analyzed in
terms of structural fitness. The % normalized complementarity was one of the best
scoring function for ranking the reversible peptides inhibitors as a function of their
structural complementarity within S3, S2, S1, S1’ subpockets of thrombin.
These scoring functions proved to correlate with the experimentally determined
dissociation constants for some compounds (see Table 12); however we couldn’t find
>60% correlation with all the experimental values, suggesting that other factors are
contributing to the free energy of interaction between peptides and thrombin such as
possible local induced fit at the active site of enzyme upon ligand binding. All docking
experiments were performed in vacuo, without water of hydration and with the frozen
protein target, thus limiting the real environment of the ligand by some artificial
geometrical constraints imposed by the active site. In reality, the active site is flexible,
can have induced fit as suggested by X-Ray data (68-86) so that the S1’ subpocket in
thrombin can be bigger than usual and can accommodate bulky hydrophobic amino acids
side chains such as Ile, Leu even though in natural substrates this subpocket is fitting
small and polar amino acids such as Gly, Ala, Ser, Thr.
Structural evidence shows that the side chain of Lys60F defining the S1’ cavity in
the active site of thrombin is moved significantly thereby forming a larger groove which
can accommodate bulky residues (67).

Based on these X-ray data we can further

improve the docking experiments by leaving free of constraints 12 Å of the active site of
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thrombin making significant contacts with the ligand (i.e. leaving “melted” the active site
of thrombin during docking experiments); this experiment would mimics the induced-fit
due to ligand binding. Thus the normalized complementarity between ligand and the
target protein would improve as a scoring function for a more reliable prediction of the
structural fitness between the peptide inhibitors and the target protein (91-93).
Other novel approaches to molecular docking involve the screening of fragments
of small molecules, “fragment-based drug discovery” (95). We will use our original
designed sequence of peptides to further extend the binding site of the ligand into the
active site of thrombin by performing in silico fragment docking of shorter peptide
sequences derived from the original D-Phe-Pro-D-Arg-X-CONH2, such as the tripeptide
D-Phe-Pro-D-Arg or the dipeptide Pro-D-Arg and extend the fragments linked at N or Cterminus with different amino-acids analogs and further screen toward more powerful
drug-like molecules that can fill other pockets within the active site of thrombin like S4
and S2’ or S3’. Using this approach of fragment screening and linking of fragments the
chances of discovering more potent inhibitors for thrombin will increase and novel druglike molecules containing both peptide and small organic molecule fragments would
score in the low nanomolar inhibitory constant. This approach was used recently by a
group of investigators at Astex Therapeutics in UK to discover thrombin inhibitors in the
low nM range potency which were selective primarily for binding to S2-S4 pockets in the
active site of thrombin, bypassing thus the requirement for having specific interactions at
S1 pocket (95).
Another important contribution to future discovery and lead optimization of
peptide-derivative reversible inhibitors for thrombin will have to reconsider the
guanidinium group in P1 position which is key to inhibitor potency through salt-bridge
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formation with Asp189 in the S1 specificity pocket. The compounds with guanidinium
or amidine groups in P1 demonstrated good in vivo efficacy, but their use was restricted
by poor oral bioavailability. A new class of compounds were discovered in the last years
to be highly potent inhibitors of thrombin in the low nanomolar range of their Kis but
they are lacking the highly basic group in P1, making them better drug-like molecules,
i.e. higher oral bioavailability. These compounds contain hydrophobic groups in P1
position such as chlorophenyl and they are binding through aromatic interactions with
Tyr 228 side chain, deeply in the S1 pocket (95). We are further investigating through
molecular docking and chemical synthesis and structure-activity relationship a new series
of peptide-based inhibitors with D-amino-acids at P1 position which have aromatic and
halogenated derivatives of Phe, Tyr, Trp or even His-derivatives (imidazole ring would
bring less basicity at P1 position than guanidinium group).

These compounds are

expected to enhance their interactions at S1 position through hydrophobic or aromatic
interactions and are predicted to have a higher oral bioavailability.
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Chapter 2
Solid Phase Peptide Synthesis of individual and of peptide libraries
2.1. INTRODUCTION
Large combinatorial libraries of random peptides have een used for a variety of
applications that include analysis of protein-protein interactions, epitope mapping, and
drug targeting. The major obstacle in screening these libraries is the loss of specific but
low affinity binding peptides during washing steps. Loss of these specific binders often
results in isolation of peptides that bind nonspecifically to components used in the
selection process (1-10). To avoid these problems, we constructed focused libraries of
peptides derived from the original sequences: D-Phe(P3)-Pro(P2)-D-Arg(P1)-X(P1’)CONH2 and D-Phe(P3)-Pro(P2)-Arg(P1)-D-Pro(P1’)-Y(P2’)-CONH2 using a modified
'one-bead-one-compound' approach. The chemical synthesis of 10 peptides at a time for
each variation in X or Y within the sequence spaces presented above was achieved by
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coupling in parallel at X and Y positions followed by “pool and split” synthetic method.
The “split” step was performed at P3 position were further variations were performed
with unnatural amino acids, analogs of Phe. Steric and aggregation effects may appear
due to sequences that are hard to synthesize, thus optimizing the coupling steps (10-20)
become a very important achievement during synthesis of peptide libraries. Owing to the
robustness of amide bond chemistry, the ability to explore extensive chemical diversity
by incorporation of unnatural and natural amino acids, and the ability to explore
conformational diversity, through the incorporation of various constraints, arrays of
conformationally constrained peptides were synthesized to gain mainly hairpin and betaturn structures (10-18).

We took advantage of the well defined sequence space

containing D-amino acids at specific positions (such as D-Arg at i+3 position and D-Pro
at i+4 position) and synthesized individual peptides or peptide libraries after which the
individual components were tested for their secondary structure elements using circular
dichroism (CD) (Chapter 5). The presence of beta turns was confirmed by circular
dichroism investigations for most peptides tested in which D-Arg occupied the i+3
position within the sequence space D-Phe(P3)-Pro(P2)-D-Arg(P1)-X(P1’)-CONH2. This
chapter presents the solid phase synthesis with modified F-moc chemistry approach of Cteminal amidated peptides which were further tested for their inhibitory potential against
thrombin and were found to inhibit thrombin at 0.9- 1000 µM (Chapter 3).
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2.2. MATERIALS AND METHODS
2.2.1. Solid phase polypeptide synthesis (SPPS), based on Fmoc
chemistry synthesis of individual designed peptides.
The individual peptides both with natural and unnatural amino-acids analogs were
synthesized using the 432A Synergy Personal Peptide Synthesizer from Applied
Biosystems. The F-moc protected amino acids (both L and D) were purchased from
NovaBiochem as powder. Each amino acid was packed in a separate cadrige provided by
Applied Biosystems, such that the molar ratio between the amino acid and the resin with
free NH2 groups (10 µmole sites) was 4:1. Each synthesis yielded approximately 25
µmole yield for each tetra, penta or hexapeptide. The AM-NH2-resins from Applied
Biosystems or Rink-Amide-resins from Novabiochem were used to generate amidated
peptide.

The substitution level varied from 0.46-0.8 mmoles F-moc for one g of

amidated resin. Fmoc chemistry involved the following steps (1):
(1) Deprotection of the Fmoc (base labile) with piperidine-20 minutes (2) activation of
carboxyl

group

using

HBTU

8

mmol

(2-(1

H-benzotriazol-1-yl)-1,1,3,3-

tetrameethyluronium hexafluorophosphate)/HOBT; (3) coupling of the amino acids using
DIEA (0.4 M N,N-dilsopropylethylamine) solved in

N-methypyrrolidone (NMP)or

Dimethylformamide (DMF); tetrahydrofuran was used as a drying agent between
couplings; DMF was used as solvent throughouth the whole synthesis. The peptide was
cleaved from the resin and the side-chains were deprotected after the last F-moc was
removed with 20% piperidine using 50 µL of ethanedithiol (EDT), 50 µL of thioanisole
(as scavengers), and 900 µL TFA (trifluoroacetic acid) (for each 0.2 mg of resin).
Precipitation of the polypetide was done with 15 mL of methyl tert- butyl ether (MTBE).
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All the scavengers and TFA were filtered out using a glass filter (medium size pores) and
the peptides were washed four times with 10 mL of MTBE, for removal of organic
reagents. Solubilization of peptides was performed with 20 mL of de-ionized water and
10 mL of acetonitrile. These steps in F-moc solid peptide synthesis were performed also
for the libraries of peptides which were synthesized using one-bead-one peptide chain
method. For libraries of peptides with variable P1’ position within the sequence space DPhe-Pro-Arg-D-Pro-P1’-CONH2, 5 or 10-parallel coupling of each amino acid in P1’
were performed in separated vials, after which the mixing of all vials was performed in
one single beaker and the synthesis further proceeding with the coupling of the common
amino-acids. The coupling was performed always with 4 fold excess of the F-moc
protected amino acid with respected to the free deprotected NH2 group on the resin
support. The yield of individual synthesized peptides was further determined by highpressure liquid chromatography (HPLC) and electrospray ionization mass spectroscopy
(ESI-MS).

2.2. Reversed Phase (RP) High Pressure Liquid Chromatography
(HPLC) of individual peptides and of peptide libraries.
RP-HPLC was used to determine the purity of peptides using a Waters 2695 HPLC
system with built in Photo Diode Array (PDA) system. The buffer system contained:
buffer A: 0.1% TFA in de-ionized water (aqueous phase); buffer B: 100% CH3-CN
(acetonitrile) (organic phase). The following gradient was used for peptide separation in
the reversed phase mode: 0% - 55% buffer B (acetonitrile) in 40 minutes, 55% - 0%
acetonitrile in 15 min with a total run time of 55 min, at a flow rate of 1 ml/min. The
reversed-phase columns C18, 100 Å and C8, 300 Å, both from Varian, Microsorb Rainin
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were commonly used during the analytical control of peptide purity. Some peptides were
further purified using semipreparative columns, C18, 300 Å from Varian-Rainin. The
elution of the peptides was monitored using the PDA of the HPLC in the wavelength
range of 205 nm – 320 nm.
The concentration of each peptide in water was determined from UV absorption
measurements. The molar extinction coefficient for each residue was considered to be
around 300 at 230 nm (an average value including side-chain contributions and spillover
from the peptide Π→Π* transition) (10). In addition the concentration of pure peptides
was determined from weighing known the molecular weight for each peptide as
determined from the amino acid composition.

2.3. Electrospray Ionization-(+) mode, Mass Spectroscopy analysis of
peptides.
The theoretical molecular weight of peptides was calculated from the amino acid
sequence and the LCQ Finnigan mass spectrometer was used to confirm it. The mass
scans were acquired in electrospray positive mode (ESI-(+)) using a flow rate of 0.2
ml/min during direct injection of peptide samples into the ion source.

The ESI

spectrometer was tunned to acquire the 230 oC temperature of the capillaries before each
injection. A combination of acetonitrile, methanol and water were used to dissolved all
peptide samples before injection into the ion source. The exact mass for each peptide
was calculated from amino acid sequence, using the EXPASY tool for proteomic
analysis from Swiss Prot data bank. Positive ionization mode electrospray (ESI) mass
spectroscopy was performed for each peptide.

266

267

2.4. RESULTS AND DISCUSSIONS
The individual peptides were synthesized mostly with the automatic Peptide
Synthesizer from Applied Biosystems while the peptide libraries were synthesized
manually using the “split and pool” method. Each peptide was tested by reversed-phase
HPLC and ESI-MS (+) mode for their purity and mass (Table 13).

All peptides

synthesized were homogeneous pure and with the expected molecular weight. In general
these peptides were directly used in the kinetic assay with a couple of exceptions when
the re-purification by HPLC was necessary to be applied to increase the peptide purity.
Table 13: Representative individual peptides synthesized with their theoretical and
experimental mass together and their purity as determined by reversed-phase
HPLC.
Sequence N Æ C

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

α

N-CBZ-Pro-DArg-Gly-CONH2
Transcinnamic-Pro-DArg-Ser-CONH2
L-Tic-Pro-DArg-Cys-CONH2
L-Thi-Pro-DArg-Gly-CONH2
L-Tic-L-Thi-DArg-CONH2
Dphe-Pro-DArg-DThr-CONH2
L-Tic-Pro-DArg-DAla-CONH2
Dphe-Pro-DArg-DCys-CONH2
Transcinnamic-Pro-DArg-Cys-CONH2
DPhe-Pro-DArg-Met-CONH2
L-Tic-Pro-DArg-Thi-CONH2
Transcinnamic-Pro-Darg-Ile-CONH2
Dphe-Pro-DArg-DSer-CONH2
Dphe-Pro-DArg-DGln-CONH2
L-Tic-Pro-DArg-Gly-CONH2
DPhe-Pro-DArg-Thi-CONH2
DPhe-Pro-DArg-Thr-CONH2
L-Tic-Pro-DArg-CONH2
α
N-CBZ-Pro-DArg Ala-CONH2
DPhe-Pro-DLys-CONH2
267

Theoreti
cal M.W.
(g.mol-1)

Experi
mental
M.W.
(g.
mol-1)

HPLC:
Purity in
percentage

462.5
488.5
533.7
481.6
486.58
519.61
501.7
521.65
504.6
549.7
583.7
514.6
565.58
546.63
487.6
571.7
519.61
430.5
476.6
375.47

462.30
488.45
533.33
482.40
486.41
519.47
501.40
521.40
504.40
549.40
583.40
514.40
565.47
546.40
487.4
571.40
519.50
430.40
476.6
390.3

100
95
98
90
60
100
98
100
94
99
98
98
100
100
100
85
95
100
60
100

268
21

Transcinnamic-Pro-DArg-CONH2

22
23
24
25
26
27

401.47

401.33

100

α

476.6

476.40

100

Dnaphthylalanine-Pro-DArg-Gly-CONH2
Dnaphthylalanine-Pro-DArg-CONH2
D-tetrahydroharman-Pro-Darg-DAlaD-tetrahydroharman-Pro-Darg-Ile
Transcinnamic-Pro-DArg-DAla-CONH2

525.3
468.1
540.1
582.2
472.6

525.3
468.3
540.33
582.35
472.20

98
98
90
90
95

N-CBZ-Pro-DArg-DAla-CONH2

Figures 110 (A, B, C) are the ESI-MS (positive mode) of different peptide
libraries synthesized by maintaining the same amino acid in the P3 position but varying
amino acids at P1’ position.

Their corresponding theoretical and experimentally

determined m/z ratio is also included. The synthesis was conducted to assure equimolar
yield for each peptide variation. In most cases the yield of each peptide within the library
mix was determined by the efficiency of coupling in P1’ position. Amino-acids such as
L-Pro or L-His were less efficient in coupling. Double coupling procedures were applied
in the cases were the yield of coupling was small. The Kaizer test (1) and other important
coupling or deprotection procedures were performed as already published and reviewed
in many F-moc solid phase peptide synthesis reviews (1-3). As can be seen from Figure
110 the peptide libraries were successfully synthesized using one-bead-one peptide
method with parallel couplings in P1’ and further mixing in one pool of the whole
peptide library since the ESI-MS scan of the whole library mixture shows all expected
m/z ratios as predicted by calculated theoretical molecular mass for each individual
peptide.
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Figure 110 (A):
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Figure 110 (B):
D-Naphtylalanine (Nal)-Pro-D-ArgP1’-CONH2
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stacey(DNal)(5) #1-12 RT: 0.02-0.38 AV: 12 NL: 9.19E4
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Figure 110 (B). Zoomed section of the ESI_MS scan.
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Figure 110 (C) :
Trans-cinnamic/Dihydro-cinnamic-Pro-D-Arg- P1’-CONH2
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Figure 110 (A-C): ESI-MS (+) mass spectrometry of peptide libraries synthesized
using “one-bead-one compound” synthetic procedure.
Some peptide libraries were partially purified by reversed phase HPLC and the
masses of their mixtures were re-tested by ESI-(+). As can be seen from figures 111 and
112 the yield of some peptides in these libraries are enhanced as compared with starting
material (figure 110-C).
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Figure 111. Mass spectroscopy result of a mixture of peptides purified by HPLC:
Trans-cinnamoyl-Pro-D-Arg-D-Ser-CONH2 (MW = 487.60, m/z = 488.33),
Dihydrocinnamoyl-Pro-D-Arg-D-Ser-CONH2 (MW = 489.62, m/z = 490.40)., Transcinnamoyl-Pro-D-Arg-D-Pro-CONH2 (MW = 497.64, m/z = 499.00), Trans-cinnamoylPro-D-Arg-D-Thr-CONH2 (MW = 501.63, m/z = 502.47),Trans-cinnamoyl-Pro-D-ArgD-Asn-CONH2 (MW = 514.63, m/z = 515.40), Dihydrocinnamoyl-Pro-D-Arg-D-Asnm/z = 517.47) ,Trans-cinnamoyl-Pro-D-Arg-D-GlnCONH2 (MW = 516.65,
CONH2(MW = 528.66, m/z = 529.05), Dihydrocinnamoyl-Pro-D-Arg-D-Gln-CONH2
(MW = 530.68, m/z = 531.40), Dihydrocinnamoyl-Pro-D-Arg-D-Cys-CONH2 (MW
=506.69, m/z = 529.69 (+Na, MW = 23), Trans-cinnamoyl-Pro-D-Arg-L-Thi-CONH2
(MW = 553.77, m/z = 554.31), Trans-cinnamoyl-Pro-D-Arg-D-His-CONH2(MW =
537.67, m/z = 537.33-539.47), Dihydrocinnamic-cinnamoyl-Pro-D-Arg-D-HisCONH2(MW = 539.69, m/z = 540.38), Trans-cinnamoyl-Pro-D-Arg-D-Thr-CONH2(MW
= 501.63, m/z = 524.63 (524.27, + Na (MW =23)).
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Figure 112: Mass spectroscopy result of a mixture of peptides: Trans-cinnamoyl-ProD-Arg- D-Pro-CONH2 (MW = 497.64, m/z = 498.23), Dihydrocinnamoyl-Pro-D-Arg-DPro-CONH2 (MW = 499.66, m/z = 500.40), Trans-cinnamoyl-Pro-D-Arg-D-Thr-CONH2
MW = 501.63, m/z = 502.22), Dihydrocinnamoyl-Pro-D-Arg-D-Thr-CONH2 (MW =
503.65, m/z = 504.24).

Other original ESI-(+)-MS of peptide libraries and of purified peptides are presented in
APPENDIX X.
The peptide libraries were subjected to reversed-phase HPLC for further
purification of individual peptides. In Appendix XI some of the HPLC preparative runs
and analytical HPLC control of purity of some peptides are presented. The structure274
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activity relationship was performed only for purified peptides using in vitro kineticsassay of thrombin inhibition (Chapter-3).
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Chapter 3
Kinetics analysis of thrombin inhibition by synthetic peptides
3.1. INTRODUCTION
The search for small, orally bioavailable, non-peptidic synthetic inhibitors of
thrombin has been intense in many pharmaceutical companies (1-10).

Two small

molecular weight inhibitor types are emerging as structure-activity relationships were
primarily investigated in the last years. The first is argatroban and NAPAP type (11-12),
were the lipophilic groups on either side of the basic P1 chain pack together to interact
with the hydrophobic S2 site (13-15). Napsagatran (Ro 46-6240) developed by Hilpert et
al. (16) has a more complex P1 residue (see Scheme 7) but belongs to the same group as
argatroban and NAPAP. The only interaction with the catalytic residue Ser 195 is via a
hydrogen bond to the carboxylate function in both argatroban and napsagatran.
Unfortunately, none of these compounds is orally active due to either poor absorption
from the gastrointestinal tract and/or rapid clearance via the bile (17). A second inhibitor
type is based on the substrate-derived irreversible chloromethyl ketone inhibitor PPACK
and includes compounds such as DuP-714 and efegatran (1-17). These compounds
interact covalently with the hydroxyl group of catalytic Ser-195 residue. Though oral
activity has been claimed for these compounds, the selectivity toward thrombin is weaker
due to the conserved catalytic Ser 195 within the active site of different serine proteases
(18-25).
In addition to the above mentioned groups of thrombin inhibitors, potent and
selective inhibitors of thrombin were derived based on the D-Phe (P3)-Pro (P2)-Arg (P1)
sequence in which Arg residue was replaced by bezamidine or by 1-amidinopiperidine
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which conserved the salt-bridge with Asp-189 from the active site of thrombin (18-22).
An important difference between thrombin and trypsin is the replacement of Ser 190 in
trypsin by alanine in thrombin. This renders the S1 pocket of thrombin bigger and more
hydrophobic. As part of an effort to generate highly selective thrombin inhibitors some
research groups were exploring other substituents at P1 position while maintaining
conserved the hydrophobic moieties at P3 and P2 position. Thus, the P1 position was
probed with substituted five-membered hetaryl amidines which gave a different special
display of the substituents than the often used paraaminomethylbenzamidines. An
additional small substituent on the hetrocyclic ring was expected to result in a
disfavorable interaction with the Oγ atom of Ser190 in trypsin thereby increasing the
selectivity toward thrombin. Indeed, the compounds were shown more than 1000 fold
higher selectivity toward thrombin than trypsin (25-30).
We choose to develop peptide-inhibitors using the original sequence D-Phe (P3)Pro (P2)-Arg (P1) but maintaining constant the Pro at P2 and switching the L-Arg into DArg to obtain a nonhydrolyzable scissile bond -D-Arg-X- . We also scanned the P3
positions with different amino-acids analogs or with trans, cis and dyhidrocinnamic acid
in an effort to increase the lipophilicity for the S3 pocket and to investigate other
conformational constraints at P3 position which would enhance the affinity of the peptide
ligand for the target thrombin. The structure-activity-relationship (SAR) for 66 peptides
derived from the sequence D-Phe (P3)-Pro (P2)-D-Arg (P1) is the subject of the actual
chapter. The peptides were screened for their structural fitness within the active site of
thrombin by molecular docking (Chapter 1). In all doking experiments the carbonyl
carbon from D-Arg (P1) was shown to have more than 4.5 Å interatomic distance from
the Oγ of Ser195 from the active site of thrombin. It is very well known from X-ray data
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(31-40) that the carbonyl carbon of L-Arg from P1 is within less than 3 Å to Oγ of Ser195
in compounds were the scissile bond L-Arg-X is hydrolysable (40-50). Based on other
X-ray studies an interatomic distance higher than 4.5 Å between carbonyl carbon of DArg (P1) and Oγ of Ser195 from thrombin would render the scissile bond D-Arg-X
nonhydrolyzable (45-50). Based on these structural evidences and based on our own
docking experiments we synthesized peptides with D-Arg in P1 and investigated the P1’,
P2’ and P3’ positions within the peptide for best sequence space that would confer both
protease stability and higher inhibitory potential. The P3 position was scanned with Phe
analogs (D-Naphthylalanine (Nal), L and D-tetraisoquinoline (Tic), D-tetrahydroharman
acid (D-Tpi), L-beta-2-thienylalanine (L-Thi)) and with trans, cis and dihydro-cinnamic
acid. All peptides were non-hydrolyzable as demonstrated by their mass spectroscopy
analysis after preincubation for 1 hour at room temperature with thrombin, which showed
the intact peptides, supporting the structural predictions from docking experiments.

3.2. MATERIALS AND METHODS
All kinetics experiments for thrombin inhibition were performed using the colorimetric
assay

with

S2238

[H-D-Phenylalanyl-L-pipecolyl-L-Arginine-p-nitro-anilide

dihydrochloride (H-D-Phe-Pip-Arg-pNA.2HCl)] (Chromogenix) as the specific
chromogenic substrate for thrombin. The experiments were conducted at 25oC, using a
thermostated Cary-UV-VIS Spectrophotometer in phosphate buffer, pH=7.46, of 0.1 I
(ionic strength), containing 0.2 M NaCl and 50 µg/ml BSA (bovine serum albumin). The
addition of BSA was required by the fact that thrombin is adhering on plastic cuvettes
through electrostatic interactions, decreasing the final rate of reactions up to 100 fold as
compared with the reaction run in the presence of BSA. The final reaction volume was
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1ml. The hydrolysis of the chromogenic substrate was monitored by measuring changes
in absorbance at 405 nm using the built-in Kinetics software of Cary-UV-VIS
spectrophotometer. Each kinetic reaction was performed to completion during 12-20
minutes and the signal for changing absorbance at 405 nm was recorded each 1 second.
Kinetics of thrombin inhibition were performed using 2 different substrate
concentrations:
(1) In one set of experiments the reactions were performed in pseudo-first order
kinetics conditions (i.e. at substrate concentration below the Km, in most cases 0.7 Km,
or near Km). Of course the most rigurous pseudo-first order kinetics are run at substrate
concentration below Km, but the signal at 405 nm should be reliable such that the fit of
the experimental data to the pseudo-first order mathematical model can be done.

The

Km of bovine thrombin for S2238 is around 4 µM as determined experimentally using
the steady-state assay. Therefore, the pseudo-first order kinetics were conducted at 2.8
µM (0.7 Km). The pseudo-first order kinetics were used to determine the observed rate
of hydrolysis of substrate (kobs), from which the inhibitory constant was determined (KI
= [I] / (kobsuninhib/kobsinhibited -1) (I), where [I] = inhibitor concentration, kobsuninhib =
observed pseudo-first order rate in the absence of inhibitor and kobsinhibited = observed
pseudo-first order rate in the presence of [I] concentration of inhibitor).

The Ki were

derived from this equation by assuming competitive inhibition model. In this case using
the relationship, v= kcat [E] [S]/(Km (1+ [I]/Ki) +[S]) or
[E]/v = 1/kcat + (Km (1+ [I]/Ki))/(kcat [S]) it follows that a plot of [E]/v vs. [I] at
constant [S] will be linear if competitive inhibition holds.

Furthermore, under the

conditions [S] <<< Km, the pseudo-first-order rate constant k equals v/[E]. Therefore,
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k-1 vs. [I] should be linear and Ki can be obtained by using the equation:
1+[I]/Ki = [E]i/vi . v0/[E]0 = k0/ki from were the equation Ki = [I]/( ko/ki -1) which is the
same with the equation (I) were ki and k0 are the pseudo-first order constants determined
in the presence and in the absence of the inhibitor, respectively.
Each kinetic trace was fitted to the first order reaction mathematical model At =

A0e-kt where At = the absorbance at 405 nm at any time during 20 minutes of run, A0=
the absorbance at 405 nm at time t=0, and k= the observed pseudo-first order rate
constant. The fit was performed using the Nonlinear Regression built-in software of the
Cary UV-spectrophotometer, and the kobs obtained from the fit were compared for the
reactions performed in the presence of inhibitor with those obtained for reactions
performed in the absence of inhibitor.
(II) In another set of experiments the kinetics were run at five times Km (5Km) or
eight times Km (8Km) concentration of substrate S2238 (saturation kinetics) in order to
determine the type of inhibition for each peptide using Lineweaver-Burk or EadieHofstee plots. The reactions were allowed to go to completion, during 12-20 minutes and
the slopes at different time points were used to determine the velocities at that point. The
difference between the absorbance at 405 nm after 20 minutes of run (which is
proportional with the total amount of substrate present in the reaction mixture and
represent the infinite absorbance value) and the absorbance at 405 nm taken in the middle
of the slope for each data point is proportional to the substrate concentration in reaction
mixture at that point. In all calculations a molar extinction coefficient of 8,800 [M-1cm-1]
at 405 nm was used for the reaction product (pNA). We assumed that upon hydrolysis of
S2238 substrate for each molecule of S2238 one molecule of para-nitroanilide was
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liberated. The progress curve analysis was performed using the software provided by the
Cary-UV-VIS spectrophotometer. The following formulas were used to calculate the
substrate concentrations (in µM) and velocity (in µM/min) at any point on the progress
curve:
(1) S (substrate) = {[A00-Amidle]/8,800} x 106 (µM) were A00 represents the infinite
absorbance value (i.e. the absorption after the reaction proceeded to completion).
(2) V (velocity) = {(∆A/min)/8,800} x 106 (µM/min) were ∆A/min is the variation of
absorbtion/min (i.e. is the slope in the point on the kinetic curve were the velocity is
calculated).
(3) Amidle (Absorbtion in the midle of 1 minute interval at which the slope is calculated)
is calculated using the formula:
Amidle = {[Astop-Astart] /2 +Astart};
The exact concentration of thrombin was determined from the UV absorption
spectrum using the molar extinction coefficient for thrombin (65,735 M-1cm-1) at 279
nm.
The final concentration of thrombin used in all kinetics experiments was determined
from a preliminary pseudo-first order kinetics experiment in which the final
concentration of substrate S2238 was kept constant (0.7 Km = 2.8 µM), while the
final concentration of thrombin was varied between 10nM-40nM. A plot of kobs as a
function of enzyme concentration determined that 30 nM thrombin final
concentration was a reliable concentration since is in the linear range of kobs =
f(enzyme concentration) and thus a linear relationship between the A (405 nm) and
the enzyme concentration is expected (Figure 113).
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The effect upon Km and Vmax were determined by assuming different models for
thrombin inhibition.

For the most peptide-inhibitors tested at low concentration of

peptide a competitive inhibition model was assumed and in this case Km’ (i.e. Km in
the presence of the inhibitor) was increased with the value Km multiplied by
(1+[I]/Ki), were the Km is the thrombin’ Km for S2238 while the Vmax remained
unchanged since the peptide is binding to the free enzyme E. At higher concentration
of peptide (> 10 µM) both a non-competitive and an uncompetitive model for
inhibition was assumed.

In the case of non-competitive inhibition the peptide could

bind both to free enzyme E and to the complex ES (enzyme-substrate) and in this case
Km remained unaffected while the Vmax is decreased and is given by equation
Vmax/(1+[I]/Ki) were Vmax is the maximal velocity in the absence of the inhibitor,
[I] is the concentration of peptide inhibitor and Ki is the inhibitory constant. In the
case of uncompetitive competition the peptide inhibitor could bind to the ES complex
only, thus both Km and Vmax were decreased by (1+[I]/Ki) value.
In order to confirm the validity of the assay for determining the inhibition constant,
the steady-state saturation kinetics was used to evaluate the Ki for inhibition of
thrombin by the commercially available inhibitor (“Thromstop”) (Ki = 25nM for
bovine thrombin).

3.3. RESULTS
Kinetics of thrombin inhibition by synthetic peptides
The preliminary steady-state kinetics were conducted to determine the Km and
the kcat of bovine thrombin for the substrate S2238. The Km value was confirmed to be
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in the range already published (1-17), i.e. 4.16 + 0.63 µM and the Vmax was also in the
range published, i.e. 7.60 (µM/min). The kcat (Vmax/Et) was however for fold lower
than the published value for thrombin (4.21 [sec-1]), suggesting that the enzyme was not
fully active.

However, for steady-state kinetics the % activity of thrombin is less

important, thus all the kinetics experiments were conducted with this bovine thrombin
inhibitor.
In the first set of experiments the linearity of the observed pseudo-first rate of
hydrolysis (kobs) as a function of the enzyme concentration was determined by
maintaining the substrate concentration constant (0.7 Km) and varying the concentration
of enzyme between 10 nM and 30 nM. In Figure 113, the graph describing the linearity
of kobs with the enzyme concentration is presented. The experimental data were fitted to
a linear regression analysis. It can be seen that when the enzyme concentration was
between 10 nM and 30 nM there was a linear relationship between kobs and the enzyme
concentration.

This experiment determined us to choose 30 nM, the enzyme

concentration of thrombin at which all kinetics experiments were performed.
The pseudo-first order kinetics experiments with different peptides inhibitors
were conducted at concentrations of S2238 substrate below Km (0.7 Km), or near Km
(2Km) as already described in “Materials and Methods” and the concentration of each
peptide was varied between 1-500 µM.
The individual kinetic traces with some of the peptides that were tested for the
inhibitory activity are presented in the Figure 114 (A-T). The kinetic raw data were
imported from Cary-UV spectrophotometer by use of the program Sigma Plot and the
nonlinear fit of the kinetics traces to first order reaction (At = A0e-kt) was confirmed with
the software NonLin Regression package. For the most potent inhibitors with inhibitory
284

285
constant Ki (KI = [I] / (kobsuninhib/kobsinhibited -1)) in the range of 100-150 µM the
linearized function of the first order fit was used to confirm the kobs obtained from
nonlinear regression analysis of kinetic traces. The linearized form of the first order
mathematical model is described by the equation: ln (A00-At) = lnA0-(kobs) t, where A00
and At have the significance as described in “Materials and Methods” (figure 114, H and
I).

Figure 113: The linearity of kobs with the enzyme concentration over the range 10
nM-40 nM.
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Figure 114 (A-S): The pseudo-first order kinetics for thrombin inhibition by
different peptides.
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Some peptides showed a variation in Ki (for most cases an increased Ki) with
increasing concentration of peptide concentration in the inhibition assay mix (figure 114115). It is well documented that many peptides are aggregating into macromolecular
complexes, a process determined by ionic strength and pH (40). The reason we observed
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these aggregation phenomena only in some peptides and not in all cases studies may be
related with their sequence. Primarily, the high content of aromatic amino acids in some
peptides sequences may enhance the aggregation through pi-pi stacking interactions
between the aromatic rings. D-Phe-Pro-D-Arg-D-Pro-Phe-CONH2 showed an increased
KI as the concentration of peptide was increased in the final reaction assay: at 1 µM
concentration of peptide Ki was 1.88 µM; at 5 µM concentration of peptide-Ki was 93.34
µM and at 10.0 µM concentration of peptide-Ki was 169.00 µM. These results suggest
that the peptide may aggregates at higher concentration which can cause a lost in affinity
for thrombin and thus we obtained a higher Ki. Other peptides such as D-Phe-Pro-DArg-D-Pro-Ala-CONH2 and D-Phe-Pro-D-Arg-D-Pro-Trp-CONH2 showed the same
effect, i.e. an increase in Ki with increased peptide concentration (D-Phe-Pro-D-Arg-DPro-Trp- CONH2 had Ki = 64.41 µM at 20.0 µM in the inhibition assay and Ki = 107.98
µM at 50 µM peptide concentration in the inhibition assay; D-Phe-Pro-D-Arg-D-Pro-AlaCONH2 had a Ki = 58.66 µM at 20 µM final peptide concentration in the reaction mix
and a Ki = 146.64 µM at 50 µM final peptide concentration in the reaction mix). For
most peptides, the Ki remained constant at higher concentration of peptide and the
thrombin inhibition was mostly following a competitive model (see progress curve
analysis in Figure 117).
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Figure 115: Variation of Ki with increasing concentration of peptide in the assay
mix.

Figure 116: Variation of Ki with increasing concentration of peptide in the assay
mix.
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A detailed presentation of all Kis of different peptides screened for their
inhibitory activity against thrombin is presented in tables 14-15.
Table 14. Hexapeptides, pentapeptides and tetrapeptides inhibitors for thrombin
and their experimentally determined Kd = Ki (µM). Ki was determined from
pseudo-first order reactions of thrombin inhibition as described in Materials and
Method (Section 3.2.)
Peptide library
N

CONH2
D-Phe-Pro-D-Arg-Arg
D-Phe-Pro-D-Arg-Ala
D-Phe-Pro-D-Arg-Gly
D-Phe-Pro-D-Arg-Glu
D-Phe-Pro-D-Arg-His
D-Phe-Pro-D-Arg-Ser
D-Phe-Pro-D-Arg-Trp
D-Phe-Pro-D-Arg-Tyr
D-Phe-Pro-D-Arg-Pro
D-Phe-Pro-D-Arg-Cys
D-Phe-Pro-D-Arg-Gln
D-Phe-Pro-D-Arg-Lys
D-Phe-Pro-D-Arg-Ile
D-Phe-Pro-D-Arg-D-Ala
D-Phe-Pro-D-Arg-D-Pro
Gly-Arg-D-Pro-Phe

Ki (µM)

D-Phe-Pro-D-Arg-Val
D-Phe-Pro-D-Arg-Gly-Asp
D-Phe-Pro-D-Arg-Gly-Asn

91.09 + 21.99
16.64 + 0.01
5.89 + 0.33
555.68 + 89.77
122.08 + 0.06
17.60 + 0.62
65.55 + 6.85
50.5 + 5.0
89.50 + 3.94
12.61 + 0.22
43.06 + 6.78
66.56 + 19.73
6.33 + 0.03
2.06 + 0.03
489.26 +112.95
1138.95 +
482.27
56.32 + 9.59
156.25
112.35

D-Phe-Pro-D-Arg-Gly-Asp-Ala

705.88

D-Phe-Pro-D-Arg-Gly-Asp-Met

993.4

D-Phe-Pro-D-Arg-Gly-Asp-Lys

643.77

D-Phe-Pro-D-Arg-Gly-Asp-Gly

1,730

D-Phe-Pro-D-Arg-Tyr-Phe

3,333

D-Phe-Pro-Arg-D-Pro-D-Phe

2,362
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D-Phe-Pro-Arg-D-Pro-D-Arg

980.4

D-Phe-Pro-Arg-D-Pro D-Tyr

3,639

Table 15. Tetrapeptide library containing natural and unnatural amino acids
analogs and their experimentally determined Kd = Ki (µM).

Sequence N Æ C

Ki

Ka

(dissociation

(apparent

constant)

association

(µM)

constant) =
1/Ki
(L/Mol)

1

L-Tic-Pro-DArg-Cys-CONH2

1,050

0.952 x 103

2

L-Tic-L-Thi-DArg-CONH2

562.5

1.77 x 103

3

L-Tic-Pro-DArg-DAla-CONH2

121.25

8.24 x 103

4

L-Thi-Pro-DArg-Gly-CONH2

175

5.71 x 103

5

L-Tic-Pro-D-Arg-Thi-CONH2

312.7

3.19 x 103

6

D-Phe-Pro-D-Arg-DCys-CONH2

2.4

416.6 x 103

7

D-Phe-Pro-D-Arg-Cys-CONH2

12.51

80.0 x 103

8

D-Phe-Pro-D-Arg-Met-CONH2

37

27.03 x 103

9

D-Phe-Pro-D-Arg-DThr-CONH2

0.940

1063.8 x103

10

D-Phe-Pro-D-Arg-Thr-CONH2

12.5

80.0 x 103

11

D-Phe-Pro-D-Arg-DSer-CONH2

12.3

81.3 x 103

12

D-Phe-Pro-D-Arg-Ser-CONH2

17.06

58.6 x 103

13

D-Phe-Pro-D-Arg-Gly- CONH2

5.89

169.7 x 103

14

D-Phe-Pro-D-Arg-Thi-CONH2

8.16

122.5 x 103

15

D-Phe-Pro-D-Arg-DGln-CONH2

19.31

51.8 x 103

16

D-Phe-Pro-D-Arg-Gln-CONH2

43.06

23.22 x 103

17

D-Phe-Pro-D-Arg-Ala- CONH2

16.64

60.1 x 103

18

D-Phe-Pro-D-Arg-DAla- CONH2

2.06

485.4 x 103
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19

D-Naphthylalanine(Nal)-Pro-DArg-

11.62

86.05 x 103

2.71

369.01 x 103

520.5

1.92 x 103

147.5

6.77 x 103

6.23

160.5 x103

CONH2
20

D-Naphthylala(Nal)-Pro-DArg-GlyCONH2

21

D-tetrahydroharman(D-Tpi)-ProDArg-D-Ala

22

D-tetrahydroharman(DTpi)-Pro-DArg-Ile

23

Transcinnamic-Pro-D-Arg-GlyCONH2

24

Ciscinnamic-Pro-D-Arg-Gly- CONH2

31.5

31.7 x 103

25

Transcinnamic-Pro-D-Arg-Ile-

161.8

6.18 x 103

CONH2
26

Ciscinnamic-Pro-D-Arg-Ile-CONH2

53.6

18.6 x 103

27

Transcinnamic-Pro-D-Arg-Ser-

83

12.05 x 103

CONH2
28

Ciscinnamic-Pro-D-Arg-Ser-CONH2

117.6

8.5 x 103

29

Transcinnamic-Pro-D-Arg-Cys-

30.5

32.8 x 103

CONH2
30

Ciscinnamic-Pro-D-Arg-Cys-CONH2

394

2.5 x 103

31

Transcinnamic-Pro-D-Arg-D-Ala-

44.6

22.42 x 103

69.4

14.4 x 103

CONH2
32

Ciscinnamic-Pro-D-Arg-D-AlaCONH2

33

Transcinnamic-Pro-D-Arg-CONH2

240

4.1 x103

34

Dihydrocinnamic-Pro-D-Arg-Cys-

64

15.6 x 103

105.8

9.45 x 103

171.2

5.84 x 103

CONH2
35

Dihydrocinnamic-Pro-D-Arg-GlyCONH2

36

D-Tic-Pro-D-Arg-Gly-CONH2
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The structure-activity relationships presented in Tables 14 and 15 showed that the
amino-acid at P1’ position was a major factor in determining the inhibitory potential of
each peptide for thrombin. Also, the P3 position within the peptide ligand was an
important factor in determining the inhibitory potential and only D-naphthylalanine (DNal) was showing at least two fold higher inhibitory activity than D-Phe when Gly was
occupying P1’ position while P2 (L-Pro) and P1 (D-Arg) remained constant. Figure 117
(A-Q) present a comparison between different peptide sequences with respect to their
inhibitory activity against thrombin contrasting the P1’ and P3 positions with respect to
their effect upon the Ki (inhibitory constant) (the 1/Ki = Kassociation is presented for
some graphs). In addition the screening of pentapeptide libraries with the sequence
D-Phe-Pro-Arg-D-Pro-P2’-CONH2 is presented for the SAR at P2’ (Figure 117 (A)).
Figure 117 (A-S). Comparison of SAR for peptides with different sequence space
where containing single amino acid variations (for details related to the Ki of each
peptide refer to tables 14 and 15).
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(S)

In order to determine the mechanism of thrombin inhibition by different lead peptides
progress curve analysis was performed for all kinetics of inhibition run at 3Km or 5Km
of substrate S2238 concentration (saturation conditions) (Figure 118).
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The kinetics of

312
thrombin inhibition were run at 1 ml final volume, in the buffer for thrombin assay (0.1 I
(ionic strength) potassium phosphate buffer, pH 7.48, containing 0.2 M NaCl and 50
µg/ml BSA as additive) as described in Materials and Methods on Section 3.2. EadieHofstee or Lineweaver Burk plots were performed for all major lead compounds in order
to determine the effect upon Km and Vmax and the models for thrombin inhibition were
assumed to be competitive at low concentration of peptide or non-competitive or
uncompetitive at higher concentration of peptide (> 10 µM) as presented in Materials and
Methods (Section 3.2).
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A) Progress curve analysis of thrombin inhibition by peptide
[D-Phe-Pro-D-Arg-D-Ala-CONH2]
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B)

Figure 118 (A-B). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as Eadie314
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Hofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.

C) Progress curve analysis of thrombin inhibition by
peptide [D-Phe-Pro-D-Arg-D-Cys-CONH2]
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D)
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Figure 118 (C-D). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.
The progress curve analysis for thrombin inhibition by peptide [D-Phe-Pro-DArg-D-Cys-CONH2] was used to obtain the Eadie-Hofstee plot. From Eadie-Hofstee the
inhibitory effect of peptide was determined by assessing the effect upon Km and Vmax,
from which the Ki was calculated assuming the competitive or mixed inhibition model
(1-10).
As can be seen from the results of thrombin inhibition a mixed competition model
can be proposed in which the peptide binds with high affinity to the active site
(competitive inhibition) (Ki1 = 2.4 uM) but it binds independently to another binding site
(it can overlap partially with the active site) in the ES (enzyme-substrate) complex
(Ki2=7.9 uM). In this model the Km remains almost unchanged as can be seen from the
above results (12.85 uM) only at low concentration of peptide (below 5 uM). As the
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concentration of peptide is increasing above 5 uM the mixed inhibition behavior became
more powerful and we obtained an effect upon both the Km and the Vmax.
The same type of mixed inhibition behavior was obtained for the peptide D-PhePro-D-Arg-Ser-CONH2 (i.e. competitive and uncompetitive inhibition). The peptide
affected both the Km and vmax during the kinetics of thrombin inhibition (Figure 118 E)
again at lower concentration of peptide being mostly competitive inhibition while at
higher concentration behaving mostly as uncompetitive inhibition (peptide is binding to
ES complex and both Km and vmax are decreased).

E)

Figure 118 (E). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.
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F)

Figure 118 (F). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.
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G)

0 µM
20 µM

Figure 118 (G). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.

320

321

H)

Figure 118 (H). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.
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I)
Eadie-Hofstee plot for thrombin inhibition by peptide
[D-Phe-Pro-D-Arg-Ala-CONH2]

Figure 118 (I). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots. The Ki calculated from the slope of the curve for 5 µM
inhibitor was around 17 µM which was the same with the Ki calculated at pseudo-first
order kinetics (see table 8). At 10 µM inhibitor a mixed type of inhibition is observed.
In this case the two Kis were: Ki (I) = 26.31 µM and Ki (II) = 8.53 µM.
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J)

Figure 118 (J). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.

323

324

K)

Figure 118 (K). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.
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L)

0µM

100 µ M
300 µ M

Figure 118 (A-L). Progress curve analysis of kinetics for thrombin inhibition run at
saturation concentration of substrate S2238 in the presence of different peptide
inhibitors. The concentration of substrate and the velocity on different points of each
curve were determined as described in Materials and Methods and presented as EadieHofstee or Lineweaver-Burk plots. The vmax and Km were calculated for each inhibitor
based on the inhibition plots.

3.4. DISCUSSIONS
The main purpose of this research investigation was to discover peptides with
potential inhibitory activity against thrombin. We were interested primarily in finding
reversible peptides inhibitors directed against the active site of thrombin which would
allow the inhibition of blood clotting.
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Originally we discovered that synthetic pentapeptides such as D-Phe-Pro-D-ArgGly-Asp and D-Phe-Pro-D-Arg-Gly-Asn are having 8 fold more inhibitory effect than the
peptides D-Tyr-Pro-Arg-D-Pro-D-Tyr and D-Phe-Pro-D-Arg-Tyr-Phe (figure 117 (S) and
sequences D-Phe-Pro-D-Arg-Gly-Asp and D-Phe-Pro-D-Arg-Gly-Asn have the highest
%inhibition of thrombin at 300 µM final concentration, more then 60% inhibition in the
case of D-Phe-Pro-D-Arg-Gly-Asp and more than 70% inhibition of thrombin in the case
of D-Phe-Pro-D-Arg-Gly-Asn sequence (Figure 117 (S)).
Another set of sequences like peptides D-Phe-Pro-D-Arg-Gly-Asp-Ala, D-Phe-ProD-Arg-Gly-Asp-Lys and D-Phe-Pro-Arg-D-Pro-D-Arg and D-Phe-Pro-D-Arg-Gly-AspMet have more then 30% inhibition or more then 20% inhibition of thrombin respectively
at 300 µM final concentration of peptide in the reaction mixture. Other sequences like DPhe-Pro-D-Arg-Tyr-Phe or D-Tyr-Pro-Arg-D-Pro-D-Tyr have very small inhibitory
activity (less than 10%) at the same final concentration of inhibitor (300 µM).
All peptides showed to be resistant to hydrolysis by thrombin since the
preincubation of thrombin (30 nM) with each peptide (20 µM) for 30 minutes at room
temperature in the same buffer used for kinetics of thrombin inhibition didn’t resultated
in the production of tripeptide D-Phe-Pro-D-Arg-COOH (MW= 418.5) as would have
been expected if hydrolysis would have taken place (i.e. D-Phe-Pro-D-Arg-X-CONH2
has the scissile bond -D-Arg-X- stable to hydrolysis). The results from ESI-MS analysis
of the reaction mixture thrombin+peptide are presented in Appendix XII.
From these original data we concluded that there is a structure-activity
relationship (SAR) between the specific amino acid sequences and the inhibitory activity.
From this initial study we hypothesized that the peptides which have the sequence D-Phe-
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Pro-D-Arg-Gly-Asp(Asn) are better inhibitors then those that are conserving the D-PhePro-D-Arg sequence but have aromatic amino acids in the next two consecutive positions
from N to C terminus (like Tyr and Phe).
These original SAR studies in the pentapeptides and hexapeptides series
supported the hypothesis that the sequence space D-Phe-Pro-D-Arg-P1’-CONH2 is more
effective than the sequence D-Phe-Pro-L-Arg-D-Pro-P2’. We proceeded further and we
synthesized tetrapeptide libraries using the sequence space D-Phe-Pro-D-Arg-P1’ were
the P1’ position was occupied with all structural classes of natural L-aminoacids, such
that an SAR at P1’ position was investigated. We were successful in finding a StructureActivity Relationship (SAR) between specific amino acid sequences and the inhibitory
activity. The peptides D-Phe-Pro-D-Arg-Gly-CONH2, D-Phe-Pro-D-Arg-Ala-CONH2,
D-Phe-Pro-D-Arg-D-Ala-CONH2, D-Phe-Pro-D-Arg-D-Cys-CONH2, D-Phe-Pro-D-ArgCys-CONH2, D-Phe-Pro-D-Arg-Ser-CONH2, D-Phe-Pro-D-Arg-D-Ser-CONH2, D-PhePro-D-Arg-Ile-CONH2,

D-Phe-Pro-D-Arg-Thr-CONH2,

D-Phe-Pro-D-Arg-D-Thr-

CONH2 are lead inhibitors having Ki values below 15 µM (see table 14). The new
inhibitor D-Phe-Pro-DArg-(L)Thi-CONH2 has a Ki of 8.6 µM and was discovered as
being a new lead compound in the series D-Phe-Pro-DArg-P1’ and contains an unnatural
amino acid analog in the P1’ position.
These results support the view that the structure of the amino-acid at P1’ position
in the sequence context D-Phe-Pro-DArg-P1’-CONH2 may induce significant changes in
the conformation of the peptide inhibitor bound reversibly to the active site or to an
independent site of thrombin possible near the active site groove. We are hypothesizing
that these changes in the conformation of the peptides are accompanied by local changes
in the conformation of thrombin (induced fit) such that amino acids and amino acids
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analogs with bulky hydrophobic side chains are fitting in P1’ position (such as L-Ile and
L-Thi) even though they are occupying the P2’ positions in natural substrates (such L-Ile)
(40-50). Other group of researchers (Usakiewicz J.J.S et al., 2000) (51) have shown
using bivalent peptide inhibitors which are blocking active site and the fibrinogen binding
site that the L-Thi in P1’ position induces a conformation changes in thrombin such that
the Lys60F side chain of thrombin is moving significantly and is forming a large nonpolar
S1’ subsite to accommodate larger bulky residues in P1’ (X-Ray structures of the bivalent
peptide inhibitors with thrombin were the basis for the observed structural changes (51).
The proposed changes in the conformation both in the inhibitors and in the active site of
thrombin itself may be responsible for the 5-500 fold determined differences in their
inhibitory activity (see Tables 14-15).

The molecular models of the conformation

adopted by the peptides into active site of thrombin support also the experimental data
(see figure 109 (A-D)) by showing the change in the conformation of the peptide
backbone and of specific side chains of the residues at P3-P1’ positions as one single
amino acid at P1’ is changing.
Also, significant differences between the Kis of tetrapeptides from the series DPhePro-DArg-P1’ suggest that the interaction between the amino acid at the P1’ position and
the S1’ pocket in thrombin is very specific. These results are consistent with the X-ray
data which showed that the S1’ pocket of thrombin is a small cavity lined with amino
acids of the back side of the apolar S2 pocket (His57, Tyr60A and Trp60D) and the side
chain of Lys60F (51). This S1’ pocket can accommodate small polar amino acid side
chains as observed from P1’ amino acids in a number of natural thrombin substrates (P1’
in most physiological substrates is occupied by Gly, Ser, Thr, Ile, Leu and Val). The
computational model of the active-site docked tetrapeptides from the series D-Phe-Pro-D328
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Arg-P1’ and their experimentally determined Ki values (see tables 14-15 and figure 109)
support the X-ray data since the best inhibitors are having L/D amino acids with small
side chain (like Gly) or with polar (like Cys, Ser, Thr) or small nonpolar side chains
(Ala).
The most important experimental findings are related to the change in the affinity
as the configuration of the amino-acid in the P1’ position changes from L to D. The
switch from L to D in the P1’ is related to a 13 fold increase in the affinity of
tetrapeptides from the series D-Phe-Pro-D-Arg-P1’-CONH2. These experiments are the
first in the field of reversible peptides inhibitors for thrombin to show that a switch in the
configuration from L to D for the amino-acids mostly encountered at P1’ in the
physiological thrombin’s substrates (such as L-Ser, L-Thr and L-Ala) causes at least a 10
fold increase in the affinity for thrombin (figure 117 E-F). The structural basis for this
favorable switch in the affinity was further investigated through molecular modeling
experiments and as described earlier on section 1.1. we observed a more favorable
hydrogen bonding network for the D-amino acid in P1’ than for the L-isomer (see figure
15 D).
These differences in the binding affinities upon switching from L into D for aminoacids in P1’ was confirmed both kinetically (by measuring the observed rates in pseudofirst order kinetics-see figures ) and through ITC data (the heat released for peptides with
L-Ala in P1’ is lower (1.2 kcal/mole of injectant) than the heat released during the
titration of the same peptide but with D-Ala in P1’ (4.5 kcal/mole of injectant) (see
figures 120-123 and Appendix XIII).
We were also developing peptides with new P3-analogs of D-Phe (see figure 25).
The SAR for P3 position (table 15) showed that the tetrapeptides from series D-Phe-Pro329
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DArg-P1’ are the best together with the peptides from series D-Nal (naphthylalanine)Pro-DArg-P1’.

Thus, D-Nal substitution at P3 position increases the affinity of a

tetrapeptide 2 fold (compare the compound with compound). The order of activity for
the peptides containing analogs of D-Phe in the P3 position is: D-(Nal) (naphtyl-alanine)
> (D)Phe> Dihydrocinnamic>Transcinnamic > >(D)Tic> L-Thi> (L)Tic >D-Tpi with
conserved residues at P2=Pro and P1=D-Arg. New peptides libraries containing D-Nal at
P3 position and variable favorable D/L natural or unnatural amino acids at P1’ position
are under current investigation.
One of the most important mechanistically findings suggest that the
experimentally determined thrombin inhibition is not 100% competitive but rather has
around 10% non-competitive and uncompetitive, mixed inhibition behavior.

It is

possible that the peptides are binding to the ES complex with higher affinity than to free
enzyme (E), at higher concentration than their Ki (figure 118). However, the results have
to be interpreted with caution since the peptides might bind partially overlapping the
binding sites of the substrate, a process which would explain the mixed inhibition
behavior of these peptides (see figures 115, 116). Also, it is possible that some of these
peptides are assembling in higher molecular complexes at higher concentration (> 2 their
Ki) and this phenomena could be responsible for the deviation from the competitive type
of inhibition behavior. We found inhibitors which were showing an increased Ki with
increasing concentration of peptides, such as the inhibitors D-Phe-Pro-L-Arg-D-Pro-LPhe-CONH2 or the trans and cis-cinnamic-peptide derivatives (see figures 115, 116).
However, other inhibitors which were showing mixed inhibition behavior were not
necessary showing the increased in Ki as the concentration of peptide was increasing in
the reaction mixture, such is the case of peptides D-Phe-Pro-D-Arg-D-Ala-CONH2 and
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D-Phe-Pro-D-Arg-D-Ser-CONH2 (see figure 118). These contradictory results supports
the view that the mixed inhibition behavior is not due entirely to the assembly of peptides
in higher macromolecular complexes but to binding of individual peptides to other sites
nearby the active site of thrombin. Further structural studies such as X-ray of binary
complexes between these lead peptides and thrombin will respond to this question raised
from kinetics of thrombin inhibition.
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Chapter 4
Isothermal titration calorimetry (ITC) studies of thrombin binding
with peptides inhibitors
4.1. INTRODUCTION
Isothermal Titration Calorimetry (ITC) is a rapid, multi-probe SAR technique for
confirming the success of lead optimization cycles without needing to determine the
structure of every complex in this iterative process (1-20). The mechanism of action, and
alterations to it, can be readily assessed using ITC. Different binding mechanisms show
characteristic ITC profiles that can be represented schematically as in the Figure 119.

∆G ∆H

-T∆S

∆G ∆H -T∆S

∆G ∆H -T∆S

Figure 119: ITC derived thermodynamic signatures for different ligands
characterized by different noncovalent interactions with the same target protein
shown as changes in the free energy (∆G), change in the enthalpy (∆H) and change
in the entropy (∆S). Scheme A: good hydrogen bonding and a conformational change;
Scheme B: binding dominated by hydrophobic interactions; Scheme C: favorable
hydrogen bondings and hydrophobic interactions (1-10).
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Each section in Figure 119 represents an interaction driven by different
mechanisms but with identical affinities. These histograms are particularly powerful
when comparing related leads. For instance, the successful addition of a hydrophobic
group for improved affinity would manifest itself in the ITC data as an increase in the
negative value of ∆G and –T∆S (scheme B).

An additional H-bond would

characteristically increase the negative ∆G and ∆H but make the -T∆S more positive
(scheme A) (11-15).
One major goal in drug design is to make drugs which bind to their target with the
highest binding affinity.

Higher affinity is known to results in lower dosage

requirements, greater specificity, better drug efficacy, reduced side effects, and less drug
resistance. The thermodynamic signatures for each drug binding to its own target can be
determined by ITC and a QSAR (quantitative structure-activity relationship) can be
derived based on change in the enthalpy (∆H) and change in the entropy (∆S)
characterizing the binding interaction. It has been already shown (Figure 119-scheme A)
that hydrogen bonding formation and favorable van der Waals interactions between drug
and target results in a favorable enthalpy of binding. Hydrogen bonding formation is a
result of optimal placement of hydrogen bond donor and acceptor groups on the drug and
target, and is highly directional and specific (21-25). In the same time hydrogen bond
donors and receptors may be in close proximity in a crystal structure but may have little
effect on binding affinity, due to conformational effects (20-21). A common strategy in
drug design is the addition of non-polar groups to increase the hydrophobic interactions
between target and compound.

However, hydrophobic interactions are non-specific

compared with hydrogen bonding.

Freire’s research demonstrated that drugs with

favorable enthalpy and entropy have highest affinity, due to specific hydrogen bond
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formation and van der Waals interactions as well as hydrophobic interactions with the
target (20-24). A better strategy for identifying lead compounds is proposed to be related
to finding compounds with favorable ∆H, and further optimize these drugs by addition of
hydrophobic groups.

This could result in a highly-specific drug with tight binding

affinity (21,23, 25).

4.2. MATERIALS AND METHODS
The ITC experiments for some lead compounds were performed at 220- 250C, using an
VP-ITC microcalorimeter from Microcal and the data were fitted using the built-in
Microcal-Origin software. The buffer for titration was the same buffer used in kinetics
studies, e.g. 0.1 I (ionic strength) potassium phosphate buffer, pH 7.46, containing 0.2 M
NaCl and 50 µg/ml BSA as additive). All samples were degassed before the titration
using the Thermo-Vac (sample degassing and thermostat) associated with the instrument.
All experiments were performed by having in the syringe the ligand (peptide) and in the
cell the thrombin (bovine, from Sigma), both equilibrated with the same buffer. The ratio
between the peptide (ligand-L) and protein (P) (i.e. L/P) was varied in between different
titration experiments from 0.01-0.05 (as molar ratios) in order to determine the best
signal/noise ratio for the heat released/injection during titrations. Other parameters were
changed such as the amount of protein used in the cell (between 8-80 µM) and the
concentration of peptide stock in the syringe (0.5-2 mM peptide). The variations of these
parameters resulted in better assessment of the factor “C” which is described by the
following equation: C= Ka [M]n, were Ka is the association constant for any
macromolecule interacting with a ligand, [M] is the molarity of the protein and n is the
stoichiometry of binding. In ITC (25) C is reported to be 5<C<100 in order to achieve a
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good signal/noise, i.e. the concentration of macromolecule [M] is varied so that enough
heat is released upon binding a specific ligand such that the integration of the heat
released is accurate within the 1-5% experimental error. In our experiments we varied
[M] so that C was always between 20-50, assuming that n=1 and varying Ka in the limits
determined by the results from kinetics for each peptide inhibitor. 15-25 injections were
performed for each peptide individually, having the reference power stable at 15 µcal/sec
as suggested by the company specifications for the VP-ITC instrument. The stirring of
the syringe was also constant for all experiments at 300 rpm, and the spacing between
injections was standardized between 500-800 seconds such that the baseline was
achieved after each injection. The volume of ligand was between 5-15 µL as determined
by the L/P ratio achieved during titration.

4.3. RESULTS
All titration experiments were characterized by both exothermic and endothermic heat of
binding and saturability, confirming the kinetic data which showed that peptides are
specific inhibitors for thrombin. A nonspecific binding of peptides to the target thrombin
would have been characterized by nonsaturable binding event. In control experiments the
peptides were titrated directly into the buffer or the buffer was titrated into buffer (figure
124).

The heat released upon titration of peptides into buffer was very small and

nonspecific (Figure 124).

As can be seen from Figure 120 and 122 the titration

experiment determined the exothermic and the endothermic effect for the heat of binding
reaction in the case of peptide [D-Phe-Pro-D-Arg-D-Ala-CONH2]. Depending on the L/P
ratio during titration the binding was exclusively exothermic (figure 120) or was having
both exothermic and endothermic components (figure 122).
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signatures characterizing each of the binding process are presented in Figures 121 and
132.

Figure 120. Titration of peptide [D-Phe-Pro-D-Arg-D-Ala-CONH2] into thrombin
using 1.03 mM peptide (ligand-L) in the syringe, 0.0084 mM thrombin (protein-P) in
the cell and a ratio of L/P of 0.01 as increment during the titration. The raw data are
shown as filled data points while the fitted result to “sequential binding site model’ is
shown as a continuous line. The area underneath each injection peak (top panel) is equal
to the total heat released for that injection. When this integrated heat is plotted against the
molar ratio of ligand added to macromolecule in the cell, a complete binding isotherm for
the interaction is obtained (bottom panel). The molar ratio between ligand and protein for
each injection during the titration is plotted on x-axis while the y-axis shows both the
changed in the heat/second (µcal/sec) and the transformed data as kcal/mole of injectant.
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Figure 121. The ITC signatures for the peptide [D-Phe-Pro-D-Arg-D-Ala-CONH2]
titrated into thrombin (Figure 120) as are described for each of the 4 sequential binding
sites.
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Figure 122. Titration of peptide [D-Phe-Pro-DArg-D-Ala-CONH2] into thrombin
using 1.03 mM peptide (L) in the syringe, 0.012 mM thrombin (P) in the cell and a
L/P: 0.02 increments. The raw data are shown as filled data points while the fitted result
to “sequential binding site model’ is shown as a continuous line. The area underneath
each injection peak (top panel) is equal to the total heat released for that injection. When
this integrated heat is plotted against the molar ratio of ligand added to macromolecule in
the cell, a complete binding isotherm for the interaction is obtained (bottom panel). The
molar ratio between ligand and protein for each injection during the titration is plotted on
x-axis while the y-axis shows both the changed in the heat/second (µcal/sec) and the
transformed data as kcal/mole of injectant. The inset picture on the lower panel shows
the thermodynamic parameters resulted from the fit of experimental data to a “sequential
binding site” model (4 sequential binding sites in this case).
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Figure 123. The ITC signatures for the peptide [D-Phe-Pro-D-Arg-D-Ala-CONH2]
titrated into thrombin (Figure 122) as are described for each of the 4 sequential
binding sites.
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Figure 124. Titration of peptide [DPhe-Pro-D-Arg-D-Ala-CONH2] into buffer at
25oC.

4.3. DISCUSSIONS
For most cases the affinity constant determined from ITC experiments was at the
same order of magnitude with the affinity constant determined from kinetics studies.
From example in the case of the peptide [D-Phe-Pro-D-Arg-D-Ala] the equilibrium
constant determined from kinetics was around 485 x 103 L/mol while one of the
equilibrium constant determined from ITC experiments was 335.7 x 103 L/mol. In the
case of peptide [D-Phe-Pro-D-Arg-Cys] the equilibrium constants (association constants)
determined from ITC were 72.1x103, 111.1 x 103 and 140 x103 (for 3 sequential binding
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sites) while the equilibrium constant determined from kinetics was 80 x 103 L/mol,
suggesting a good agreement within 5% experimental error with the affinity constant
determined from ITC data.

In conclusion the ITC titration experiments were very

reliable method to assess the binding affinities between different peptide inhibitors and
thrombin. Furthermore the detailed thermodynamic analysis of the ITC binding isotherm
(as shown in figures 121 and 123) showed that all titration experiments were
characterized by both exothermic and endothermic heat of binding and saturability,
confirming the kinetic data which showed that peptides are specific inhibitors for
thrombin (additional ITC data are presented in Appendix XIII). A nonspecific binding of
peptides to the target thrombin would have been characterized by nonsaturable binding
event. In control experiments the peptides were titrated directly into the buffer or the
buffer was titrated into buffer. The heat released upon titration of peptides into buffer
was very small and nonspecific (Figure 124).
The data were best fitted to a “sequential binding sites” suggesting that the
peptides may bind to thrombin with a positive allosteric mechanism, in which the peptide
binding to one site may increase the affinity of peptide to another site on thrombin. Since
the kinetic data showed both competitive and mixed inhibition we assumed that the
“sequential binding sites” are related to overlapping sites of the active site binding
pocket, spanning the subpockets S3, S2, S1 and S1’ for which the peptide inhibitors were
designed to interact. Thus, the overlapping site may results from conformational changes
on the active site pocket induced by peptide binding. This hypothesis was partially
confirmed by the ITC results (Figure 121-A, compared with Figure 119) were the
positive (-T∆S) term was accompanied by negative free energy (∆G) and enthalpy (∆H).
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Other fitting procedures were tried, like fitting to two independent binding sites or one
single-binding sites, but the statistical analysis of the binding curves based on Chi2) were
shown that the models were not reliable (the fitting procedure is performed till Chi2
achieve the lowest value during consecutive iterations procedure).
The fitted data to “sequential” binding sites are consistent with the kinetics results
which showed that the peptides are not binding only to the active site (competitive
inhibition) but there is at least one more independent or “linked” binding site since the
kinetics were shown mixed inhibition at higher peptide concentration (10Ki) (Figure
118).
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Chapter 5
Structure-conformation analysis of peptides inhibitors for thrombin
using circular dichroism spectroscopy
5.1. INTRODUCTION
With a view towards better understanding the structural requirements of the
peptide inhibitors of thrombin the conformation of some peptide lead inhibitors (see
tables 14 and 15 in Chapter 3) has been studied by circular dichroism (CD). All peptides
exhibited a high dependence of structure on the sequence of amino-acids at P3 and P1’
positions (see tables 14 and 15-Chapter 3). The tetrapeptides tend to adopt beta-turns in
solvents like H2O and phosphate buffer at pH=7.4 with the same composition as the
buffer used for kinetics of thrombin inhibition (see Chapter 3). We wanted to propose a
structure-conformation relationship which could explain why some peptides were more
potent in inhibiting thrombin when changes at P3 and P1’ positions within the peptide
chain were performed (as reflected in the experimentally determined Kis (see tables 14
and 15). We hypothesized that the amino-acids at the specified positions could affect the
conformation of the peptide by imposing specific intramolecular hydrogen bonds which
could give rise to small alpha-helices or beta turns. Other known peptides such as
spontaneously folding beta-hairpin peptide (Lys-Lys-Tyr-Thr-Val-Ser-Ile-Asn-Gly-LysLys-Ile-Thr-Val-Ser-Ile) and related cyclic (cyclo-Gly-Lys-Tyr-Ile-Asn-Gly-Lys-Ile-IleAsn) and linear (Ser-Ile-Asn-Gly-Lys) were reported to fold in known secondary
structure elements such as beta-hairpin (1-15). The beta-hairpin peptides displayed a CD
minimum at 216 nm (14). These are the first CD data reported on peptides with the

349

350
sequence space D-Phe-Pro-D-Arg-P1’-CONH2 and are showing a good correlation
between the structure of folded peptide and its in vitro potential for inhibiting thrombin.

5.2. MATERIALS AND METHODS
All CD data were collected using a Jasco Spectropolarimeter using the following
parameters: scanning mode: 195 nm-320 nm, resolution: 0.5 nm, response time: 1 second.
The data were collected as 15 scans and the final spectra are presented as an average over
15 independent accumulations. The peptides were solubilized in 30 mM KH2PO4 buffer,
pH=5.5 or in the phosphate buffer used in all kinetics studies (pH=7.46, of 0.1 I (ionic
strength), containing 0.2 M NaCl. The spectra didn’t show any changes with the shift in
pH from pH=5.5 to pH 7.46 for all compounds tested, as was expected based on their
amino-acid sequence. The Arg side chain remained protonated for all the conditions
tested while the amino acids at P1’ position didn’t show any change in their protonation
status either through the range of pH tested, since they were hydrophobics and polar
neutral with pKa of side chain above pH 7.46. The spectra presented in Figure 32 are for
compounds solubilized in phosphate buffer without salt at pH 5.5. The presence of salt
had no effect upon the spectral features.

5.3. RESULTS
The peptides were dissolved in 30 mM phosphate buffer at pH 5.5 or in the same
buffer used in kinetic studies for all CD experiments as described in the Materials and
Methods and the spectra were collected as 15 independent accumulations which were
further averaged using the built-in software provided by Jasco Spectropolarimeter.
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Figure 125 presents the CD scans of some peptides tested in kinetic studies. A SAR
between the global conformation adopted in solution and their inhibitory potential was
under current investigation.
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Figure 125(A-K): Circular dichroism (CD) of different peptides tested as being lead
inhibitors for thrombin. All spectra were collected in the buffer used for thrombin
inhibition kinetics without BSA and were corrected for any buffer effect by subtracting
the buffer from the original sample spectrum (in G the spectrum of the sample is
superimposed over the buffer spectrum (horizontal, red line); the buffer didn’t have
significant absorption in the region 195-320 nm).

5.4. DISCUSSIONS
Our circular dichroism investigations suggest that the D-Arg- in i+2 position
followed by D-amino acids (polar and neutral hydrophobic like D-Thr, D-Gln, D-Ser and
D-Ala) or L-Pro in i+3 position favors beta turn (I and III), beta hairpin or alpha-helical
structures in solution at low and neutral pH. The literature reported characteristics for
type II β-turn are: weak, red-shifted negative nπ*-near 225 nm; strong positive band
with maximum between 200-205 nm; strong negative band between 180-190 nm (1-20)
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while the characteristics of type I and III β-turn resemble α-helix, with a negative nπ*
band and a negative ππ*-couplet (15-21) (see the CD of peptides D-Phe-Pro-D-Arg-ValCONH2, Dhe-Pro-D-Arg-D-Ser-CONH2 and figure 125 (C, H, I). Replacement of Dwith L-amino acids in i+3 position was accompanied by a significant lost in the beta turn
structure with a shift toward an unorganized like structure with the exception of L-amino
acids with high alpha helix propensity (such as L-Ile). The aromatics (L-Phe, L-Tyr and
L-Trp) in i+3 position are disturbing the beta turn and alpha helix structure while the
replacement of D-Phe with L/D-Tic at i-th position is accompanied by a shift toward
beta-strand-like structure (see figure 125 (D, E and G).
Some peptides however were shown the alpha helical characteristic (such as DPhe-Pro-D-Arg-Ile-CONH2, D-Phe-Pro-D-Arg-Thi-CONH2) supporting the view that a
pre-organized secondary structure is more active toward inhibiting thrombin (the above
mentioned peptides with induced secondary structure are one of the lead compounds
inhibitors for thrombin, with Ki in the range of 8-1 µM (see tables 14 and 15).
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Chapter 6
Fourier Transformed Infrared (FTIR) microscopy of
trans-and cis-cinnamoyl peptides
6.1. INTRODUCTION
FTIR microscopy of solid peptides films containing trans and cis-cinnamic acid at P3
position in the sequence space D-Phe-Pro-D-Arg-P1’-CONH2 was used to characterize
the conversion of trans–cinnamoyl peptides into their cis-cinnamoyl isomer. It has been
shown that the aliphatic double bond stretch vibration of the trans-cinnamoyl peptide can
be shifted 3-4 wavenumbers upon the conversion into the cis-isomer (1-10). Our FTIR
results are showing that this wavenumber shift is reproducible in peptides were the transcinnamic acid was incorporated through an amide bond during the solid phase synthesis
of tetrapeptides trans-cinnamoyl-Pro-D-Arg-P1’-CONH2. The results of FTIR spectra
are showing that trans-cinnamoyl peptides are having the double bond stretch vibration
band (located between 1586-1648 cm-1) (10-15) shifted 3-10 wavenumbers upon
exposure to UV light and conversion into cis-isomer. This structural evidence was
further used to interpret the structure-activity relationship of trans and cis-cinnamoyl
peptides. We found a lower inhibitory activity for the cis-cinnamoyl peptides than for the
trans-cinnamoyl peptides (figure 117 (Q) suggesting that the cis-isomer may adopt a
constrained conformation within the active-site of thrombin with less favourable contacts
within S3’ subpocket.
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6.2. MATERIALS AND METHODS
Fourier transform infrared (FTIR) studies of solid peptide films
The cis-cinnamoyl peptides were obtained from trans-cinnamoyl peptides by
exposing the solution of trans-cinnamoyl peptide to UV-light (354 nm) for 5 minutes.
The solution of each peptide sample was spotted onto microscope slides (Low-6
microscope slides-Kenley technologies) which are reflecting back in the IR region. A
Perkin Elmer Spectrum Spot light FTIR microscope (with imaging system) was used to
collect the FTIR spectra.

All scans were collected at 2 cm-1 spectral resolution and at

least 8-10 scans were averaged and corrected for water interference by subtracting the
background of water vapors. The FTIR spectra were further deconvoluted to assess the
presence of the double bond stretch using Grams software (from Thermo-Galactic
Applications) and a mixed Gaussian and Lorentzian fitting procedure. The goodness of
the fit was determined based on the chi2 analysis. As a control pure trans-cinnamic acid
was used to assign the double bond stretch for trans and cis isomer.

6.3. RESULTS
As already reported in the literature there is a 3-10 wavenumbers shift between
trans and cis isomers of cinnamic acid in the region 1586-1648 cm-1) (5-10). Based on
our knowledge these are the first FTIR data of trans/cis-cinnamoyl peptides characterized
by a different inhibitory activity against thrombin. These results are showing that the
FTIR microscopy applied to solid films of peptides is a very sensitive method to assess
fine structural changes such as the conversion between trans and cis-isomer of cinnamic
acid within the backbone of a peptide. Figure 126 shows the FTIR spectra for the major
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pepides withtrans and cis-cinnamic acid at P3 position (see also Chapter 3 for kinetic of
thrombin inhibition by these peptides). The calculated spectral curves resulted from
fitting to a mixed Gaussian and Lorentzian functions. During fitting procedure the
wavenumber intervals for the Amide I region of the peptide backbone was (1595-1688
cm-1), the Amide II region (1500-1600 cm-1) and the aliphatic double bond stretch region
(1583-1643 cm-1). The results are showing that in the case of cis-isomer the double bond
stretch vibration mode is shifted to higher wavenumbers. In some cases we observed an
opposite shift in the wavenumbers, i.e. the trans-isomer has the double bond stretch mode
shifted toward higher wavenumbers. We don’t have an explanation for these observed
differences in the wavenumber shifts, however there was a consistency in having always
3-10 wavenumber shift of the aliphatic double bond stretch between the two cinnamoylpeptide isomers, supporting the conversion of trans into cis isomer upon UV irradiation,
eventhough the conversion amy not have been 100%. The SAR studies (see Section 3related to the kinetic analysis of the data, figure 117 (Q)) supported the double bond
constrain imposed by the trans or cis-cinnamic acid as a significant factor in determining
a different affinity for thrombin of trans vs. cis-cinnamoyl peptides. The cis-cinnamoyl
peptides have in some cases five fold less affinity than the corresponding trans-cinnamoyl
peptides (table 15). The dihydrocinnamic-peptides (with more flexibility in adopting
different conformations due to the release of the double bond constrain) were more active
than the cis-cinnamoyl peptides in inhibiting thrombin and depending on the amino acid
at P1’ position more or less active than the trans-cinnamoyl peptides.

Overall the

inhibitory activity toward thrombin was as follows: Trans-cinnamoyl > dihydrocynnamic
> cis-cinnamoyl-peptides (see table 15 and figure 117).
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Chapter 7
Solution 2-D-transferred NOESY- NMR experiments of binary
complexes [thrombin-inhibitor] and ternary complexes [thrombinpeptide inhibitor-thromstop]
7.1. INTRODUCTION
The observation of trNOEs relies on different tumbling time (τc) of free and bound
molecules. Low or medium molecular weight molecules (MW <1000-2000) have a short
correlation time (τc <10-10s) and, as a consequence, such molecules exhibit positive NOEs
(maximum value +0.5) depending on their molecular weight, shape and field strength.
Large molecules, have much longer correlation time (τc >10-5 s) however and thus exhibit
strongly negative NOEs (maximum value of -1). When a small molecule is interacting
with a large molecular weight protein and becomes bound to it, it behaves as a part of the
large molecule and adopts the corresponding NOE behavior, i.e. it shows negative NOEs,
so-called trNOEs (an equilibrium between the free the bound ligand is assumed).
Specifically, the information of the bound ligand (having the macromolecule-like
property) is transferred to the free ligand through cross-relaxation events. These trNOEs
reflect the bound conformation of the ligand. Thus, binding the ligand to a target protein
receptor can be easily distinguished by looking at the sign and the size of the observed
NOEs, specifically “negative” trNOEs are detected if the ligand is binding to the
macromolecule. The trNOEs experiment can be designed such that trNOEs originating
from the bound state of the ligand can be discriminated from the trNOEs of the free
ligand in solution. In practice, the change in sign (from positive to negative) of NOE of a
small molecule is a quick, certain indication that the binding has occurred (1-10).
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Figure 127 presents a schematic representation of the difference between the NOESY and
the tr-NOESy experiments in the case of a small molecule ligand (containing 4 different
protons (a, b, c and d). The part A correspond to the small positive NOEs from crossdiagonal peaks in the case of free ligand in solution (the “positive” NOEs have a different
color (sign) than the diagonal). Part B correspond to the situation of ligand interacting
with the target macromolecule when the large “negative” NOEs are building-up (the
NOEs have the same sign with the diagonal). The arrows shows the assigned protons
which are involved in the transferred-NOEs (6-11).
A

B

Figure 127: Schematic representation of a 2D-tr-1H-NOESY experiment .
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Both the 1D and 2D transferred NOE experiments were used extensively to determine the
conformation of weak to medium affinity ligands when bound to a large protein.
Recently the method has been proposed as a tool for performing NMR screening (12-15).
There are two major types of tr-NOEs experiments:
1. Intramolecular magnetization transfer NOESY.
2. Intermolecular magnetization transfer NOESY.
The major factors which limit the tr-NOESY type of experiments are binding affinities
between the ligand and the macromolecule (which should be in the order of uM to mM
range, i.e. the ligand should be in fast exchange with the receptor molecule) and the
concentration of ligand with respect to the receptor molecule. A molar ratio of 10:1 to
20:1 ligand : receptor is expected to assure that the bound ligand magnetization is
transferred to the excess free ligand through chemical exchange, and thus, the NMR
information characterizing the bound structure is observed via the sharp resonances of the
free ligand (12-15).

Therefore the method of tr-NOESY is not suitable for the

identification of ligands with poor solubility or high affinity binding constants (i.e. Kd
(dissociation constants) in the nM range).

Another disadvantage is the presence in the

spectrum of strong diagonal peaks that hamper the observation of cross-peaks between
ligand resonances having similar chemical shifts. In addition, the strong diagonal peaks
may introduce t1 noise or baseline problems that interfere with the observation of weak
cross peaks (1-6).

7.2. MATERIALS AND METHODS
2-D-transferred NOESY experiments were performed for two tetrapeptides DPhe-Pro-D-Arg-Ala-CONH2 and D-Phe-Pro-D-Arg-Gly-CONH2 which have the Kis at
low µM and are suitable for these kinds of experiments (8, 9). The 2D-transferred
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NOESY experiments were conducted at 25oC, with 10% D2O in all samples, in a buffer
30 mM phosphate, containing 0.2 M NaCl, pH 5.6. The sequence pulse and the mixing
time (120 ms) were very similar with those described for other thrombin-peptides system
(8, 9). The NMR experiments were conducted both in the presence and in the absence of
a strong inhibitor (thromstop) in order to test if the peptides which were shown good
inhibitory activity are competing for the same sites with thromstop, i.e. at the active site.

7.3. RESULTS AND DISCUSSIONS
The NMR results showed in Figure 128 support the hypothesis of having
competition for the active sites for both D-Phe-Pro-D-Arg-Ala-CONH2 and D-Phe-ProD-Arg-Gly-CONH2 peptides. However, this competition is not 100%. Specifically the
intensity of the negative NOEs built up in the complex thrombin-peptides were
diminished in the ternary complex thrombin-peptide-thromstop (figure 128 (A, B, C and
E and F). Part of the peptides molecules are binding to other sites than the active-sites, a
result which is consistent with the kinetic data (Figure 118-Chapter 3).

Based on

Wurtrich (5-6) assignments of 1H chemical shift for different amino-acids within a
peptide sequence space, we were able to assign the transfer of NOE in between CαH-NH
(D-Arg) and CαH-NH of the amino acid after Arg within the sequence space D-Phe-ProD-Arg-P1’-CONH2, i.e. CαH-NH of Ala or Gly. Based on transferred NOE experiments
D-Arg and and the amino acids at P1’ position (Gly or Ala for the peptides we
investigated) are involved in binding to the active site of thrombin since their negative
NOEs were decreased in intensity by competition with the more potent inhibitor
Thromstop.
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2D-transferred NOESY (negative NOESY)
Thrombin:peptide
D-Phe-Pro-D-Arg-Ala-CONH2] (1:10)

(B)
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(E)

2D-transferred NOESY (negative NOESY)
Thrombin : peptide [dPhe-Pro-dArg-Gly-CONH2)
(1:10)

CαH-NH (Gly)

CαH-NH (Arg)

2D-transferred NOESY (negative NOESY)
Thrombin:peptide [dPhe-Pro-dArg-Gly-CONH 2 ]:Thromstop (1:10:1)

CαH-NH (Gly)

CαH-NH (Arg)
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(F)

Thrombin : peptide [dPhe-Pro-dArg-Gly-CONH2] : Thromstop (1:10:1)

Thrombin : peptide [dPhe-Pro-dArg-Gly-CONH2](1:10)

Figure 128. (A-F). Transferred NOESY experiments for binary complexes
(thrombin-peptide) and ternary complexes (thrombin:peptide:thromstop)
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APPENDIX X
Figure 129. ESI-MS of some purified peptides from a mixture of peptide libraries,
which were used in kinetic studies.
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Dihydrocinnamoyl-Pro-D-Arg-D-Ser-CONH2
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Table 16: Candidate tetrapeptides synthesized in this study with their calculated and
experimental molecular weights.
Inhibitor (Tetrapeptides)

Theoretical
M.W. (g.mol-1)

Trans-cinnamoyl-Pro- D-Arg-D-Pro-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-His-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-Ala-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-Ser-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-Cys-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-Thr-CONH2
Trans-cinnamoyl-Pro-D-Arg-L-Thi-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-Tic-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-Asn-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-Gln-CONH2
Trans-cinnamoyl-Pro-D-Arg-D-3Benzothienylalanine
Trans-cinnamoyl-Pro-D-Arg-D-3,5-

497.64
537.67
471.60
487.60
504.67
501.63
553.77
559.76
514.63
528.66
640.81

Experimental Mass
(m/z)
± [H+]
498.23
538.28
472.19
488.21
506.40 ± H+
502.22
554.31
560.23
515.45
529.05
681.00 (+H+, K+)

620.69

644.7 (+H+,Na+)
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385
DifluoroPhenylalanine
Trans-cinnamoyl-Pro-D-Arg-Gly- CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Pro-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-His-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Ala-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Ser-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Cys-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Thr-CONH2
Dihyrocinnamoyl-Pro-D-Arg-L-Thi-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Tic-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Asn-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-Gln-CONH2
Dihyrocinnamoyl-Pro-D-Arg-D-3Benzothienylalanine
Dihyrocinnamoyl-Pro-D-Arg-Gly-CONH2

385

512.52
499.66
539.69
473.62
489.62
506.69
503.65
555.79
561.78
516.65
530.68
642.83

513.46
500.28
540.38
474.01
490.48
505.87
504.24
556.30
562.20
517.34
531.40
644.79

514.59

515.27

386
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Figure 130. Reversed-Phase HPLC analysis of libraries of synthetic peptides

(A) [Transcinnamic-Pro-D-Arg-P1’-CONH2]

Each individual peak was collected and then subjected to ESI-MS(+) analysis to
detrmien the mass of the peptide.
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Figure 130-(B) RP-HPLC of tetrapeptide library
D-Tic-Pro-D-Arg-P1’-CONH2

Each individual peak was collected and then subjected to ESI-MS(+) analysis to
detrmien the mass of the peptide.
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Figure 130-C: RP-HPLC of tetrapeptide library D-Nal-Pro-D-Arg-P1’-CONH2

Each individual peak was collected and then subjected to ESI-MS(+) analysis to
detrmien the mass of the peptide.
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Figure 131 (A-J): HPLC-for some of the peptides inhibitors for thrombin
131-A: DPhe-Pro-DArg-DSer-CONH2
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131-C: D-Phe-Pro-D-Arg-D-Gln-CONH2
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APPENDIX XII
Figure 132: Control for stability to hydrolysis of peptides inhibitors using ESI-(+)
mass spectroscopy.
The expected MW of tripeptide which would result by hydrolysis of peptide bond D-ArgX [sequence space D-Phe-Pro-D-Arg-X-CONH2] is 418.5 The absence of the 419.5
m/z ratio from the ESI-MS scan demonstrates that the peptide was stable to hydrolysis by
thrombin.
(A) Thrombin (30 nM) + peptide D-Phe-Pro-D-Arg-D-ALA-CONH2 (20 µM)
(MW=488.3, m/z =489.3) incubated for 30 minutes at room temperature in the same
buffer used for kinetic studies (see Materials and Methods Section 3.2).
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(B) Thrombin (30 nM) + peptide D-Phe-Pro-D-Arg-D-Ser-CONH2 (20 µM)
(MW=564.6, m/z = 565.3) incubated for 30 minutes at room temperature in the
same buffer used for kinetic studies (see Materials and Methods Section 3.2).
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(C) Thrombin (30 nM) + peptide D-Phe-Pro-D-Arg-Thi-CONH2 (20 µM)
(MW=571.6, m/z = 571.3) incubated for 30 minutes at room temperature in the same
buffer used for kinetic studies (see Materials and Methods Section 3.2).
thrombindpheprodargthi #11-17 RT: 0.34-0.53 AV: 7 NL: 1.60E5
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(D) Thrombin (30 nM) + peptide D-Phe-Pro-D-Arg-Thr-CONH2 (20 µM)
(MW=518.4, m/z = 519.4) incubated for 30 minutes at room temperature in the same
buffer used for kinetic studies (see Materials and Methods Section 3.2).
thrombindpheprodargthr #2-3 RT: 0.05-0.08 AV: 2 NL: 4.18E6
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(E) Thrombin (30 nM) + peptide D-Nal-Pro-D-Arg-Gly-CONH2 (20 µM)
(MW=524.4, m/z = 525.3) incubated for 30 minutes at room temperature in the same
buffer used for kinetic studies (see Materials and Methods Section 3.2).
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(F) Thrombin (30 nM) + peptide D-Phe-Pro-Arg-D-Pro-CONH2 (20 µM)
(MW=514.4, m/z = 515.4) incubated for 30 minutes at room temperature in the same
buffer used for kinetic studies (see Materials and Methods Section 3.2).
thrombindpheproargdpro(p29)2 #1-7 RT: 0.01-0.20 AV: 7 NL: 7.60E6
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(G) Thrombin (30 nM) + peptide D-Phe-Pro-D-Arg-D-Cys-CONH2 (20 µM)
(MW=532.4, m/z = 533.4) incubated for 30 minutes at room temperature in the same
buffer used for kinetic studies (see Materials and Methods Section 3.2).
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APPENDIX XIII
Figure 133.Titration of peptide [D-Phe-Pro-D-Arg-Ala-CONH2] into thrombin.
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Figure 134. Titration of peptide [DPhe-Pro-DArg-Gly-CONH2] into thrombin.
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Figure 135. Titration of peptide [DPhe-Pro-DArg-Cys-CONH2] into thrombin.
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